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Abstract 
Staphylococcus aureus (S. aureus) is a bacterium that commonly colonises the skin 
and nares of around one third of otherwise healthy individuals. While colonisation is 
benign, S. aureus can cross skin and mucosal barriers to cause infections that 
manifest as clinical disease. Clinical outcomes are diverse and range from mild, non-
complicated and often self-limiting skin and soft tissue infections (including boils, 
abscesses and cellulitis) to more severe and life-threatening conditions including 
pneumonia, toxic shock syndrome and bacteraemia. Medication isn’t always needed 
for mild S. aureus infections as often they resolve with time but, for severe or 
persistent cases, antimicrobial treatment is generally required. Following decades of 
widespread and intensive usage of topical, enteral and parenteral antimicrobials to 
treat S. aureus infections; AMR has become an established and ubiquitous problem 
in the treatment of infections caused by this microorganism, especially when in the 
methicillin resistant form (i.e. MRSA).   
The aim of this thesis was to examine aspects of S. aureus epidemiology (including 
MRSA and methicillin-sensitive S. aureus (MSSA)) in Scotland using statistical 
methods and data from several large public health databases. More specifically this 
involved: descriptions of spatial and temporal trends of morbidity and mortality; 
comparisons of epidemiological and molecular attributes (including antimicrobial 
resistance) of (1) MSSA and MRSA, and (2) the dominant clones of MRSA (i.e. 
EMRSA-15 and EMRSA-16); descriptions of spatial and temporal trends of 
antimicrobial prescribing in primary and secondary care and any associations 
between prescribing rates and MRSA antimicrobial resistance; and carrying out a 
hospital-level risk factor analysis of MRSA, testing hypotheses that hospital size, 
hospital connectivity (through shared transfer patients) and hospital category have an 
effect on hospital-level incidences of MRSA in mainland Scottish hospitals. 
Results showed that total S .aureus bacteraemia and MRSA bacteraemia in Scotland 
statistically declined over time (p<0.0001), but MSSA bacteraemia did not (p>0.05). 
While combined mortality rates (i.e. all MSSA deaths (both primary and secondary 
cause), or all MRSA deaths (both primary and secondary cause)) mirror these 
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findings; case-fatality ratios (CFR) show no declines over time for either MRSA or 
MSSA. Results also show that several epidemiological factors point towards a 
predominant community source for MSSA isolates (i.e. outside healthcare) and 
hospital source for MRSA. Evidence for this included: (1) the lack of resistance 
genes in the MSSA population, (2) MRSA was more associated with long-term care 
and high-risk patients in the specialties care of the elderly, high dependency units 
/intensive care units (HDU/ICU), and surgery and conversely MSSA with specialties 
that commonly served outpatients, and (3) the abundance of non-EMRSA-15/non-
EMRSA-16 ‘other’ clones in the MSSA population as compared with the hospital-
associated CC22 (EMRSA-15) and CC30 (EMRSA-16) clones. EMRSA-15 was by 
far the most dominant MRSA clone in Scotland with EMRSA-16 declining 
significantly and non-EMRSA-15/non-EMRSA-16 clones causing an increasing 
number of infections (over the time period 2003-2013). EMRSA-16 was resistant to 
a larger number of antimicrobials than EMRSA-15, typically 9 versus 5, and while 
resistance varied for EMRSA-16 over the study period, resistance remained stable 
for EMRSA-15. There was little difference between clinical and screening MRSA 
isolates. Analyses of antimicrobial prescribing showed that prescribing rates of 
several drugs increased over time (2003-2013). Prescribing was far higher in primary 
care settings than in secondary care, although this differed between antimicrobials. 
Significant positive associations between prescribing and resistance rates were found 
for gentamicin (pr - p<0.0001, se - p<0.0001) and trimethoprim (pr - p<0.01, se - 
p<0.0001) in both primary (pr) and secondary (se) care, and clindamycin (p<0.0001) 
in primary care only. Finally, in Scotland there is a threshold of connectivity above 
which the majority of hospitals, regardless of size, are positive for MRSA. Higher 
levels of MRSA are associated with the large, highly connected teaching hospitals 
with high ratios of patients to domestic staff. 
While there were a number of data limitations, this body of work provides a better 
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Lay summary 
Staphylococcus aureus (also known as S. aureus) is a bacterium that is found on the 
skin of approximately one third of the population. Individuals can be colonised by 
the bacterium without being aware as carriage of the bacterium is symptomless. 
However, if there is a wound to the skin or tissue, then S. aureus can cross the skin 
barrier and cause an infection. The severity and types of disease that follows can vary 
from a simple skin infection that clears with or without a short course of antibiotics; 
to more complex and life-threatening conditions involving multiple organs. 
Bacteraemia, when bacteria are found in the blood, is a rare but extremely serious 
outcome of S. aureus infection. 
Methicillin-resistant S. aureus, also known as MRSA, is the antibiotic resistant 
variant of the bacterium that has been widely reported in the media over the last 
decade. This variant, although far less common than the methicillin-sensitive 
bacterium, (known as methicillin-sensitive S. aureus or MSSA) tends to cause more 
serious infections which are more difficult to treat and result in a higher proportion 
of deaths. 
MSSA bacteraemia rates have not changed over time, whereas total S. aureus and 
MRSA bacteraemia rates have steadily declined and importantly, government targets 
to reduce bacteraemia cases were met for total SAB, but this was driven by a 
disproportionate reduction in MRSA. Mortality rates mirrored morbidity trends with 
a decline in total SAB and MRSA but the number of cases who went on to die, a 
metric known as the case-fatality ratio, has not changed over time for MSSA or 
MRSA.  
Bacteria can be resistant to a number of different antibiotics, which means that, if an 
individual is infected with an antibiotic-resistant bacterium, then those drugs will not 
clear the infection. MRSA are resistant to an average of five antibiotics but resistance 
to as many as 14 is described in Scotland. On the other hand, approximately 20% of 
MSSA are sensitive to all tested antibiotics, meaning that they can be treated with 
any drug, and nearly 60% of MSSA are resistant to one antibiotic only (penicillin).  
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Antibiotic prescribing is considerably higher in primary care settings (such as GPs 
and community pharmacies) compared to prescribing in secondary care facilities 
(such as hospitals), although this differs between drugs. Importantly, it was shown 
that an increase in antibiotic prescribing is associated with an increase in resistance 
for several antibiotics in Scotland.  While prescribing levels of some drugs increased 
during the period that was investigated, the prescribing levels for the ‘drugs of last 
resort’, which are the last line of defence against MRSA, remain low. 
Bacteraemias can occur in different hospitals but they are most commonly 
independently associated with hospitals that are large, receive many transfer patients 
from other hospitals (a measure known as ‘connectivity’), and have a high ratio of 
patients to domestic staff.  
There are several potential implications of this work.  
(1) It highlights the need to investigate case-fatality ratios further and to find a way 
to reduce S. aureus related deaths. This could impact funding in this area to provide 
more resources for the development of bedside rapid testing for timely and 
appropriate treatment of patients.  
(2) It describes levels of antibiotic resistance in MSSA and MRSA, and the 
association between prescribing and resistance. This has potential policy implications 
since it could lead to the review of antimicrobial prescribing practices. 
(3) It shows that to further reduce bacteraemia due to S. aureus and potentially other 
hospital-associated infections, there needs to be a focus on large, highly connected 
teaching hospitals with high ratios of patients to domestic staff. 
In conclusion, we must continue to monitor MRSA as it is still an important public 
health problem but the overall population-level burden has declined over time. This 
is due to the combined efforts and activities to reduce spread and is a great public 
health success story. MSSA remains a major cause of infection causing outcomes 
including bacteraemia, but these infections are more easily treated and are less 
frequently fatal.  
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Chapter 1: Introduction to the thesis  
 
1.1 Literature review  
1.1.1 Clinical background 
1.1.1.1 Disease outcomes 
Staphylococcus aureus (S. aureus) is a bacterium that commonly colonises the skin 
and nares of around one third of otherwise healthy individuals. More specifically, 
longitudinal studies have shown that approximately 20% (range 12–30%) of people 
are persistently colonised, about 30% are intermittent carriers (range 16–70%), and 
50% (range 16–69%) are non-carriers [1]. While colonisation itself is benign, S. 
aureus can cross skin and mucosal barriers via an invasive device such as a catheter 
(primary source), or following a wound (secondary source) [2] to cause an infection 
that manifests as clinical disease. Clinical outcomes range from mild, non-
complicated and often self-limiting skin and soft tissue infections (SSTIs) including 
boils, abscesses and cellulitis to more severe and life-threatening conditions 
including pneumonia, toxic shock syndrome (TSS) and bacteraemia (bacteria present 
in the bloodstream) (Figure 1-1). Bacteraemia can lead to systemic metastatic 
infections and infective endocarditis (IE), and trigger sepsis, septic shock and 
multiple organ failure. While SSTIs are considerably more common, there has been a 
public health focus on reducing the more serious outcomes, in particular bacteraemia, 
due to high associated burden and case-fatality ratios [3-7]. In the decades before 
antimicrobials, mortality rates due to S. aureus bacteraemia exceeded 80% [8] and S. 
aureus continues to be a leading cause of bacteraemia in high-income countries [9]. 
1.1.1.2 Methicillin-resistant S. aureus (MRSA) 
A proportion of the S. aureus population is commonly resistant to the antimicrobial 
agent methicillin therefore giving rise to MRSA. Both methicillin-sensitive S. aureus 
(MSSA) and MRSA cause important healthcare-associated infections (HAIs) but can 
also cause infections in community-settings. When MRSA is the causative agent of 
bacteraemia, the risk of treatment failure and mortality is greater and length of 
hospital stay is extended [10-12]. Additionally, the associated costs of managing 
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these patients are reportedly 1.4-2.8 times higher for patients with MRSA compared 
to  patients with infections caused by MSSA [13].        
1.1.1.3 Treatment 
Medication is not always necessary for mild S. aureus infections as often they 
resolve without intervention in time but, for severe or persistent cases, antimicrobial 
treatment is generally required. Empirical therapy, where treatment begins before a 
definitive diagnosis is made, is based on clinical experience and often involves the 
prescribing of broad-spectrum antimicrobials (where antimicrobials act against a 
wide range of organisms). In contrast, where a definitive diagnosis exists, or if 
broad-spectrum drugs have not improved a patient’s condition, narrow-spectrum 
antimicrobials (effective against specific families of bacteria), may be prescribed. 
Where a definitive diagnosis for MSSA bacteraemia has been made, treatment with 
beta-lactam antimicrobials is the most effective treatment and even superior to 
vancomycin, which is an important drug in the treatment of MRSA bacteraemia [14].  
For MRSA, recent guidelines issued by the Infectious Disease Society of America 
recommend for example, daptomycin or vancomycin for bacteraemia and 
endocarditis (plus rifampicin for prosthetic valve infections), and clindamycin, 
linezolid and vancomycin for pneumonia [15]. Similarly, in 2006, the Joint Working 
Party of the British Society for Antimicrobial Chemotherapy recommended 
glycopeptides (i.e. vancomycin, teicoplanin) or linezolid be considered for 
pneumonia and SSTI if the risk of bacteraemia is high, and a minimum of 14 days 
treatment with glycopeptides or linezolid for uncomplicated bacteraemia but longer 
for patients with, or at higher risk of, endocarditis [16]. Following decades of 
widespread and intensive use of topical, enteral or parenteral antimicrobials to treat 
S. aureus infections; antimicrobial resistance (AMR) has become an established and 
ubiquitous problem for this microorganism. Therefore, antimicrobial guidelines tend 
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1.1.2 S. aureus resistance to antimicrobials 
1.1.2.1 AMR background 
Since their introduction into general clinical usage, antimicrobials have greatly 
contributed to the improvement of health and to increasing life expectancies globally 
[17]. However, as long as there have been antimicrobials, there has been resistance 
and with continued usage, AMR persists. Hence, AMR can be considered as a 
historic, current and future issue associated with a range of microorganisms. The 
importance of this public health threat was recently highlighted in the WHO’s first 
global report on surveillance of antimicrobial resistance which advised that every 
country needed to do more to monitor the problem [18]. Yet, with the rise of AMR 
and since only two new classes of antimicrobials have been introduced since the 
1970s, there has been much discussion on the possibility of a ‘post-antibiotic era’ in 
which the successful and powerful drugs of the past will no longer be effective [19]. 
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To address this, there have been calls for improved antimicrobial stewardship to 
better regulate drug usage, and improved surveillance, monitoring and regulation [20, 
21], and even suggestion of an intergovernmental panel on AMR to tackle the issue 
[22]. 
1.1.2.2 A history of AMR in S. aureus 
Chambers and DeLeo [23] described four waves of AMR in S. aureus (Figure 1-2). 
The first began in the 1940s soon after penicillin became routinely established in 
healthcare with the evolution of penicillin-resistant strains from the lineage known as 
phage type 80/81 which persists today. Within two decades, approximately 80% of S. 
aureus isolates were penicillin resistant [24].  
In the second wave, resistance to the semi-synthetic penicillin-related antibiotic 
methicillin (also known as meticillin) was first recognised in nosocomial isolates in 
1961 [25] following introduction of the β-lactam drug into clinical practice in 1959 
[26, 27]. 
The mid- to late 1970s marked the start of the third wave with the emergence of new 
resistant strains containing previously unseen variants of the mobile genetic element 
‘Staphylococcus Cassette Chromosome’ (SCCmec) (variants SCCmecII and III) in 
nosocomial settings.  
In the fourth wave which began in the mid to late 1990s, MRSA strains were no 
longer restricted to healthcare settings but also recognised as causing infections in 
the community. Such strains (causing community-associated MRSA (CA-MRSA) 
infections) tend to contain smaller, more mobile and often previously undiscovered 
SCCmec variants and appear to be causing morbidity and mortality in people without 
the usual hospital-associated risk factors for the infection. In addition, in 2002 during 
the fourth wave, vancomycin-intermediate S. aureus (VISA) strains and vancomycin-
resistant S. aureus (VRSA) strains (which are not inhibited at concentrations below 
15l ml
-1
) were isolated for the first time.  
It is possible that we are now in a new, fifth wave with livestock-associated clones 
(including CC398) causing human infections [28, 29], and with other SCCmec types 
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including SCCmecIX, X, XI and divergent mec variants (i.e. non-mecA) being 
discovered [30, 31]. 
Figure 1-2: A timeline of four waves of antibiotic resistance in S. aureus.  
 
Φ80/81: phage type 80/81 
VISA: vancomycin intermediate S. aureus 
CA-MRSA: Community-associated MRSA  
VRSA: Vancomycin-resistant S. aureus 
MRSA-I: MRSA with SCCmec I; MRSA-II: MRSA with SCCmec II; MRSA-III: MRSA with SCCmec III; 
MRSA-IV: MRSA with SCCmec IV  
Arrows show each of the four waves. Source: [23] 
 
 
1.1.2.3 How do methicillin-sensitive strains become methicillin-resistant? 
S. aureus isolates become methicillin resistant when they acquire, by horizontal gene 
transfer, one of the SCC, which harbour the mec gene-carrying element SCCmec. 
The mec gene confers resistance to not only methicillin (and derivative oxacillin) but 
to all beta-lactams [32, 33] including penicillins, carbapenems and cephalosporins to 
which resistance can also be acquired independently largely through acquisition of 
resistance gene-carrying mobile genetic elements (MGEs). Resistance to other 
antimicrobials, which is largely gained through acquisition of MGEs or through point 
mutation of chromosomal genes [34], has also been discussed throughout the 
literature. Rates of such resistance vary between countries, regions and even 
hospitals with this variation thought to reflect drug usage and selection pressures.  
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When treated with penicillin and penicillin-related β-lactams; proteins in MSSA 
strains naturally bind to the structural β-lactam ring found in the antimicrobial 
compound. Through this interaction, the drug is able to inhibit bacterial cell wall 
synthesis and clear infection.  However, with the acquisition and integration at open 
reading frame X (orfX) of the mobile genetic element SCCmec [35]; MSSA strains 
become methicillin-resistant since the cassette carries mecA, the gene that encodes 
the modified penicillin binding protein, PBP2a (also known as PBP2’) [25, 26, 36-
38]. Since the binding proteins in methicillin-resistant strains are modified, the 
bacteria have a low affinity for attachment to all β-lactam rings. The uninhibited 
binding protein then catalyses the formation of cell wall peptidoglycan [39] allowing 
bacteria to continue multiplying and infections to persist. Penicillin-resistant strains 
confer resistance in a different way, producing the plasmid-encoded enzyme 
penicillinase which hydrolyses and destroys the β-lactam ring [23].  
1.1.2.4 Resistance to other antimicrobials 
As described in Chapters 3 and 4, resistance to several other antimicrobials is 
common for MRSA. Chapter 3 also shows that multi-drug resistance in MSSA is 
rare. The mecA gene confers resistance not only to methicillin (and derivative 
oxacillin) but to all β-lactams [32, 33]. Resistance to all antimicrobial classes has 
been described in S. aureus although resistance to the glycopeptides (vancomycin for 
instance) is still rare [34]. Resistance to β-lactams, aminoglycosides, erythromycin, 
clindamycin, tetracycline and chloramphenicol, is gained by acquiring the gene from 
a MGE; resistance to fluoroquinolone and rifampicin is due to point mutations within 
chromosomal DNA; and resistance to fusidic acid, trimethoprim, co-trimoxazole and 
mupirocin can be either by MGE or point mutation [34]. An overview of different 
antibiotic classes with example of drugs, their data of discovery, and modes of 
resistance, is shown in Figure 1-3. The modes of resistance are further described in 
detail elsewhere [40]. 
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1.1.2.5 Resistance to heavy metals 
Heavy metals can be toxic to bacteria and disrupt bacterial cellular processes [41, 
42]. However, bacterial species can acquire resistance to heavy metals with 
determinants against compounds such as zinc, cadmium, mercury, and arsenic 
carried on plasmids and mercury on the chromosome [43]. Heavy metal resistance is 
important not only since bacteria can grow in the presence of these materials, but 
also because the genes for heavy metal resistance can be linked to genes for AMR 
and thus research suggests that resistance to heavy metals may be a driver of AMR 
[43]. For example, a cluster of metal resistance determinants exist on the SCCmec 
element, closely linking it to the mecA gene and β-lactam resistance [43]. In 
addition, whereas the growth of cadmium resistant S. aureus was inhibited by 
ampicillin, streptomycin, penicillin and tetracycline; the growth of lead-resistant S. 
aureus was not inhibited in the presence of streptomycin and ampicillin, indicating 
linked resistance determinants [44]. 
1.1.2.6 Resistance to antiseptics and disinfectants   
Antiseptics (i.e. chemicals applied to skin or living tissue that kill or inhibit the 
growth of microorganisms, e.g. alcohol gels, surgical hand scrubs) and disinfectants 
(i.e. chemicals applied to surfaces that kill or inhibit the growth of microorganisms, 
e.g. bleach, floor cleaner) are vital components of infection control [45]. However, 
bacteria  have  adapted  to  antiseptic and disinfectant  exposure  by  acquiring  
plasmids  and  transposons  that  confer  resistance. Furthermore, there is some 
suggestion in the literature that antiseptic and disinfectant resistance may be linked to 
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1.1.2.7 Selective pressures 
Mutants containing genes for antimicrobial resistance are selected for when isolates 
are under selection pressure, and genes only become fixed in a population when they 
show a strong selective advantage to the bacteria that outweighs any fitness cost [47].  
However, previous studies have shown that there is often a fitness cost and reduced 
growth rate associated with the harbouring of MGEs carrying drug resistance genes, 
especially if the resistances are not beneficial (such as would be the case in a low 
selection pressure environment) [48-50]. Furthermore, if resistance does infer a 
fitness cost, then resistance tends to be eliminated once the selective pressure is 
removed [50]. This is not a straightforward issue since the effect of resistance on 
fitness can differ depending on environmental conditions, can be altered by 
compensatory mutations or epistasis, and some mutations appear to be cost free [49].  
While, in general, antimicrobial drug use leads to selection of resistant mutants, 
resistance can also be gained in the absence of selection pressure through 
co-resistance where one gene confers resistance to another or multiple antimicrobial 
classes. For example, erythromycin resistance is conferred by the msrA gene (carried 
on MGE) as well as the erm genes (ermA, ermB, ermC, ermT, also MGE) which also 
confer resistance to clindamycin [51]. In addition, clindamycin resistance in 
Staphylococcal species can be either constitutive (meaning that isolates will display 
the resistant phenotype under routine screening conditions) or inducible (isolates 
display resistance phenotype only in the presence of erythromycin and clindamycin). 
Therefore, isolates with the inducible phenotype will appear to be erythromycin 
resistant and clindamycin sensitive when not tested in the presence of each other 
[52]. 
 
1.1.3 Risk factors 
1.1.3.1 Hospital-associated infection (HAI) 
S. aureus is a common healthcare- or hospital-associated/acquired infection. In 2009, 
it was suggested that MRSA caused 171,200 HAIs in Europe each year (44% of all 
HAIs) [15]. Much of the literature concerning risk factors has focused on MRSA 
rather than MSSA. Healthcare-associated MRSA (HA-MRSA) tends to affect 
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individuals in hospitals and residential care homes with specific risk factors 
including previous hospitalisation or residency at a care facility, recent antimicrobial 
therapy, indwelling vascular devices or catheters, prior surgical procedures, and age 
(neonates and the elderly being particularly affected)[27, 53]. Underlying illnesses 
can also predispose individuals to infection, including the loss of the normal skin 
barrier, the presence of underlying diseases such as diabetes or AIDS, and defects in 
neutrophil function [23].  
1.1.3.2 Colonisation 
Being colonised with MRSA is a known risk factor for infection [54-56] and 
individuals who are known to have been colonised with MRSA for more than one 
year are at high risk for subsequent MRSA morbidity and mortality [57]. In a study 
of Scottish hospital admissions, colonisation was found to be associated with the 
number of admissions per patient, hospital specialty (department) of admission, age, 
and source of admission (home, other hospital or care home) [58]. In another Scottish 
study of anatomical sites for MRSA screening, combining nasal and perineal swabs 
gave the best 2-site combination that identified 82% of true MRSA carriers [59]. 
1.1.3.3 Community-associated infection (CA-MRSA) 
S. aureus is also a major pathogen outside the hospital environment. CA-MRSA 
typically affects younger and previously healthy individuals [38] without the typical 
HA-MRSA risk factors [25, 60]. Some groups within the community are at particular 
risk including: intravenous drug users (IDUs) [38, 61, 62], men who have sex with 
men [63], athletes and players of contact sports [64], prisoners and those of lower 
social-economic status [65], and military personnel [38, 60, 66, 67]. CA-MRSA has 
also been isolated and noted as causing morbidity in aboriginal communities in 
Australia [68-75], Canada [76-79], native American Indians in the USA [76, 80], 
New Zealand [81], Malaysia [30] and elsewhere. A study of CA-MRSA in aboriginal 
Australians found that such populations were at a higher risk of invasive CA-MRSA 
and bore a disproportionate burden of invasive infections, a propensity likely to be 
linked to the high prevalence of skin infections and domestic crowding in this 
population [68]. 
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1.1.3.4 Livestock- (LA-) or farm- (FA-) associated MRSA 
In addition to being a human disease, MSSA and MRSA are also significant 
veterinary pathogens [82] causing infection in a range of animal hosts [83].  Such 
infections are important in terms of animal wellbeing, livelihood, economy and also 
for the potential risk of transmission to humans [82, 84, 85] and within human 
populations [86, 87]. Particularly at risk from this emerging zoonotic disease known 
as livestock- or farm-associated MRSA (LA- or FA-MRSA) are those who work 
closely with livestock and domestic animals including farm workers [28, 87, 88], 
veterinary staff  [89], and their families [87]. MSSA and MRSA belonging to clonal 
complex 398 (CC398), as defined by multilocus sequence typing (MLST), are 
designated LA-MRSA due to the frequent colonisation of livestock and those with 
frequent livestock contact. There have been reports of increasing spread to and 
between individuals with limited or without any direct livestock contact: families of 
farm workers [90], those living on pig farms but without contact [91], those without 
any apparent contact [92] and transmission within hospitals [93, 94]. However, 
livestock contact and the intensity of contact remain the primary risk factors for LA-
MRSA carriage, persistent carriage and infection [95]. 
1.1.3.5 Hospital-level risk factors 
A hospital-level risk factor analysis for Scotland is described in Chapter 6 of this 
thesis. There has been some work on hospital-level risk factors but none 
incorporating as many variables as in this Chapter and none carried out in Scotland. 
Hospital size has been found to be associated with hospital-level bacteraemia 
incidences [96, 97], as has hospital connectedness in England [98] and the 
Netherlands [96]. By decreasing the number of transfer patients between hospital 
collectives, the rate of spread of high-risk clones through the hospital network in 
England was reduced [99]. Similarly, transferring patients within and between 
hospitals was also found to be a patient-level risk factor of nosocomial infections in a 
retrospective analysis in France [100], and transfer from another institution, a patient 
risk-factor for both MSSA and MRSA bacteraemia [101]. Hospital type or category 
and hence activities and procedures conducted in such facilities were also previously 
found to be an important hospital-level risk-factor [96, 97].  
The Epidemiology of MRSA in Scotland 
12 
 
1.1.4 Surveillance and infection control measures 
1.1.4.1 Surveillance  
It is a mandatory requirement by law that all NHS diagnostic laboratories in Scotland 
report every episode of MSSA or MRSA bacteraemia (collectively known as S. 
aureus bacteraemia (SAB)) to Health Protection Scotland (HPS). HPS has monitored 
trends of MSSA bacteraemia since 2005 and MRSA since 2003. It is also mandatory 
that all NHS diagnostic laboratories send every blood isolate of SAB (along with 
accompanying clinical data) to the Scottish MRSA reference laboratory (SMRSARL) 
for further testing of the isolate e.g. AMR, toxin gene. This SMRSARL contributes 
information on Scottish SAB to the European Centres for Disease Control (ECDC) 
antibiotic resistance surveillance system (EARS-Net) [102].  
In the Scottish context, a case of SAB is defined as: “A person from whose blood S. 
aureus has been isolated and reported by a diagnostic microbiology laboratory in 
Scotland in the absence of a positive blood culture with the same organism in the 
previous two weeks”. This therefore excludes positive isolates from a single patient 
submitted within two weeks of each other which is assumed to be from a single 
episode. The case definition includes all SAB to avoid the need for potentially 
subjective assessment of whether an individual case’s bacteraemia was associated 
with healthcare interventions [102]. 
The Scottish government set targets to reduce all SAB to 70% of the 2005/2006 
levels by 2010 [103]. Each year, the Scottish Government and National Health 
Service (NHS) Scotland agree on a number of national NHS performance targets, 
which are known as HEAT targets (as explained below). These targets are grouped 
as one of four priorities: firstly, health improvement for Scottish people; secondly, 
efficiency and governance improvements; thirdly, access to services; and lastly, 
treatment appropriate to individuals.  
1.1.4.2 Control measures 
Several public health policies and initiatives aimed at reducing the burden of MSSA 
and MRSA were developed and implemented in Scotland. Implementing effective 
infection control measures to reduce the number of cases and the spread of the 
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bacteria in nosocomial settings has been a priority in recent years. Several control 
measures have been implemented.  
1.1.4.2.1 MRSA screening  
Universal screening (i.e. when all patients are screened) was trialled with the 
‘Pathfinder’ pilot study which was a prospective cohort study of MRSA colonisation 
in admissions to six acute hospitals in three NHS Health Boards in Scotland [11]. 
The study found that 7.5% of admissions were colonised and several risk factors 
were associated with colonisation including: if a patient was re-admitted following 
previous discharge or admitted from a care home or other hospital, increasing age 
(i.e. the elderly), and specialty of admission (this was highest in care of the elderly, 
dermatology, nephrology, and vascular surgery) [11]. There have been further 
publications focusing on screening in Scottish hospitals including; universal MRSA 
screening and risk factors for being colonised [58], interim findings from the 
‘Pathfinder’ screening project [104], screening of healthcare workers [105] and 
patients acceptance of screening [106]. 
Results from the ‘Pathfinder’ study and work that followed suggested that clinical 
risk assessment (CRA) based screening was as effective as universal nasal screening 
[107]. CRA was then implemented in Scottish hospitals, where three risk based 
questions are asked and subsequent nasal and perineal swabs taken. MRSA screening 
of patients in Scotland generally applies to individuals admitted to four acute 
specialties considered high-risk (medicine for the elderly, dermatology, renal 
medicine, and vascular surgery) and most elective hospital admissions (excluding 
paediatrics, obstetrics and psychiatry). This measure has been in place since January 
2010 [105] with patient isolation and/or nasal, throat and skin decolonisation of those 
found to be infected or colonised [108]. Figure 1-4 shows the percentage of 
admissions to the Aberdeen Royal Infirmary, NHS Grampian, that were screened for 
MRSA colonisation before and after universal screening was introduced, and the 
MRSA prevalence at admission (August 2008 to December 2010) [9]. In the same 
study, screening was associated with a 19% reduction in prevalence of MRSA 
bacteraemia [9].  




Nasal decolonisation of patients and healthcare workers with the topical 
antimicrobial mupirocin has been shown to dramatically decrease the risk of S. 
aureus spread and infection in healthcare settings [109]. In a double-blind, 
randomised, placebo-controlled clinical trial, intranasal mupirocin ointment 
eliminated nasal carriage in 58% of healthy workers within two days and 86.7% of 
individuals by the end of therapy (five days) compared with 9.4% of individuals at 
the end of treatment with a placebo (p < 0.001) [110]. However, while studies 
investigating the long-term efficacy of decolonisation with mupirocin have found 
that initial clearance over several weeks is effective; recolonisation, also known as 
nasal relapse, is common within three months [110, 111].  
Other methods to decolonise patients have also been considered such as the long-
term use of chlorhexidine baths [112] and pre-admission home-based MRSA 
decolonisation protocols [113].  
1.1.4.2.3 Source isolation 
Once carriers or infected individuals have been identified, an important step to 
reduce onwards transmission is to isolate cases [107]. Case isolation, in a single 
hospital room for example, can stop colonisation or infection of other hospital 
patients, staff or the environment. Individuals should then be decolonised to prevent 
or treat infection [107]. 
1.1.4.2.4 Antibiotic stewardship  
Antibiotic stewardship, the move towards more efficient drug use, has also been high 
on the agenda as a public health activity that not only stands to positively affect SAB 
but other conditions and pathogens.  
The UK Five Year Antimicrobial Resistance Strategy, 2013 to 2018, further shows 
commitment to tackling the issue of AMR in the UK. The strategy specifically 
focuses to; improve the knowledge and understanding of AMR; conserve and 
steward the effectiveness of existing treatments; and stimulate the development of 
new antibiotics, diagnostics and novel therapies. An example of how the UK is 
raising awareness of the issue of AMR has been the participation in the ‘European 
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Antibiotic Awareness Day’ (EAAD), held on the 18
th
 of November each year, since 
2008 [114]. 
The Scottish Antimicrobial Prescribing Group (SAPG) was also established by the 
Scottish Government in 2008 to develop policy, monitor drug prescribing, provide 
support and implement change in prescribing behaviours where necessary [115]. 
Additionally, two strategies known as ‘early switch’ (ES) and ‘early discharge’ (ED) 
are considered important for reducing the number of HAI especially serious MRSA 
skin infections [116]. They involve patients’ antimicrobial therapies being switched 
from intravenous to oral, and then they are discharged early to finish their treatments 
and recovery at home. These strategies are also considered cost-effective and to 
positively impact antimicrobial stewardship [116].  
1.1.4.2.5 Hand hygiene, cleaning and audits 
Hand hygiene is a vital strategy for reducing transmission of many pathogens 
including S. aureus. Hand hygiene compliance of healthcare workers is especially 
important in healthcare settings where there is a large at-risk population [117]. In a 
recent review, Marimuthu et al [118] described the effect of improved hand hygiene 
on nosocomial MRSA control in several studies. It was highlighted that there are a 
number of different activities that have been included in successful hand hygiene 
enhancement strategies, leading to increased rates in hand hygiene compliance and 
reduced rates of infection [118]. Such strategies included: alcohol-based handrubs or 
gels, staff education, reminders, audits, performance feedback and administrative 
involvement, culture change programmes, patient empowerment, leadership 
accountability and marketing/communication [118]. Importantly, hand hygiene 
campaigns have had previous success in Scotland with a campaign in NHS 
Grampian, where in combination with other infection control strategies; this resulted 
in reduced MRSA transmission [119]. 
Hospital cleaning is also crucial for the control of infectious diseases. Targeted 
protocols and legislation regarding cleaning and cleaning rotas have been 
implemented [120], as well as regular hospital audits and spot checks, enhanced 
hospital cleaning with ‘deep cleans’ and varied cleaning/decontamination schedules 
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[121], and novel cleaning technologies [122] have been important strategies. In 
addition, extra infection control staff can contribute to higher adherence to hand 
hygiene and more efficient hospital cleaning [108].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Figure 1-4: Adherence to MRSA admission testing and MRSA prevalence during universal 
surveillance  
.  
Study carried out in Aberdeen Royal Infirmary, August 2008 to December 2010  




1.1.5 Epidemiological trends 
Morbidity and mortality trends in Scotland are described in Chapter 2 of this thesis. 
SAB morbidity and mortality trends have been previously described for North East 
Scotland. Firstly, between 2006 and 2010, prevalence density of all SAB in 
Aberdeen Royal Infirmary, a teaching hospital in NHS Grampian, declined by 41%, 
from 0.73 to 0.50 cases per 1000 AOBDs (p=0.002), and 30-day all-cause mortality 
after SAB from 26% to 14% (p=0.013) [9]. Significant declines were observed in 
Adherence to methicillin-resistant Staphylococcus aureus (MRSA) admi sion testing during 
universal surveillance (August 2008 to December 2010). 
Timothy Lawes et al. BMJ Open 2012;2:e000797
©2012 by British Medical Journal Publishing Group
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MRSA bacteraemia only [9]. Secondly, in a study of the impact of SAB on mortality 
within 90 days post admission in an NHS Grampian hospital in 2005-06; MRSA 
infections were also found to inflate the risk of death compared to individuals with 
non-S. aureus conditions and compared to individuals with MSSA. The risk of death 
for those with MRSA was 5.6 times higher and with MSSA was 2.7 times higher 
compared with individuals without SAB [123]. After adjustment for co-morbidity, 
hospitalisation, age and sex; the risk of death was still 2.9-fold and 1.7-fold higher 
than non-S. aureus conditions for MRSA and MSSA respectively [123]. 
To put Scottish MRSA in an international context, Figure 1-5 shows the percentage 
of invasive S. aureus isolates that were MRSA (%MRSA) in 2013 by country, for all 
EU Member States (MS) and EEA counties (Switzerland, Iceland, and Norway). 
Data are collected and disseminated by the European Centre for Disease Prevention 
and Control (ECDC). The Figure shows that the United Kingdom (which is reported 
as one state rather than its four separate components; England, Northern Ireland, 
Scotland, and Wales) has MRSA levels (%MRSA) between 10-25%, a figure which 
is in line with several other European countries.  
Figure 1-5: The percentage (%) of invasive S. aureus isolates that were methicillin-resistant (i.e. 
MRSA), by country, for EU/EEA countries, 2013.  
 
Source: [124] 




1.1.6 Antimicrobial prescribing 
1.1.6.1 Daily Defined Doses (DDD) 
The international standard which the WHO recommends for comparing antimicrobial 
usage is the metric DDD which is defined as the assumed average dose per day for a 
drug used for its main indication in adults [125]. This is calculated to make 
prescribing internationally comparable between drugs, which may have different 
routes of administration (e.g. topical, enteral or parenteral) or drug formulations (e.g. 
capsules, tablets, injection, suspension). This is therefore a proxy for the average 
number of patients exposed to the antibiotic in question each day.   
1.1.6.2 Scottish prescribing 
In Scotland, prescribing in primary care (i.e. dispensed from community pharmacies) 
and secondary care (i.e. in hospitals) is collected and monitored through two systems, 
the Prescribing Information System for Scotland database (PRISM) and the Hospital 
Medicines Utilisation Database (HMUD). These prescribing rates are reported as 
DDD per 1000 population and described further in Chapter 4.  
The first Scotland-wide study to describe prescribing rates and the associations with 
MRSA AMR is presented in Chapter 5 of this thesis. Previous studies of Scottish 
prescribing have been carried out in NHS Grampian with: (1) a time-series analysis 
that captured the delay in the effect of prescribing of several antimicrobial classes in 
a single hospital and its association with the proportion of total S. aureus that was 
MRSA (%MRSA) after varying lag periods [126], and (2) a case-control study in 
two hospitals which found prescribing rates of macrolides and quinolones to be 
significantly and positively associated with an increase in %MRSA [127].   
1.1.6.3 European prescribing 
To put Scottish prescribing rates in an international context, Figure 1-6A (primary 
care) and Figure 1-6B (secondary care) show the total antimicrobial consumption 
(antimicrobials for systemic use) as the total DDD per 1000 population and per day 
for each MS plus EEA counties, Switzerland, Iceland, and Norway in 2013. National 
rates of primary and secondary care prescribing are reported by the ECDC for all MS 
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and EEA. The United Kingdom is reported rather than its four separate states, i.e. 
England, Northern Ireland, Scotland, and Wales. Greece had the highest and the 
Netherlands the lowest primary care consumption among MS, with the UK being 
somewhere in between. However, for secondary care consumption, the UK had by 
far the highest and Luxembourg the lowest. In general, consumption rates in primary 
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Source: Antimicrobial consumption interactive database (ESAC-Net) 
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1.1.7 Molecular epidemiology  
1.1.7.1 Clonal complexes 
There are at least five distinct lineages of MRSA that have emerged due to 
independent acquisition of the SCCmec cassettes and the mecA gene [128] and then 
subsequent clonal expansion. MRSA is highly clonal and within each clonal group 
(called a clonal complex (CC)) there is a founder clone and then other strains which 
have evolved forming lineages through mutation from that founder clone. This 
differs from MSSA which is thought to be highly diverse [124] and it also differs 
from the naturally transformable pathogenic species Streptococcus pneumoniae and 
Neisseria meningitidis which evolve more frequently by recombination than though 
mutation [129].  
There is also diversity within MRSA lineages due to the acquisition of different 
SCCmec types. The presence of toxin and virulence genes can be used to further 
classify strains (e.g. isolates can be pvl positive indicating that they carry the Panton-
Valentine Leukocidin toxin gene (pvl)). In addition, the presence of the pvl toxin 
gene as well as genes for other toxins including toxic-shock syndrome toxin (tst), is 
often associated with increased pathogenicity. In contrast to HA-MRSA, but like 2% 
of all MSSA, CA-MRSA strains are frequently (but not universally) positive for pvl 
which is believed to cause more aggressive infections [38, 39, 130]. 
1.1.7.2 Major UK clones 
While numerous clones of MRSA circulate in the UK, two major epidemic clones 
have dominated healthcare settings in recent decades [131, 132], namely EMRSA-15 
(CC22, ST22 SCCmecIV) and EMRSA-16 (CC30, ST36 SCCmecII) which are 
reported to have collectively accounted for greater than 85% of all MRSA infections 
[10, 126, 131, 133, 134]. As summarised by Wyllie et al [132], recent UK studies 
have noted that these clones followed different epidemic curves with EMRSA-16 
first dominating the UK MRSA scene, peaking and then declining to give way to the 
rise and dominance of EMRSA-15 [10, 126, 131, 133, 134]. A shift in dominance 
appears to have occurred after 2003 in a large, acute-care teaching hospital in 
London [34] and after 2006 in Oxfordshire hospitals [132].  
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From a Scottish perspective, EMRSA-15 and EMRSA-16 comprised 15.4% and 
80.0% respectively of all MRSA isolates in Aberdeen Royal Infirmary  between 
1997 to 2000 [126] but by the later period 2003 – 2007, EMRSA-15 and EMRSA-16 
comprised 71.4% and 15.1% in the same hospital. MRSA strain distribution and 
antimicrobial resistance patterns in NHS Grampian originating from patients 
attending GP surgeries and hospitals over a 5 year period (from 2003 – 2007) were 
also described [10]. The study described the proportions of each clone from different 
clinical specimens (e.g. blood, urine, swab) with EMRSA-15 the most common 
strain in each category. The authors also found a shift in the relative rates of 
epidemic strains with an increase in community-associated strains and, in addition, 
they reported no difference in antibiotic resistance between clinical and screening 
isolates. A rise in the number of community-associated epidemic strains including 
CC5-MRSA-IV and CC8-MRSA-IV was also reported in NHS Grampian [10]. 
EMRSA-15 has been consistently the most dominant clone from 1997 to 2009 [135]. 
Using Scotland-wide data, characteristics of EMRSA-15 and EMRSA-16 are 
compared and described in Chapter 4 of this thesis. 
1.1.7.3 Main Typing methods 
Various phenotypic and genotypic methods for typing, classifying and studying 
clones and strains of S. aureus and MRSA are available. 
1.1.7.3.1 Phenotypic methods 
Phenotypic antimicrobial testing is routinely conducted on isolates. An isolate’s 
ability to survive in the presence of a wide range of antimicrobials can be tested 
manually using antimicrobial discs or using automated methods, e.g.  by Vitek 
machine.  
Phage typing was widely used for about 30 years, but has now been largely 
superseded by molecular techniques. It categorises different clones based on their 
susceptibility to lysis by various bacteriophages and therefore creates a ‘lytic 
spectrum’ profile for each isolate.  
Biotyping involves three tests (urease production, hydrolysis of Tween 80, and 
isolate pigmentation) which are carried out to identify phenotypic properties [136]. 
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Isolates can be classified as urease positive (urease becoming pink) or negative 
(urease becoming yellow); hydrolysis weak, positive, or negative based on the zone 
cleared in the inoculums; and pigmentation of isolates can be white, yellow or cream. 
Broadly speaking, EMRSA-15 (CC22) isolates are urease positive and cream/white 
in pigment and EMRSA-16 (CC30) are urease negative and yellow.  
Phenotypic methods are considered less useful for highly sophisticated strain 
differentiation and classification since they are based on unstable characteristics, can 
show poor reproducibility [137], and often highlight phenotypic variations occurring 
in genetically identical bacterial strains [138].  
1.1.7.3.2 Genotypic / molecular methods 
Pulsed field gel electrophoresis (PFGE) separates SmaI-digested genomic DNA 
fragments by size which creates a banding pattern on an agarose gel that can be 
visualised and used to compare the relatedness of bacterial isolates. PFGE has a high 
discriminative power for typing, is suitable for looking at recent evolution of strains 
[23], is robust, highly reproducible, and is therefore considered to be the ‘gold 
standard’ technique for MRSA typing [139, 140]. However, major disadvantages 
include that it is a laborious and time-consuming method and requires expensive 
equipment and software [137, 140].  
PCR ribotyping also separates digested genomic DNA but targeting the 16S-23S 
rRNA region of S. aureus which is amplified during PCR. This region is 
polymorphic. Each of the ribosomal RNA operons contains a spacer region of 
potentially different length, and amplification of these regions may yield a 
characteristic banding pattern. Comparison of the banding pattern can reveal the 
relatedness of strains [137, 138]. PCR ribotyping is a PCR-based genotyping 
technology that is simple, fast, reliable and reproducible, but the discriminatory 
power is not as high as with other methods (i.e. it can only broadly classify isolates 
as EMRSA-15 CC22, EMRSA-16 CC30, and ‘others’).  
Spa typing is based on the analysis of variable-number tandem repeats (VNTR) in 
the polymorphic repeat region of the 3' coding end of the Staphylococcal protein A 
(i.e. spa) gene [141] and takes into account the number of point mutations in the 
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repeat region as well as the number of repeat variations [23]. The repeat
 
region of the 
spa gene is subject to spontaneous mutations,
 
as well as loss and gain of repeats. 
Since the repeats are assigned an
 
alpha-numerical code, the spa type is deduced from 
the order
 
of specific repeats [139]. Spa typing is considered an excellent tool for 
short-term local epidemiological analyses, as well as for national and international 
surveillance of S. aureus. Spa types are written as the letter t- followed by a number 
assigned to a specific spa pattern (e.g. t032). The spa Ridom database 
(http://www.ridom.de/) holds information on all known and classified spa types. 
EMRSA-15 CC22 is associated most often with t032 but also with t005, t022, t223, 
t309, t310, t417, t420. Advantages to this typing method are that it has a high degree 
of typeability and reproducibility [141], and the use of a single-locus marker is less 
expensive,
 
time-consuming, and error prone than multilocus techniques,
 
such as 
multilocus sequence typing (MLST) [141]. PFGE is superior to spa typing and 
probably
 
also MLST in terms of discriminatory power [139].  
The MLST sequence-based typing method involves the analysis of ~450-500bp of 
internal fragments of seven ‘housekeeping’ genes and the identification of any single 
nucleotide variations between isolates [26]. Each S. aureus strain is assigned a 
unique sequence type (ST) number and if two isolates are found to have identical 
sequences at each of the seven loci, they are considered to be a clone and given the 
same ST number/name. In addition, if two STs differ by single nucleotide 
polymorphisms (SNPs) at fewer than three loci (i.e. the same at 5 or more loci), they 
are considered to be different alleles and assigned different STs but still recognised 
as being closely related and classified as being in the same clonal complex [23]. 
MLST is highly discriminatory and has made it possible to study the evolutionary 
history of S. aureus and MRSA since it measures variations that accumulate slowly 
over time. However,
 
MLST is not suitable for routine surveillance of MRSA because
 
of the high cost and the necessity of access to a high-throughput
 
DNA sequencing 
facility [139]. The MLST database (http://www.mlst.net/) holds information on all 
sequence types. 
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1.1.7.3.3 Next generation sequencing (NGS) 
Next generation sequencing (NGS) is a term that encompasses the high-throughput 
technologies for sequence analysis of DNA [142]. NGS involves sequencing DNA 
fragments and aligning them to a reference genome [143]. Sequencing can be 
completed in 1-2 days however the aligning stage, bioinformatic and phylogenetic 
analyses are complex, labour-intensive, and time consuming, and interpretation of 
results require a level of skill and expertise [143]. Currently, automated algorithms or 
pipelines are being developed that can identify and provide information on spa type, 
MLST type, AMR, heavy metal resistance, virulence genes, and more [143]. Further 
considerations surrounding NGS are issues of data storage and ethical considerations 
[142]. 
NGS is not currently routine clinical or diagnostic practice in diagnostic or reference 
laboratories in Scotland although it is well used in research to retrospectively 
investigate outbreaks and epidemiological surveillance of S. aureus, to understand 
the evolution of the bacteria, to look for associations between phenotype and 
genotype (i.e. for AMR), and to conduct genome-wide association studies. If they 
were to become routine, the usefulness of these techniques could be extended to 
epidemiological surveillance (local, national, global) and outbreak detection (at point 
of first secondary case) potentially creating a gold standard for typing isolates [144]. 
Unlike many phenotypic techniques which have a problem with reproducibility and 
interpretation; NGS provides a comparable, reproducible, portable, scalable, and 
standardised approach for S. aureus typing and detection of virulence and AMR 
[145]. It would also enable: culture-free sequencing, rapid species identification, 
antimicrobial susceptibility testing, and testing of virulence determinants and toxins 
[144].   
With the costs of NGS rapidly decreasing and new generation bench top sequencers 
becoming more accessible [143], NGS techniques could replace traditional 
microbiological techniques in routine diagnostic and reference laboratories in the 
very near future.  
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1.1.8 Scottish health care system  
1.1.8.1 Background 
The National Health Service (NHS) in Scotland was created following the National 
Health Service (Scotland) Act 1947 and, since, has provided free public health 
services to all permanent residents. Health is a matter that is devolved to the Scottish 
government from the UK parliament. Prescriptions have been free of charge in 
Scotland since May 2010 although dentist and optician care still carry charges. 
Private health care is also available in Scotland. In the financial year ending in March 
2013, there were: 4,881 general practitioners (GPs); 10,081 hospital doctors and 
dentists; 46,467 nurses and midwives; and a total of 1,312,946 inpatients in all acute 
and long stay hospitals in Scotland (Information Services Division). 
1.1.8.2 Health Boards 
Since its reconfiguration in 2007, healthcare in Scotland has been provided by 
fourteen separate regional Health Boards (HBs). Figure 1-7 shows the (A) old (until 
2007) and (B) new NHS Health Board boundaries. Changes involved: NHS Argyll 
and Clyde being broken up and part-absorbed into what was previously NHS Greater 
Glasgow and subsequently NHS Greater Glasgow and Clyde, and NHS Highlands. 
NHS HBs tend to differ in health care policies. The 2013 mid-year population 
estimates by NHS Health Board and age categories (0-14, 15-64 and 65 & over) are 
shown in Table 1-1 with NHS Greater Glasgow and Clyde having the largest total 
population (1,137,930), followed by NHS Lothian (849,700), NHS Lanarkshire 
(652,580) and NHS Grampian (579,220). The Scottish Public Health Observatory 
(ScotPHO) states that while percentages belonging to each age group does not vary 
between NHS HB, in some rural HBs, namely: NHS Borders, NHS Dumfries & 
Galloway, NHS Western Isles, NHS Highland and NHS Orkney; the percentages of 
'working age population' (15-64) is lower, while elderly populations are higher. 
In 2013, there were teaching hospitals in four NHS HB only: NHS Grampian 
(Aberdeen Royal Infirmary), NHS Greater Glasgow and Clyde (Glasgow Royal 
Infirmary, Southern General, West hospitals), NHS Lothian (Edinburgh Royal 
Infirmary and Western General) and NHS Tayside (Ninewells).   
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Table 1-1: 2013 mid-year population estimates by NHS board and age categories (0-14, 15-64 
and 65 & over). 




Ayrshire & Arran 58,649 237,127 76,434 372,210 
Borders 17,754 70,414 25,702 113,870 
Dumfries & Galloway 22,470 92,770 35,030 150,270 
Fife 60,118 237,776 69,016 366,910 
Forth Valley 49,591 197,294 52,795 299,680 
Grampian 91,711 390,935 96,574 579,220 
Greater Glasgow & Clyde 179,379 774,073 184,478 1,137,930 
Highland 50,604 203,235 67,161 321,000 
Lanarkshire 111,293 431,385 109,902 652,580 
Lothian 135,549 581,448 132,703 849,700 
Orkney 3,291 13,719 4,560 21,570 
Shetland 4,066 15,031 4,103 23,200 
Tayside 63,355 266,667 82,138 412,160 
Western Isles 4,175 16,959 6,266 27,400 
SCOTLAND Total 852,005 3,528,833 946,862 5,327,700 
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1.2 Thesis aims 
1.2.1 General aims and motivation 
This thesis describes the epidemiology of MSSA and MRSA in Scotland by 
analysing several large public health databases. The motivation was to explore 
previously undescribed public health databases and contribute to the body of science 
concerning the epidemiology of this important infectious disease. 
1.2.2 Chapter 2 – MSSA and MRSA morbidity and mortality trends 
This chapter examines background spatial and temporal trends in SAB morbidity and 
temporal trends in S. aureus mortality (due to all S. aureus disease outcomes) in 
Scotland. Specific aims were (1) to examine spatial and temporal morbidity trends, 
(2) to assess whether government targets to reduce all SAB to 70% of the 2005/2006 
levels by 2010 were met and maintained, and (3) to compare mortality rates and case 
fatality ratios where MRSA and MSSA were the primary and secondary causes of 
death. 
1.2.3 Chapter 3 – MRSA declines while MSSA remains a public 
health concern 
This chapter examines microbiological and epidemiological data corresponding to 
isolates causing SAB from Scotland over an 11 year period. The primary aim was to 
explore the main microbiological and epidemiological differences between MSSA 
and MRSA populations in order to explain why MSSA bacteraemia rates have not 
seen the decline of MRSA rates and why MSSA remains an important public health 
issue.    
1.2.4 Chapter 4 - Antimicrobial resistance of MRSA 
The first aim of this chapter was to confirm that EMRSA-15 and EMRSA-16 were 
the two dominant clones in Scotland and if there was any evidence of a shift in 
dominance as reported elsewhere in the UK. The second aim was to analyse and 
explain antimicrobial resistance patterns for the dominant clones in Scotland in terms 
of resistance to twenty individual antimicrobials, antibiogram length and antibiogram 
diversity for clinical isolates and non-clinical ‘screening’ isolates. This chapter 
utilised 8 years of data from the Scottish MRSA reference laboratory.  
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1.2.5 Chapter 5 - Antimicrobial prescribing and its association with 
MRSA epidemiology 
The work included in this chapter is intended as a pilot study to inform a larger 
analysis looking at trends and associations between prescribing and resistance for a 
greater number of antimicrobials and several pathogens. Therefore, the overall 
purpose is to test methods, and describe pitfalls in using such data and conducting 
such a study. Specific aims of this study are two-fold. Firstly, to examine spatial and 
temporal trends in Scottish primary and secondary care prescribing rates. Secondly, 
to investigate whether or not there are any associations between primary or 
secondary care prescribing rates and antibiotic resistance in the MRSA population.       
1.2.6 Chapter 6 - A hospital-level risk factor analysis of MRSA  
The aim of this study is to explore the hypotheses that hospital size, hospital 
connectivity and hospital category affect the hospital-level incidences of MSSA and 
MRSA bacteraemia morbidity rates in mainland Scottish hospitals. The objective is 
twofold; (1) to identify risk factors in hospitals with cases versus those without, and 
(2) to investigate risk factors associated with increasing number of cases in general 
hospitals (classification A1, A2, A3 and A4) only. This study has been submitted as a 
manuscript to the journal BMC Infectious Diseases. 
1.2.7 Chapter 7 – Conclusions 
This chapter pools overall conclusions from each of the chapters and addresses the 
aims of each chapter. It also describes limitations and suggests a different approach 
that could have been taken where appropriate. Any implications or recommendations 
resulting from this thesis will be discussed. 
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Chapter 2: Examining morbidity and mortality trends 
of MSSA and MRSA in Scotland 
 
2.1 Background  
Staphylococcus aureus (S. aureus) is a bacterium that commonly colonises the skin 
and nares of around one third of otherwise healthy individuals. While colonisation is 
benign, S. aureus can cross skin and mucosal barriers to cause an infection that 
manifests as clinical disease [2]. Clinical outcomes range from mild, 
non-complicated and often self-limiting infections to more severe and 
life-threatening conditions (for more detail information on clinical outcomes, see 
Chapter 1.1.1.1). Bacteraemia (bacteria present in the bloodstream) is a clinical 
outcome of S. aureus can lead to systemic metastatic infections and infective 
endocarditis (IE), and it can trigger sepsis, septic shock and multiple organ failure. 
There has been a public health focus on reducing these more serious outcomes due to 
high case-fatality ratios [3-7] with specific actions to reduce both methicillin-
sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) bacteraemia, 
collectively known as S. aureus bacteraemia (SAB), listed on the Scottish 
Government and NHS Scotland ‘HEAT’ targets. Specifically, one target was to 
reduce all SAB to 70% of the 2005-2006 levels by 2010 [103]. For more detailed 
information on HEAT targets and disease surveillance, see Chapter 1.1.4. In 
addition, the UK Five Year Antimicrobial Resistance Strategy, 2013 to 2018, 
outlines an action plan to undertake to tackle the issue of AMR in the UK [114]. 
Several public health policies and initiatives aimed at reducing the burden of MSSA 
and MRSA were developed and implemented in Scotland. These have been 
instrumental in reducing incidence rates (for more detailed information on 
Surveillance and Control Measures, see Chapter 1.1.4.2).  
Scottish SAB morbidity and mortality trends have been previously described in 
Aberdeen Royal Infirmary, a teaching hospital in NHS Grampian (for more detailed 
information on Surveillance and Control Measures, see Chapter 1.1.5).  
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This data chapter examines Scotland-wide spatial and temporal trends in SAB 
morbidity, and temporal trends in S. aureus mortality (due to all S. aureus disease 
outcomes). Specific aims were to: (1) examine spatial and temporal morbidity trends, 
(2) assess whether government targets to reduce all SAB to 70% of the 2005-2006 
levels by 2010 were met and maintained, and (3) compare mortality rates and case 
fatality ratios where MRSA and MSSA were the primary and secondary causes of 
death. 
 
2.2 Materials and methodology  
2.2.1 Data  
2.2.1.1 Bacteraemia morbidity data   
Quarterly MSSA and MRSA bacteraemia case data per NHS Health Board (HB) 
were obtained from the Health Protection Scotland (HPS) website [153]. The data 
were dated from April (i.e. quarter 2) 2005 to December (i.e. end of quarter 4) 2013 
inclusive for MSSA, and January (i.e. quarter 1) 2003 to December (i.e. end of 
quarter 4) 2013 for MRSA. Total S. aureus (SA), MSSA and MRSA bacteraemia 
rates per 100,000 AOBDs were calculated using estimates of AOBD from HPS, as 
per the formula: 
𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑦 𝑟𝑎𝑡𝑒 =  (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠  𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 / 𝐴𝑂𝐵𝐷𝑠 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟) ∗ 100,000. 
Clinical cases of SAB were confirmed where S. aureus was isolated from a blood 
culture and positive isolates from a single patient submitted within two weeks of 
each other were defined as a single episode [102]. AOBD (acute occupied bed days) 
is a standardised measure of the number of hospitalised patients and defined as an 
acute hospital bed occupied for one night [102]. Island HBs (i.e. NHS Orkney, NHS 
Shetland, and NHS Western Isles) were excluded from all analyses owing to highly 
variable rates of bacteraemia due to low and fluctuating population sizes. NHS 
National Waiting Times Centre, also known as the Golden Jubilee National hospital 
and given its own health board status, was also excluded from all analyses since it 
does not represent a geographic region like other HBs. The proportion of total SAB 
cases represented by MRSA was also calculated per quarter and per HB from April 
2005 onwards and herein is referred to as ‘%MRSA’. 
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2.2.1.2 Mortality data 
The number of annual deaths with MSSA (2008-2013) and MRSA (1996-2013) 
reported as the primary (underlying) and secondary (contributory) cause of death was 
obtained from the General Register Office for Scotland (GROS). These figures 
include deaths to bacteraemia and sepsis which were thought to cause over 90% of S. 
aureus deaths (personal communication with Dr Giles Edwards, former infectious 
diseases consultant in NHS Greater Glasgow and Clyde, and former director of the 
SMRSARL). No data for MSSA deaths were available pre-2008. Data were not 
stratified by HB. 
2.2.1.2.1 Mortality rates (MR)  
MR were calculated and defined as the number of (1) MSSA (2008-2013) and (2) 
MRSA (2003-2013) deaths per 100,000 AOBDs (stratified by underlying and 
contributing cause, and combined as total cause of death), as per the formula: 
𝑀𝑅 =  (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑎𝑡ℎ𝑠  𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 / 𝐴𝑂𝐵𝐷𝑠 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟) ∗ 100,000. Since 
AOBD data was only available from 2003 onwards, MR prior to this year could not 
be investigated.  
2.2.1.2.2 Breakpoint analysis 
Owing to the trend of MRSA mortality data - which increases, levels-off and then 
declines - a breakpoint analysis was carried out to identify breaks in trends (i.e. 
where the trend changed direction or rate) and time periods reflecting these 
breakpoints were established. Two breakpoints were identified; (1) 1999.5 (95% CI 
1998.9-2000.2), and (2) 2008.7 (95% CI 2008.1-2009.4). Owing to these breakpoints 
and since MRSA MR data were only available from 2003 onwards; trends in two 
time periods were investigated: (T1) 2003-2007 inclusive and (T2) and 2008-2012 
inclusive.  
2.2.1.2.3 Case fatality ratios (CFR)  
CFR were also created and defined as the number of deaths per 100 cases where (1) 
MSSA (2008-2013) and (2) MRSA ((T1) 2003-2007, and (T2) 2008-2013) were the 
primary, secondary and combined (both primary and secondary) cause of death, as 
per the formula: 
𝐶𝐹𝑅 =  (𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑎𝑡ℎ𝑠  𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 /𝑛𝑢𝑚𝑏𝑒𝑟𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟) ∗ 100  
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2.2.2 Descriptive and statistical analysis 
All statistical analyses were carried out in R (version 3.1.2) [154]. 
2.2.2.1 Trends in morbidity data 
Levels of statistical significance was set at p<0.05. Data were stored in Microsoft 
Excel (2010) spreadsheets. Prior to statistical analysis, skewedness of data (SA, 
MSSA and MRSA morbidity rates, %MRSA) was assessed and it was concluded that 
no variable needed to be transformed.  
2.2.2.1.1 Temporal trends of morbidity rates 
Quarterly trends were investigated for the period 2005 (quarter 2) to 2013 (end of 
quarter 4) for MSSA, SA and %MRSA, and 2003 (quarter 1) to 2013 (end of quarter 
4) for MRSA. Independent variables investigated included: SA bacteraemia 
morbidity rate (total number of MSSA and MRSA bacteraemia cases per 100,000 
AOBD), MSSA bacteraemia morbidity rate (total number of MSSA bacteraemia 
cases per 100,000 AOBD), and MRSA bacteraemia morbidity rate (total number of 
MRSA bacteraemia cases per 100,000 AOBD). These were examined using 
regression analysis (exploring linear, quadratic or cubic where appropriate). Trends 
in %MRSA over time (2005-2013) were also investigated by regression analyses.  
2.2.2.1.2 Spatial trends of morbidity rates 
Spatial differences between HBs were investigated. SA, MSSA, MRSA morbidity 
bacteraemia rates and %MRSA were examined using a one way ANOVA with post-
hoc Tukey comparisons. %MRSA was additionally tested using a post-hoc 
Bonferroni test for further confirmation. Results show between which set of HB pairs 
that differences in the mean rate of cases or %MRSA exist (shown in figures). The 
programme also groups HBs together based on the mean rates or %MRSA, and HBs 
with statistically different rates or %MRSA will be placed in different groups. 
Groups are assigned letters to easily identify different groups. Thus, HBs in the same 
group do not have statistically different means or %MRSA, and hence will be 
assigned the same letter.  
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2.2.2.1.3 Trends over space and time 
Any interaction between year and HB was initially investigated using the model 
(𝑚𝑜𝑑𝑒𝑙 < − 𝑙𝑚(𝑥 ~ 𝐻𝐵 + 𝑌𝑒𝑎𝑟 + 𝐻𝐵 ∗ 𝑌𝑒𝑎𝑟)) with x representing the independent 
variable which was one of SA, MSSA, or MRSA morbidity bacteraemia rates or 
%MRSA. However, the standard errors (SE) of the model outputs were very high, 
suggesting that some of the categories were empty (i.e. there were zero cases for 
some HB for some quarters). Therefore, the results are not discussed. Instead, 
temporal trends in each individual HB are shown for each HB. 
2.2.2.1.4 Government targets assessment 
To assess whether government targets to reduce all SAB to 70% of the 2005/2006 
levels by 2010 were met and maintained, the proportion reduction of morbidity cases 
using 2005 data was calculated and compared.   
2.2.2.2 Temporal trends in mortality  
2.2.2.2.1 MR versus CFR 
MSSA and MRSA MR and CFR were investigated using regression analyses 
(exploring linear, quadratic or cubic where appropriate) and compared. Prior to 
statistical analysis, skewedness of data was assessed and it was concluded that none 




2.3.1.1 Temporal trends of morbidity data 
The MSSA bacteraemia rates (per 100,000 AOBD) did not significantly change over 
time (Table 2-1, p>0.05), however MRSA bacteraemia rate did significantly change 
over time (Table 2-1). The linear model was best fitting (p<0.0001, R
2
=0.35). The 
total SAB rate significantly declined over time with the linear model being the best 
fit (p<0.0001, R
2
=0.18). Temporal trends are illustrated in Figure 2-1. In addition, 
the %MRSA also significantly declined over time (Table 2-1) with the linear model 
best describing these data (p<0.0001, R
2
=0.47).  
The Epidemiology of MRSA in Scotland 
17 
 
Table 2-1: Results from regression analysis: temporal trends of SA, MRSA and MSSA rates, 
and %MRSA. 





Year - linear -2.2 0.23 <0.0001 *** 0.18 
MSSA rate 
2005-2013 





Year- linear -1.5 0.09 <0.0001 *** 0.35 
% MRSA 
2005-2013 
Year- linear -0.04 0.002 <0.0001 *** 0.47 
Sig: Significance level = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 1 = ‘ ’  
SE = standard error 
Adj. R2 = adjusted R2. 
 
Figure 2-1: Temporal trends in Scottish bacteraemia rates per 100,000 AOBD for SA, MSSA, 




















































































































































































Year and quarter 
%MRSA SA rate MSSA rate MRSA rate
The Epidemiology of MRSA in Scotland 
18 
 
2.3.1.2 Spatial trends of morbidity rates 
ANOVAs showed that there were significant differences between HBs in terms of 
mean SA (p<0.0001), MSSA (p<0.0001) and MRSA (p<0.0001) bacteraemia rates, 
and %MRSA (p=0.01). Post-hoc Tukey analyses identified differences between 
several pairs of HBs (Table 2-2, Figure 2-2). There were 9 different groupings for 
SA, 5 for MSSA, 7 for MRSA, and 1 for %MRSA.  
For %MRSA, while the ANOVA was significant (p=0.01) suggesting that at least 
one group mean was different, the Tukey multiple comparison test failed to identify 
any significant group differences and thus placed each HB in the same group. This 
was confirmed by carrying out a Bonferroni test which, although it did identify a few 
differences between some pairs of HBs, did not find those differences to be 
significant. This was further scrutinised by transforming the data (natural logarithm 
and arcsin square root transformation) and repeating both the Tukey and Bonferroni 
test, however the same result was met. 
In General, NHS Fife and NHS Forth Valley had high rates of SA, MSSA and 
MRSA, while NHS Highland was usually low. NHS Grampian had relatively high 
rates of SA and MSSA but lower than expected rates of MRSA. For SA bacteraemia 
rates, NHS Fife had the highest mean with 51.6 cases per 100,000 AOBD and NHS 
Highland the lowest mean with 25 cases per 100,000 AOBD. For MSSA bacteraemia 
rates, NHS Fife had the highest mean with 39.2 cases per 100,000 AOBD and NHS 
Highland the lowest mean with 19.3 cases per 100,000 AOBD. For MRSA 
bacteraemia, the highest bacteraemia rates were found in NHS Lothian (13.7 cases 
per 100,000 AOBD) closely followed by NHS Forth Valley (12.6 cases per 100,000 
AOBD) and NHS Fife (12.5 cases per 100,000 AOBD), and the lowest in NHS 
Highland (5.6 cases per 100,000 AOBD). The %MRSA was highest in NHS Borders 










Table 2-2: Results of ANOVA and post-hoc Tukey analysis showing the mean, standard 
deviation (SD), minimum (Min.) and maximum (Max.) for SA rates, MSSA rates, MRSA rates 
and %MRSA with HB groupings. 
 
HB Mean SD Min. Max. Grouping§ 
SA rate - ANOVA p<0.0001 
AA 35.2 9.6 18.5 60.5 de 
BO 31.6 12.7 7.4 53.9 ef 
DG 36.2 13.1 13.4 62 cde 
FI 51.6 13.3 27.6 80.1 a 
FV 45 11.6 25.7 72.1 ab 
GC 34.3 6.1 24.6 49.3 de 
GR 39.8 10.5 26.8 69.4 bcde 
HI 25 6.9 12.8 45 f 
LA 38.2 10.6 19.4 66.3 bcde 
LO 44 11.6 26.3 68.3 abc 
TA 41.6 10.5 25.9 71.6 bcd 
MSSA rate - ANOVA p<0.0001 
AA 28.5 6.9 15 48.6 bc 
BO 22.9 11.1 3.7 52.6 cd 
DG 28.5 9 13.4 48.9 bc 
FI 39.2 10.6 19.6 63.6 a 
FV 32.4 8.1 17.8 53.1 b 
GC 29.5 5.9 22.2 50.8 b 
GR 26.8 4.5 19.8 39.6 bc 
HI 19.3 5.7 9 29.2 d 
LA 27.9 6.3 8.8 44.8 bc 
LO 30.3 5 21.9 41.3 b 
TA 29.6 6.2 19.2 52.7 b 
MRSA rate - ANOVA p<0.0001 
AA 6.6 4.7 0 16.7 cd 
BO 8.7 7.2 0 32.2 abcd 
DG 7.7 6.8 0 22.3 bcd 
FI 12.5 8.6 1.4 31.4 ab 
FV 12.6 7.4 1.9 28.5 ab 
GC 10.3 6.2 2 21.3 abcd 
GR 7.4 5 0.7 18.2 bcd 
HI 5.6 4.5 0 21.8 d 
LA 10.2 7.9 1.6 28.3 abcd 
LO 13.7 9.4 2 32.9 a 
TA 12 8.6 2 29.7 abc 
%MRSA - ANOVA p=0.01 
AA 0.18 0.1 0 0.38 a 
BO 0.28 0.19 0 0.67 a 
DG 0.19 0.13 0 0.41 a 
FI 0.23 0.14 0.04 0.5 a 
FV 0.27 0.13 0.06 0.55 a 
GC 0.24 0.11 0.05 0.43 a 
GR 0.21 0.12 0.02 0.43 a 
HI 0.22 0.15 0 0.52 a 
LA 0.25 0.15 0.05 0.69 a 
LO 0.28 0.14 0.07 0.55 a 
TA 0.27 0.15 0.08 0.57 a 
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Health Board (HB) abbreviations: AA = NHS Ayrshire and Arran, BO = NHS Borders, DG = NHS Dumfries 
and Galloway, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS Grampian, GC = NHS Greater Glasgow and 
Clyde, HI = NHS Highland, LA = NHS Lanarkshire, LO = NHS Lothian, TA = NHS Tayside . 
 
§Groupings: HBs with statistically different rates or %MRSA will be placed in different groups. Groups are 
assigned letters to easily identify different groups. Thus, HBs in the same group do not have statistically different 
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Figure 2-2: Results of post-hoc Tukey analysis showing differences in prescribing rates between 
NHS Health Boards for (A) SA rates, (B) MSSA rates, (C) MRSA rates, and (D) %MRSA. 
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Health Board abbreviations: AA = NHS Ayrshire and Arran, BO = NHS Borders, DG = NHS Dumfries and 
Galloway, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS Grampian, GC = NHS Greater Glasgow and 
Clyde, HI = NHS Highland, LA = NHS Lanarkshire, LO = NHS Lothian, TA = NHS Tayside  
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2.3.1.3 Trends between NHS Health Boards (HB) over time 
All NHS HBs saw a significant decrease in rates of SA (except for NHS Borders 
which significantly increased, p=0.01), MRSA (except for NHS Borders which did 
not change), and %MRSA over time (Table 2-3). Rates of MSSA significantly 
increased over time in NHS Borders (p=0.008), and declined in NHS Dumfries and 
Galloway (p=0.0007), NHS Greater Glasgow and Clyde (p=0.001), and NHS 
Lothian (p=0.02). There was no change in MSSA rates in any other HB. Temporal 
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Table 2-3: SA, MSSA and MRSA bacteraemia rates, and %MRSA by HB over time.  
 




AA -1.93 0.56 0.002 ** 0.24 
BO 2.07 0.78 0.01 * 0.15 
DG -3.87 0.58 <0.0001 *** 0.56 
FI -2.21 0.82 0.01 * 0.16 
FV -2.38 0.67 0.001 ** 0.26 
GR -1.69 0.29 <0.0001 *** 0.49 
GC -3.48 0.38 <0.0001 *** 0.71 
LA -2.83 0.53 <0.0001 *** 0.45 
LO -4.14 0.31 <0.0001 *** 0.84 
TA -2.78 0.52 <0.0001 *** 0.45 
MSSA 
AA -0.83 0.45 0.07 . 0.07 
BO 2.35 0.63 0.0008 *** 0.27 
DG -1.91 0.51 0.0007 *** 0.28 
FI 0.47 0.71 0.52 
 
-0.02 
FV -0.1 0.55 0.85 
 
-0.03 
GR -0.03 0.31 0.91 
 
-0.03 
GC -1.2 0.34 0.001 ** 0.25 
LA -0.3 0.43 0.49 
 
-0.02 
LO -0.74 0.31 0.02 * 0.12 




AA -1.1 0.26 0.0001 *** 0.34 
BO -0.29 0.49 0.56 
 
-0.02 
DG -1.95 0.31 <0.0001 *** 0.53 
FI -2.68 0.36 <0.0001 *** 0.62 
FV -2.28 0.31 <0.0001 *** 0.61 
GR -1.66 0.18 <0.0001 *** 0.7 
GC -2.27 0.14 <0.0001 *** 0.89 
LA -2.54 0.3 <0.0001 *** 0.68 
LO -3.4 0.24 <0.0001 *** 0.86 
TA -2.9 0.3 <0.0001 *** 0.74 
%MRSA 
AA -2.22 0.6 0.001 *** 0.27 
BO -3.04 1.17 0.01 * 0.15 
DG -2.97 0.71 0.0002 *** 0.33 
FI -4.23 0.58 <0.0001 *** 0.6 
FV -3.93 0.54 <0.0001 *** 0.6 
GR -3.93 0.5 <0.0001 *** 0.64 
GC -3.76 0.35 <0.0001 *** 0.77 
LA -4.79 0.63 <0.0001 *** 0.63 
LO -4.95 0.44 <0.0001 *** 0.79 
TA -5.07 0.53 <0.0001 *** 0.73 
Sig: Significance level = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 1 = ‘ ’  
SE = standard error, Adj. R = adjusted R2. Health Board (HB) abbreviations: AA = NHS Ayrshire and Arran, BO 
= NHS Borders, DG = NHS Dumfries and Galloway, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS 
Grampian, GC = NHS Greater Glasgow and Clyde, HI = NHS Highland, LA = NHS Lanarkshire, LO = NHS 
Lothian, TA = NHS Tayside  
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Figure 2-3: Trends between HB over time (year and quarter) for 11 NHS HB in Scotland for (A) 
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Health Board (HB) abbreviations: AA = NHS Ayrshire and Arran, BO = NHS Borders, DG = NHS Dumfries and 
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2.3.1.4 Government target assessment 
Government targets aimed to reduce all SAB to 70% of the 2005-2006 levels by 
2010. In 2005, there were 2040 SAB cases in Scotland and the SAB rate was 51.1 
cases per 100,000 AOBD. In 2010, there were 1835 SAB cases in Scotland, and the 
SAB rate was 35.5 cases per 100,000 AOBD meaning a 30.5% reduction from 2005 
case rate (Figure 2-4). By 2014, SAB rates were 40.4% lower than the 2005 levels. 
This therefore means that government targets were met by the deadline and 
maintained in the years that followed (Figure 2-4).   
While the overall HEAT target was attained, this was due to disproportionately 
reductions in MRSA. In 2005, there were 1308 MSSA and 732 MRSA bacteraemia 
cases in Scotland, and the bacteraemia rate per 100,000 AOBD for MSSA was 32.7 
and MRSA was 18.3. In 2010, there were 1486 MSSA and 349 MRSA bacteraemia 
cases in Scotland, and the rate per 100,000 AOBD for MSSA was 28.8 and MRSA 
was 6.8. This represents a 12.1% reduction in MSSA rate and a 63.1% reduction in 
MRSA rate.  By 2014, there had been further declines to 15.4% (MSSA) and 85.0% 
(MRSA) of 2005 levels. This means that if the government targets focused on MSSA 
and MRSA separately, the targets for MSSA would not have been met by the target 
year or the years that followed, but that the target for MRSA would have been far 
exceeded (Figure 2-4).   
Figure 2-4: Cumulative reduction in SAB cases from 2005 levels. 
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2.3.2 Spatial trends in mortality  
2.3.2.1 Number of deaths 
The number of deaths, where MSSA and MRSA were the primary (underlying) and 
secondary (contributing) causes, are shown in Figure 2-5. The total number of deaths 
due to MRSA (either primary or secondary cause) was 2.4 times higher than those 
due to MSSA (either cause) in 2008, falling to 2.1 times and 1.4 times in 2009 and 
2010 respectively, after which MSSA became a more common cause of death (1.4, 
2.0 and 2.5 fold higher than MRSA in 2011, 2012 and 2013 respectively).  
Figure 2-5: Total number of MSSA deaths (2008-2013) and MRSA deaths (1996- 2013) in 
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2.3.2.2 Comparison in trends: MR and CFR 
MR per 100,000AOBDs were compared where the primary, secondary or combined 
(i.e. either primary or secondary) cause of death was MSSA or MRSA. There were 
no changes over the time period 2008-2013 in MR where the primary, secondary or 
combined cause of death was MSSA (p>0.05) (Table 2-4). 
MRSA MR increased significantly from 2003 to 2007 (p=0.008). However, from 
2008 to 2013, MR decreased significantly among patients in which MRSA was the 
primary cause of death (p=0.005), the secondary cause of death (p=0.003) or 
combined primary and secondary cause of death (p=0.001) (Table 2-4). These 
patterns of decline mirror those seen for morbidity rates. Figure 2-6 shows the MR 
and CFR for (A) MSSA and (B) MRSA.  
Case-fatality ratios (CFR) per 100 cases were also compared. There were no 
significant changes in CFR for either MSSA or MRSA over the time period 
2008-2013 (Table 2-4). However, the CFR over the time period 2003-2007, where 
the combined (p=0.02) and secondary causes (p=0.03) of death were MRSA, 
marginally increased.  
The CFR where MRSA was the secondary cause of death was consistently higher 
than other CFR, and was an average of 5.9 times higher (averaged across all study 
years, range 4.4-7.6) than the CFR where MSSA was the secondary cause, and an 
average of 4.5 times higher (range 2.2-8) than the CFR where MRSA was the 
primary cause. The maximum CFR where MSSA was the primary cause of death 
was 2.7 deaths per 100 cases in 2012, and where MRSA was the primary cause was 
8.7 deaths per 100 cases in 2011. The maximum CFR where MSSA was the 
secondary cause of death was 4.6 deaths per 100 cases in 2012, and where MRSA 
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Table 2-4: Model outputs – Mortality rates and case fatality ratio trends over time (2008-2013). 





All cause 2008 
- 
2013 
0.06 0.03 0.11 
 
0.39 
Primary 0.04 0.02 0.07 . 0.49 




All cause 2003 
- 
2007 
0.28 0.045 0.008 ** 0.91 
Primary 0.08 0.03 0.05 . 0.68 
Secondary 0.20 0.07 0.06 . 0.65 
MRSA 
All cause 2008 
- 
2013 
-0.68 0.08 0.001 ** 0.93 
Primary -0.14 0.03 0.005 ** 0.85 
Secondary -0.54 0.08 0.003 ** 0.89 
CFR 
MSSA 
All cause 2008 
- 
2013 
0.32 0.15 0.1 . 0.43 
Primary 0.17 0.07 0.07 . 0.5 




All cause 2003 
- 
2007 
1.6 0.37 0.02 * 0.82 
Primary 0.48 0.23 0.13  0.45 
Secondary 1.14 0.31 0.03 * 0.76 
MRSA 
All cause 2008 
- 
2013 
-1.65 0.6 0.05 . 0.57 
Primary -0.51 0.52 0.39  -0.01 
Secondary -1.14 0.64 0.15  0.3 
MR: Mortality rate 
CFR: case-fatality ratio 
Sig: Significance level = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 1 = ‘ ’  
SE = standard error 
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Figure 2-6: A comparison between mortality statistics: (A) MSSA MR and CFR, (B) MRSA MR 
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The results in this chapter show that total SAB rates, as well as MRSA bacteraemia 
rates and the proportion of SAB cases that were MRSA, significantly declined over 
the study period in all NHS HBs (albeit at different rates). In fact, declines in SAB 
exceeded targets set by the Scottish Government by the 2010 deadline and rates 
continued to remain low. This was driven by declines in MRSA and perhaps reflects 
the continuing efforts to remove MRSA from the hospital environment and reduce 
the number of cases by a combination of public health strategies. Such declines in 
morbidity rates were mirrored in mortality rates. This association is expected since 
with fewer people infected, there are fewer that could succumb to the infection.  
Conversely, MSSA rates did not decline over the study period. As a knock-on effect, 
mortality rates, where the primary or secondary cause of death was an MSSA 
infection, did not decline either. However, the outcome (i.e. death versus recovery) 
remained more favourable for individuals with an MSSA rather than an MRSA. This 
could reflect: fewer treatment options available for MRSA infections, decreased 
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treat MRSA, and delayed administration of appropriate medication [155]; slower 
clinical response with an MRSA infection [156]; or the higher pathogenicity and 
virulence of MRSA compared to MSSA [155]. The incidence of MSSA infection is 
perhaps difficult to reduce due to the abundance of asymptomatic S. aureus carriers 
who unwittingly pass on the pathogen, or become infected themselves if the 
bacterium breaches skin or mucosal barriers. One in three individuals is thought to be 
colonised with S. aureus, and carriage is a known risk-factor for infection [54-56].  
There was no decline in MSSA or MRSA CFR over time. This may reflect the need 
to concentrate on developing better patient management practices to avoid death in 
those with an S. aureus infection as well as continued efforts to avoid patients being 
initially infected. Developing and rolling out rapid real-time diagnostic tools for the 
detection of bacteria in the blood, correct identification of the microorganism and 
any antimicrobial resistance may ensure quick and appropriate treatment that could 
reduce CFR. Current standard protocols for bacteraemia detection involve culturing, 
which can take several days to isolate and confirm the pathogen. 
Where MRSA was the secondary cause of death, the CFR ranged from 
approximately 24% (2013) to 34% (2010). This CFR represents individuals who 
already had a primary infection or condition, but due to their co-morbidity (i.e. 
having MRSA as a secondary infection); the CFR is considerably inflated when 
compared with the CFR for MRSA or MSSA as a primary cause, or MSSA as a 
secondary cause.  
To test if there were any statistical differences between HBs in terms of rates, 
analysis of variance (ANOVA) analyses where conducted, and to describe where 
those statistical differences were, Bonferroni or Tukey analyses were carried out. In 
the quarterly national surveillance reports by HPS [153], funnel plots are used to 
illustrate the rate as well as identify any HB outliers (with rates above or below what 
would be expected). This is a useful, descriptive way of depicting this information 
although it does not give any indication of any statistical differences between HB 
rates. The funnel plots were not included here in order to avoid repetition with 
national surveillance reports. In addition, the models used in this chapter differed 
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from those used in national surveillance (national surveillance used case data with a 
Poisson distribution, offset by AOBD) to determine if rate had significantly changed 
over time. The outcomes are the same as have been described here.  
There is a potential limitation of the data in that morbidity data represent cases of 
bacteraemia while mortality data represent all types of MSSA or MRSA deaths. This 
would perhaps mean that they are not comparable. However, the patterns of MR and 
CFR presented in this chapter are largely consistent with that found in the literature. 
In a multi-national study, the 30-day CFR of SAB was 20.3% [3]; in a 7 year 
nationwide US study of bacteraemia, the overall SAB crude mortality rate was 
25.4% (ICU wards 34.4%, non-ICU 18.9%) [4]; in a US study of over-65 year olds, 
SAB mortality rates were 49.4% [5]; in a population-based surveillance in the 
Calgary Health Region, Canada, the overall case-fatality rate due to MRSA and 
MSSA was found to be 39% and 24% respectively [6]; and in a Japanese study the 
7-day and 30-day mortality rates of MRSA bacteraemia were 12.0% and 25.3% 
respectively [7]. In addition, while it may also be a limitation that mortality was only 
investigated for 5 years for MSSA, it seems probable that at least for mortality rates, 
trends would have paralleled morbidity trends. In addition, there are often caveats 
associated with the use of death certificate data for measuring mortality since the 
cause of death can often be recorded inaccurately (e.g. incorrect ICD-10 codes, 
primary cause given but not secondary cause, deaths within 30-days of an infection 
not related to the infection). In spite of this, death certificates are the best available 
complete source of death records in Scotland and therefore their use in this study is 
still relevant. It is particularly useful since cause of death is split into primary, 
secondary and often tertiary causes so it can be surmised if the deceased had been 
living with long-term morbidity, was co-infected at the time of death, or what a 
person died with but not necessarily of [157]. 
 
2.5 Conclusion 
MRSA morbidity and mortality rates continue to decline over time. However, there 
have been no statistical declines in MSSA, although the outcome (death versus 
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recovery) is more favourable for individuals with the methicillin-sensitive pathogen. 
In addition, there have been no declines in CFR in recent years and this is perhaps an 
area for further policy development. On the patient level, MRSA can be considered 
more severe than MSSA owing to the higher risk of death associated with infections 
due to this pathogen. However, at the population level, MSSA causes significantly 
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Worldwide, a proportion of the S. aureus population is typically resistant to the 
semi-synthetic penicillin-related antimicrobial agent methicillin, therefore giving rise 
to methicillin-resistant S. aureus (MRSA). Resistance to methicillin was first 
recognised in nosocomial isolates in 1961 [25] following introduction of the β-
lactam drug into clinical practice in 1959 [26], for more information on the history of 
antimicrobial resistance in S. aureus, see Chapter 1.1.2.2). Since, MRSA has been an 
important healthcare-associated infection (HAI) globally and it is often described as 
a ‘superbug’ due to its persistence in nosocomial settings, ability to cause outbreaks 
and resistance to an extensive number of antimicrobials. However, in recent years it 
has been widely reported by public health bodies, the media and in the published 
medical literature [2, 9, 134, 158-160] that the proportion of S. aureus isolates that is 
MRSA, as well as UK MRSA bacteraemia rates, have significantly declined over 
time (see Chapter 1.1.5 for information on Epidemiological Trends and Chapter 1.1.7 
for Molecular Epidemiology). Recent literature shows that this decline is most likely 
due to several public health interventions that have been implemented such as 
antimicrobial stewardship, universal patient screening to identify carriers and 
decolonisation to eliminate reservoirs, and case isolation, heightened hand-hygiene 
and hospital cleaning to stop transmission [118], and others (for more information on 
Surveillance and Control Measures, see Chapter 1.1.4). 
Despite such efforts, the declines of MRSA are not echoed in methicillin-sensitive S. 
aureus (MSSA) trends and MSSA morbidity and mortality rates remain unchanged 
[131]. The reasons and mechanisms underlying this inconsistency are not well 
understood. 
Bacteraemias caused by MRSA tend to have more serious complications and are 
considered more difficult to treat than those caused by MSSA. This could reflect the 
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reduced number of options available for treatment of MRSA infections due to 
antimicrobial resistance (AMR) to multiple drugs and drug classes including 
vancomycin which is commonly used to treat MRSA bacteraemias [155, 161], 
delayed administration of appropriate medication [155], slower clinical response 
with an MRSA infection [156], or the higher pathogenicity and virulence of MRSA 
compared to MSSA [155]. Consequently, patients with MRSA tend to have a higher 
risk of death which was 5.6 times higher for hospital patients with MRSA and 2.7 
times higher with MSSA compared with individuals without S. aureus bacteraemia 
(SAB) in a study from 2005-06 in Ninewells hospital, NHS Tayside [123]. After 
adjustment for co-morbidity, hospitalisation, age and sex; the risk of death (also 
described as the death hazard in this publication) was still 2.9-fold and 1.7-fold 
higher than non-S. aureus conditions for MRSA and MSSA respectively. 
Furthermore, MRSA is also associated with longer lengths of hospital stay and 
higher financial costs in managing individual patients [101, 162, 163] with the 
associated costs of managing these patients are reportedly 1.4-2.8 times higher for 
patients with MRSA compared to patients with infections caused by MSSA [13].       
However, MSSA is still an important infection which carries high individual and 
population burden which, unlike MRSA, has not diminished over time. 
In this study, microbiological and epidemiological data corresponding to isolates 
causing SAB in Scotland over an 11 year period were examined. The primary aim 
was to explore microbiological and epidemiological differences between the MSSA 
and MRSA populations in order to provide insight as to why MSSA bacteraemia 
rates have not seen the decline of MRSA rates and why MSSA remains an important 
public health issue.      
3.2 Materials and methods 
3.2.1 Data collection      
3.2.1.1 EARS-Net 
For the purpose of this study, the Scottish component of the EARS-Net (European 
Antimicrobial Resistance Surveillance Network (EARS-Net)) database was used. 
EARS-Net is a European-wide network of national surveillance systems, collecting 
country-level data on antimicrobial resistance for public health purposes. The 
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network is coordinated and funded by the European Centre for Disease Prevention 
and Control (ECDC) having been transferred from the Dutch National Institute for 
Public Health and the Environment (RIVM) in January 2010 (previously known as 
the European Antimicrobial Resistance Surveillance Network (EARSS)).     
3.2.1.2 Scottish MRSA reference laboratory (SMRSARL) 
The SMRSARL began contributing to EARS-Net from 2002 (quarter 2). This 
contribution includes the first blood isolate from an individual patient episode, i.e. 
bacteraemia (both MSSA and MRSA), from across Scotland [102]. Blood isolates 
from inpatients and outpatients in hospitals and general practitioner (GP) surgeries 
were sent on from one of the twenty-two diagnostic laboratories in Scotland (that 
initially receive and process the specimens) to the reference laboratory for further 
identification and antimicrobial screening. The isolation of S. aureus from blood 
cultures is known as a bloodstream infection (BSI) or SAB [164]. 
3.2.1.3 Data for this study 
For this analysis, data for the years 2003-2013 were extracted from the SMRSARL 
database (n=20,316). The years 2002 and 2014 were excluded as they were not full 
years of data collection. In addition, isolates that were considered duplicates of a 
single patient-visit (matched on patient name-code, age, sex, date collected and 
location) and that matched on isolate characteristics (antibiogram, PFGE and 
PCR-ribotype) were also removed. The community health index (CHI), which is a 
patient identifier, was not available as it was removed from the database prior to 
release of the data to protect confidentiality. There was a total of 14,260 MSSA 
isolates and 5758 MRSA bacteraemia isolates (n=20,018) included in this study.  
The proportion of total SAB that was MRSA was also calculated for each year of the 
study and herein is referred to as, ‘%MRSA’. 
3.2.2 Isolate classification and antimicrobial testing  
3.2.2.1 Confirmation of species 
Isolates received from diagnostic laboratories by the SMRSARL were confirmed as 
S. aureus using a latex slide agglutination test
 
(Staphytect Plus©) following 
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incubation for 24 hours on blood agar and, if tested positive for S. aureus, were 
prepared for antimicrobial sensitivity testing using Vitek® sensitivity cards. If the 
isolates tested negative for S. aureus, they were subject to further tests to check if 
they were false negatives of the previous test and indeed S. aureus, or a different 
species. These tests included: a rapid agglutination test (PASTOREX© Staph-plus 
kit, to identify S. aureus), a tube coagulase test (to further identify S. aureus), PCR 
testing for the nuc gene (for identification of S. aureus), PCR testing for the mec 
gene (for identification of MRSA), and the Vitek®2 gram positive ID card (for 
species-level organism identification).  
3.2.2.2 Typing 
Isolates confirmed as S. aureus were typed using standard procedures at the 
SMRSARL by using a combination of pulsed-field gel electrophoresis (PFGE), PCR 
ribotyping, biotyping (profiling based on a combination of isolate pigmentation, 
urease and tween tests), sequence typing (ST) (seldom carried out) and, more 
recently, spa typing. The SMRSARL types MSSA and MRSA isolates as one of 
three clones / clonal groups. (Group 1) Clonal complex 22 (CC22), which includes 
the major hospital-associated clone ST22 SCCmecIV. If an isolate is ST22 
SCCmecIV and MRSA, it is commonly referred to as EMRSA-15. (Group 2) Clonal 
complex 30 (CC30), which includes the major hospital-associated clone ST36 
SCCmecII. If an isolate is ST36SCCmecII and MRSA, it is commonly referred to as 
EMRSA-16. (Group 3) Non-CC22 / non-CC30 isolates referred to as ‘others’ which 
includes many other ST and spa types. The full diversity of the ‘others’ clonal group 
is not known as ST was rarely carried out on isolates in the database and spa typing 
has only become common practice more recently (i.e. since 2007). 
3.2.2.3 Antimicrobial testing 
Antimicrobial testing was carried out using an automated method and following 
standard operating procedures for in vitro testing of bacterial susceptibility to 
antimicrobial agents with Vitek® sensitivity cards. Susceptibility to the following 
antimicrobials was tested consistently over the study period; ceferoxin/cefoxitin 
(Cx), chloramphenicol (Ch), ciprofloxacin (Cp), clindamycin (Cl), erythromycin 
(Er), fusidic acid (Fd), gentamicin (Gn), kanamycin (Km), linezolid (Lz), 
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methicillin/oxacillin (Mt), mupirocin (high level) (Mp), neomycin (No), penicillin 
(Pn), rifampicin (Rf), streptomycin (St), sulphamethoxazole (Su), teicoplanin (Tc), 
tetracycline (Te), tobramycin (Tb), and trimethoprim (Tr). In addition, susceptibility 
to daptomycin (Dp), moxifloxacin (Mx), quinupristin (Qp), and vancomycin (Va) 
was tested for but not consistently over the whole study period and therefore these 
antimicrobials were not included in the main analyses.  
3.2.2.4 Toxin testing 
Testing for the presence of Panton-Valentine Leukocidin toxin gene (pvl) and toxic 
shock syndrome toxin gene (tst) was carried out using polymerase chain reaction 
(PCR) as is standard procedure at SMRSARL. 
 
3.2.3 Descriptive and statistical analysis 
Unless otherwise stated, All statistical analyses were carried out in R (version 3.1.2) 
[154]. 
3.2.3.1 Background epidemiology 
Temporal trends of MSSA and MRSA were examined for the years 2003-2013. The 
change over time in the number of MSSA and MRSA counts (offset by population 
size of Scotland) was investigated using a generalized linear model (using a Poisson 
distribution and a log link-function). The %MRSA was examined using regression 
analysis with linear, quadratic and cubic models tested where appropriate.  
3.2.3.2 Univariate analysis - Isolate characteristics 
3.2.3.2.1 Antimicrobial resistance 
The percentage of the MSSA and MRSA isolates resistant to twenty antimicrobials 
was calculated and displayed using radar charts. Any statistical difference in the 
percentages between the two groups was calculated using either a Pearson’s chi 
square test or Fisher’s exact test, depending on the sample size. The change in the 
percentage resistant to each antimicrobial over time was investigated for both MSSA 
and MRSA populations using linear regression analyses.  
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3.2.3.2.2 Antibiogram length 
An antibiogram is the combination or string of antimicrobials that an isolate is 
resistant to, e.g. if an isolate is resistant to penicillin, methicillin and erythromycin, 
the antibiogram is PnMtEr and the antibiogram length is 3. The antibiogram length is 
the total number of antimicrobials that an isolate showed phenotypic resistance to. 
‘Intermediate’ resistance phenotypes (which are neither sensitive nor fully resistant 
to an antimicrobial) were considered not resistant in this study. The distribution of 
antibiogram lengths of MSSA and MRSA were examined and student’s t-tests were 
used to assess if there were significant differences in mean antibiogram lengths. A 
student’s t-test was used as the central limit theorem states that for large sample sizes 
(n>30, as a rule of thumb) the sample mean will be approximately normally 
distributed.  
3.2.3.2.3 Clone  
The association of MSSA or MRSA and clone type / clonal group, (whether isolates 
were CC22, CC30, or the heterogeneous group of non-CC22 / non-CC30 ‘others’) 
was tested using a Pearson’s chi-squared test. The percentage of different clone types 
(by MSSA and MRSA) resistant to twenty antimicrobials was calculated and 
displayed in radar charts and any significant difference between these percentages 
calculated using Pearson’s chi-squared test or Fisher’s exact test (depending on 
sample size, i.e. if one of the entries in the 2x2 table is ≤5, then a Fisher’s exact test 
is used, and if >5 then a chi-squared test is used).  
3.2.3.2.4 Toxins 
Toxin typing was inconsistently carried out pre-2010 with <5% of all isolates 
screened in 2003, 2004, and 2005, <10% in 2006 and 2007, and <12% in 2008 and 
2009. In 2010, the percentage of all isolates screened increased to >90%, and in 
2011, 2012 and 2013 more than 98% of all isolates were screened for the pvl and tst 
toxin genes. Therefore, information on presence of the pvl toxin genes was only 
available for 42.6% (n=6071) of MSSA isolates and 17.1% (n=983) of MRSA, and 
information on the presence of tst toxin genes was available for 41.1% (n=5858) of 
MSSA isolates and 16.4% (n=942) of MRSA isolates.  Where information was 
available, the difference in the percentage of MSSA and MRSA isolates positive for 
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either toxin gene was tested using a Pearson’s chi-squared test. Since the level of 
testing for the toxin genes varied over time, a sensitivity analysis, using Pearson’s 
chi-squared test, was carried out to assess that there was no difference in the rate of 
presence of toxin genes over time. Data from the years 2010 to 2013 inclusive was 
compared to data from all years, for both MSSA and MRSA, for both toxins. The 
analyses showed that there was no difference in the rate of toxin presence when 
comparing years 2010 to 2013 to all years, for both toxins, for both MSSA and 
MRSA (p<0.0001). Therefore, the results describe toxin presence for all years.  
3.2.3.3 Univariate analysis - Isolate origin or niche 
3.2.3.3.1 Patient origin 
Within the database, the origin of the isolates was defined as inpatients, outpatients, 
patients attending GP surgeries or ‘other’. The numbers of outpatient and inpatient 
comprised 2.5% and 93.8% of MSSA and 1.7% and 96.7% of MRSA isolates 
respectively. As such, for the purpose of analysis of patient origin, corresponding to 
the origin designated as GP or other (or where information was missing), 631 isolates 
were removed. The difference between the proportion of MSSA and MRSA isolates 
that were originally isolated from inpatients and outpatients was tested using a 
Pearson’s chi-squared test or Fisher’s exact test (depending on the sample size).  
3.2.3.3.2 Hospital specialty 
Only isolates from inpatients were considered for this analysis (MSSA = 13,371 
isolates, MRSA = 5568 isolates) as there were insufficient numbers of isolates 
originating from outpatients, GP and unspecified other. Isolates with missing (MSSA 
= 3091 isolates, MRSA = 1306) and unspecified ‘other’ specialty (MSSA = 1563 
isolates, MRSA = 486 isolates) were also excluded. To test if MRSA was distributed 
equally across all specialties (i.e. if patients in certain specialties were more at risk); 
a 2x12 table was analysed using chi-squared analysis.  
3.2.3.3.3 Patient age and sex 
Statistical differences in the mean age of patients between MSSA and MRSA were 
determined by Student’s t-test. Pearson’s chi-squared tests or Fisher’s exact tests 
(depending on sample sizes) were used to assess the significance of any difference 
between MSSA and MRSA for the proportion of isolates from males. A logistic 
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regression model ((𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚 (𝑀𝑆𝑆𝐴 𝑜𝑟 𝑀𝑅𝑆𝐴) ~ 𝑎𝑔𝑒 +  𝑠𝑒𝑥 +  𝑎𝑔𝑒 ∗ 𝑠𝑒𝑥) was 
also used to investigate if a patient developing MRSA or MSSA bacteraemia was 
related to their age or sex.  
3.2.3.3.4 Device 
Information on whether an intravenous line, central line, catheter or any other device 
was fitted the time the patient developed bacteraemia was only available for 24.0% 
(n=3423) of MSSA isolates and 23.3% (n=1343) of MRSA isolates. The association 
between having a device and a MSSA or MRSA bacteraemia was tested within this 
subset using a Pearson’s chi-squared test.  
3.2.3.4 Multivariate analysis - nonmetric multi-dimensional scaling (NMS) 
3.2.3.4.1 NMS background 
To further investigate differences between MSSA and MRSA, a NMS analysis was 
carried out. NMS is a data reduction and nonparametric ordination technique that is 
appropriate for data that are non-normal and does not have the assumption of linear 
relationships among variables that is common to other data reduction techniques. The 
ordination is based on information in a primary matrix which is reduced to typically 
two or three axes (dimensions). Analyses aim to visualise the level of dissimilarities 
between isolates in an N-dimensional space or scatterplot using a ranked distance 
matrix that was calculated with a Euclidian distance measure. The dimensionality of 
the plot was determined by plotting a measure of fit (known as stress) to the number 
of dimensions with the optimal dimensionality being the number of dimensions with 
the lowest stress. This optimisation strategy aims to create a configuration which 
represents the smallest departure from monotonicity in the relationship between 
distance in the original space and that in the reduced ordination space. Five hundred 
iterations were used for each NMS run, using random starting coordinates. Several 
NMS runs were performed to ensure that the solution was stable and represented a 
configuration with the best possible fit. The NMS was performed in PC-ORD version 
6 (MJM software Design, Gleneden Beach, OR). 
3.2.3.4.2 Data for NMS 
Initially, information on AMR, antibiogram length, clone/clonal group, toxins, 
patient origin, biotyping (urease, tween), hospital specialties, patient age and sex, and 
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device was included in the primary matrix. However, missing data meant that toxin, 
device and biotyping data were excluded from the NMS analysis. In addition only 
inpatient data was included as other patients origins comprised less than 5% of the 
isolates (GP= 0.15%, outpatients=2.3%, unspecified other=0.05% of all isolates with 
known patient origin) in the database. The initial NMS was run with 14 variables 
(age, antibiogram length, sex, clonal type (CC22, CC30, ‘other’), and hospital 
specialties (accident and emergency, renal, medicine, paediatrics, surgery, care of 
elderly, high dependency unit/intensive care unit, orthopaedics)) and 13,658 rows. 
Unfortunately this file was too large for the programme to run so the database had to 
be reduced to approximately 5,000 rows. This was done using a stratified random 
approach. The data was stratified by year and clone and data were selected randomly 
in relation to the proportions in the full database. Sex was removed in subsequent 
NMS runs as it did not contribute in this multivariate analysis. In the final NMS 
analysis, for each isolate the continuous variables age and antibiogram length were 
included in the primary matrix, and information on clone and specialties was 
included with the binomial variables (present or absent to each): CC22, CC30, 
accident and emergency, renal, medical, surgery, paediatrics, care of elderly, high 
dependency unit/intensive care unit and orthopaedics. The NMS analysis was carried 
out on a random sample of 5000 inpatient isolates only.  
3.2.3.4.3 NMS results  
To identify variables that were associated with either group, a second matrix was 
superimposed on the ordination to create a joint plot (radiating lines). The direction 
of the lines indicates either a positive or negative relationship with an axis and the 
variables of the secondary matrix, and the length shows the strength of the 
correlation on that axis (only with quantitative variables). The ordination was rotated 
in order to maximise the difference between MRSA and MSSA along Axis 1. 
Information in the second matrix included: AMR, antibiogram length, isolate 
clone/clonal group (classed as CC22, CC30, and non-CC22/non-CC30‘others’), 
presence of pvl or tst toxin genes, patient gender and age, specialty that patient was 
in when blood specimen taken, whether a patient had a device fitted, and year. 
Furthermore, Multi-response Permutation Procedures (MRPP) analysis was 
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performed to test the hypothesis of no difference between the 2 groups (i.e. MSSA 
and MRSA) and therefore the association between variables with either group.  
 
3.3 Results 
3.3.1 MSSA and MRSA trends 
For all years examined in this study, MSSA bacteraemia was more common than 
MRSA. In 2003, the number of MSSA isolates was 1.5 times higher than MRSA but 
by 2013 this had increased to 9.8 times, and the proportion of total SAB that was 
caused by MRSA had also statistically declined (p<0.0001).This increase in 
magnitude over time was in part due to the overall significant increase in the number 
of MSSA bacteraemia isolates (p<0.0001), and also due to the significant decrease in 
MRSA bacteraemia by an average of 13% per year over the whole study period 
(p<0.0001). These trends are shown in Figure 3-1. Overall, the percentage of total 
SAB isolates that was methicillin resistant was 28.8%. This varied by year with the 
percentage approximately 40% for 2003-2006 inclusive, falling to below 30% in 
2009, to below 20% in 2010, and to below 10% by 2013. 
Figure 3-1: Trends in the number of Scottish MSSA and MRSA bacteraemia isolates (for 
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3.3.2 Univariate analysis of isolate characteristics - MSSA and 
MRSA differ by AMR, clone type and toxins 
3.3.2.1 AMR 
The percentages of both MSSA and MRSA isolates that were resistant to 20 
frequently tested antimicrobials are shown in Figure 3-2. The radar chart shows, as 
suggested above, that multi-drug resistance in the MSSA population was low. While 
more than 70% of isolates were resistant to penicillin, only 5% to 9% of the 
population was resistant to ciprofloxacin, erythromycin, fusidic acid, tetracycline and 
trimethoprim, and less than 2% was resistant to each of the other antimicrobials. 
Moreover, 21.0% of the MSSA population was fully sensitive to all twenty 
antimicrobials tested.  
In contrast, MRSA was multi-drug resistant. Averaged over the whole study period, 
resistance to methicillin (by definition) and penicillin was 100%, ceferoxin/cefoxitin 
and ciprofloxacin was greater than 98%, erythromycin was 76%, clindamycin, 
kanamycin, neomycin, tobramycin and trimethoprim between 19% and 30%, 
gentamycin, mupirocin and tetracycline between 5% and 9%, fusidic acid and 
rifampicin between 2% and 3%, and resistance below 2% for all other antimicrobials 
(n=5) (Figure 3-2).  
The percentage resistant to each antimicrobial was significantly different between the 
MSSA and MRSA populations (p<0.0001 for each antimicrobial other than 
streptomycin where p=0.03) except for chloramphenicol, linezolid and teicoplanin 
where there was no difference in the proportion resistant between the two groups (i.e. 
MSSA and MRSA) (p<0.05) (Figure 3-2). Vancomycin resistance (not shown) was 
only tested from 2008 onwards but 100% of both MSSA and MRSA isolates were 
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Figure 3-2: Radar chart showing percentage of the MSSA (n=14,260) and MRSA (n=5758) 













Asterisks indicate significant differences between the populations (p<0.05). Antimicrobial 
abbreviations: ceferoxin/cefoxitin (Cx), chloramphenicol (Ch), ciprofloxacin (Cp), clindamycin (Cl), 
erythromycin (Er), fusidic acid (Fd), gentamicin (Gn), kanamycin (Km), linezolid (Lz), 
methicillin/oxacillin (Mt), mupirocin (high level) (Mp), neomycin (No), penicillin (Pn), rifampicin 
(Rf), streptomycin (St), sulphamethoxazole (Su), teicoplanin (Tc), tetracycline (Te), tobramycin (Tb), 
trimethoprim (Tr). 
 
3.3.2.2 Antibiogram length 
MSSA and MRSA differed statistically in terms of the number of antimicrobials that 
the two groups were phenotypically resistant to (p<0.0001). The MSSA population 
was resistant to a median of 1 and MRSA resistant to a median of 5 antimicrobials 
(Table 3-1). The distribution of antibiogram lengths of MSSA is skewed to the left 
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 Table 3-1: Summary of antibiogram lengths for MSSA and MRSA.  
Organism Min 1
st
 Qu Median Mean 3
rd
 Qu Max 
MSSA 0 0 1 0.83 1 9 
MRSA 2 5 5 6.1 7 15 
Qu = quartile; Min = minimum; Max = maximum 
Figure 3-3: Distribution of frequencies of antibiogram lengths of MSSA and MRSA.  
 
 
3.3.2.3 Clone / clonal ‘group’ 
There was a statistical difference between MSSA and MRSA in terms of clone type 
composition: 5.9% of MSSA and 74.2% of MRSA belonged to CC22 (p<0.0001), 
and 20.0% and 22.2% of MSSA and MRSA respectively belonged to CC30 
(p<0.001). While Figure 3-4 shows very little difference between MSSA and MRSA 
for CC30, the large sample size resulted in the significant result. Only 3.5% of 
MRSA isolates belonged to any other clone, whereas 74.1% of MSSA isolates 
belonged to a non-CC22 / non-CC30 ‘other’ clone (p<0.0001) (Figure 3-4).  
The median antibiogram lengths for MSSA CC22, CC30 and ‘others’ were 2, 1 and 1 
respectively and there where statistical differences in the distributions of these 
lengths (p<0.0001) (Table 3-2). MSSA ‘others’ was more diverse in terms of 
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and 80 for CC30. The most common antibiogram for each clone was ‘Pn’ followed 
by ‘fully sensitive’. There were also statistical differences between the median 
antibiogram lengths of MRSA CC22, CC30 and ‘others’ (p<0.0001) with the CC30 
clone having the longest antibiogram (Table 3-2). The percentage of total MSSA and 
total MRSA belonging to each clone/clonal group (i.e. C22, CC30 or ‘others’) is 
shown in Figure 3-4, a summary of antibiogram lengths for MSSA and MRSA by 
clone shown in Table 3-2, the distribution of frequencies of antibiogram lengths of 
MSSA and MRSA by clone in Figure 3-5, and the percentages resistant to each 
antimicrobial by clone for MSSA and MRSA populations are shown in Figures 3-6A 
and 3-6B.  
Differences between clone types of MRSA are described in greater detail in Chapter 
4 of this thesis.   
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Table 3-2: Summary of antibiogram lengths for each clone by organism (MSSA or MRSA). 
Organism Clone Min 1
st
 Qu Median Mean 3
rd
 Qu Max 
MSSA 
CC22 0 1 2 2 3 7 
CC30 0 1 1 1.0 1 8 
‘Others’ 0 1 1 1.1 1 9 
 
MRSA 
CC22 2 4 5 5.2 6 13 
CC30 2 8 9 9.2 10 15 
‘Others’ 2 4 6 7.0 10 15 
Qu = quartile; Min = minimum; Max = maximum 
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Figure 3-6: Radar chart showing percentage resistant to 20 antimicrobials in different clones of 
the (A) MSSA and (B) MRSA populations.  Asterisks represents statistical difference (p<0.05). 
 (A) Mt, Km, Gn, Mp, Tc, St, Lz, Ch – no statistical differnce (p>0.05). All other antimicrobials 
significant (Tb, No p<0.02; Rf, Su, Cl p<0.01, all others p<0.0001). CC22 n = 839, CC30 n = 2858, 
Others n = 10563 
 
 (B) Mt, Pn, Lz, Tc - no statistical difference (p>0.05); all other antimicrobials significant (all 



































The presence of toxin genes in MSSA and MRSA was compared (Table 3-3). Of all 
MSSA and MRSA isolates, 42.6% and 17.1% respectively were tested for the pvl 
toxin gene and of those tested, 2.0% and 2.2% were positive. There was no 
significant difference between MSSA and MRSA in terms of the proportion with 
toxin genes (p>0.05). Similarly, 41.1% and 16.4% of MSSA and MRSA were tested 
for the tst toxin gene and of those tested, 16.0% and 7.4% were positive. There was a 
significant difference between MSSA and MRSA in terms of the proportion with 
toxin genes (p<0.0001).  
When investigating pvl gene presence between clonal group (between organisms, 
MSSA and MRSA), there was a statistical difference between the percentages of pvl 
positivity in the CC22 clone between MSSA and MRSA populations as well as for 
‘others’ (p<0.0001), but no difference between MSSA and MRSA for CC30 
(p>0.05). MRSA ‘others’ had the highest proportion positive of pvl (14.8%). 
When investigating tst gene presence between clonal group (between organisms, 
MSSA and MRSA), there was a statistical difference between MSSA and MRSA for 
CC22 (p=0.01) as well as CC30 (p<0.0001), but no difference for ‘others’ (p>0.05). 
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MSSA pvl 122 5949 8189 42.6 2.0 
p>0.05 
MRSA pvl 22 961 4775 17.1 2.2 
        
MSSA tst 938 4920 8402 41.1 16.0 
p<0.0001 
MRSA tst 70 872 4816 16.4 7.4 
        
MSSA CC22 pvl 12 308 519 38.1 3.8 
p<0.0001 
MRSA CC22 pvl 2 778 3495 18.2 0.3 
        
MSSA CC30 pvl 34 1061 1763 38.3 3.1 
p>0.05 
MRSA CC30 pvl 2 79 1198 6.3 2.5 
        
MSSA others pvl 76 4579 5905 44.1 1.6 
p<0.0001 
MRSA others pvl 18 104 82 59.8 14.8 
        
MSSA CC22 tst 9 294 536 36.1 3.0 
p<0.0001 
MRSA CC22 tst 1 758 3516 17.8 0.1 
        
MSSA CC30 tst 757 315 1786 37.5 70.6 
p=0.01 
MRSA CC30 tst 67 12 1200 6.2 84.8 
        
MSSA others tst 171 4311 6078 42.4 3.8 
p>0.05 
MRSA others tst 2 102 100 51 1.9 
 
 
3.3.3 Isolate origin or niche - MSSA and MRSA differ by niche 
3.3.3.1 Patient origin 
The overall majority of isolates were isolated from inpatients (97.4%) as compared to 
other patient origins (outpatients (2.3%), GP surgeries (0.15%), and unspecified 
others (0.05%)). As the numbers for other patient origins were low, comparisons 
were made statistically between inpatients and outpatients only. Inpatients were 2.4 
times and outpatients 3.7 times more likely to have a MSSA bacteraemia than an 
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MRSA bacteraemia. MSSA bacteraemia was 38.0 times and MRSA bacteraemia was 
58.0 times higher in inpatients than outpatients (Table 3-3). There was a significant 
difference between the proportion MRSA that was isolated from inpatients versus 
outpatients (p<0.001) with 42.4% of inpatient bacteraemias and 27.3% of outpatient 
bacteraemias caused by MRSA (Table 3-4). 








































Missing 88 504 17.46 
$ %MRSA in each patient origin = MRSA cases/MSSA cases 
 
3.3.3.2 Hospital specialty 
Information on the different hospital specialties that inpatients were present in when 
their SAB occurred or when blood specimen taken, was also compared for the MSSA 
and MRSA populations. Within all specialties, there were more MSSA bacteraemia 
than MRSA. The highest within-specialty percentages of infections that were MSSA 
were found in paediatrics (94.8%), obstetrics and gynaecology (89.9%), and accident 
and emergency (85.0%). The highest within-specialty percentage of bacteraemia that 
was MRSA was found in Care of the Elderly (i.e. of all bacteraemias in CoE, 43.6% 
was MRSA), followed by high dependency unit / intensive care unit (40.2%), and 
surgery (36.9%) (Table 3.5). Across all specialties (and excluding isolates where the 
specialty was unknown or listed as ‘other’), MSSA was most common in medicine 
(26.5%), followed by accident and emergency (13.2%), and renal (11.3%) and 
MRSA most common in medicine (28%), followed by high dependency unit / 
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intensive care unit (13.5%), renal (12.7%), and surgery (11.2%). Figure 3-7A shows 
the percentage of total MSSA isolates or MRSA isolates found in each hospital 
specialty, and Figure 3-7B shows the within-specialty proportion of isolates that 
were MSSA and MRSA. 
There was a difference between MSSA and MRSA in the percentages of each 
specialty (p<0.0001). MRSA was associated with specialty and there were 
differences with respect to MRSA across specialties (i.e. risk factor >1, Table 3-6). 
MRSA was overrepresented in care of the elderly (p<0.0001), high dependency units 
/intensive care units (p<0.0001), renal (p=0.03), surgery (p<0.0001).  MSSA was 
overrepresented in accident and emergency (p<0.0001), infectious diseases 
(p<0.001), obstetrics and gynaecology (p=0.0001), orthopaedics (p<0.0001), 
paediatrics (p<0.0001), paediatrics ICU (p<0.0001), and in these specialties, the odds 
of MRSA was <1 (Table 3-6). 




% of total 
MSSA 
% of total 
MRSA 
A&E 15 10.4 4.6 
Care of Elderly 43.6 3.6 6.9 
HDU/ICU 40.2 6.3 10.4 
ID 26 1.1 0.9 
Medicine 29.7 20.7 21.7 
Obs/Gynae 10.1 0.6 0.2 
Oncology 25.6 2.8 2.4 
Orthopaedics 21.5 3.5 2.4 
Paediatric ICU 17.4 1.3 0.7 
Paediatrics 5.2 2.2 0.3 
Renal 30.9 8.8 9.8 
Surgery 36.3 6.2 8.7 
Other 23.7 11 8.4 
Missing 29.7 21.7 22.7 
$ %MRSA in each specialty = MRSA cases/MSSA cases. Specialties: A&E = Accident and Emergency, 
HDU/ICU = high dependency unit / intensive care unit, ID = infectious diseases, Obs/Gynae = obstetrics and 
gynaecology 
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Figure 3-7: The hospital specialties that an individual was in when they developed their 
bacteraemia or had the blood specimen taken. (A) The percentage of total MSSA isolates or 
MRSA isolates found in each hospital specialty, (B) the within-specialty proportion. 
 (A)  
 
Asterisks highlights where a statistical difference between the proportions MSSA and MRSA exist (excluding 
‘missing’ and ‘others’).  
Specialty: A&E = Accident and Emergency, HDU/ICU = high dependency unit / intensive care unit, ID = 
infectious diseases, Obs/Gynae = obstetrics and gynaecology 
Note: This graph and asterisk represent differences between MSSA and MRSA, e.g., is there a difference in the 




Specialties: A&E = Accident and Emergency, HDU/ICU = high dependency unit / intensive care unit, ID = 
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Table 3-6: Specialties where patients are more at risk of MRSA.  
Specialty Organism n 
Chi-
square 
p-value OR (95% CI) 
Accident and 
emergency 
MRSA 222 179.9 <0.001 0.38 (0.32-0.44) 
MSSA 1288 
   
Care of elderly 
MRSA 393 91.04 <0.001 1.93 (1.68-2.22) 
MSSA 511 
   
HDU / ICU 
MRSA 599 92.81 <0.001 1.72 (1.54-1.92) 
MSSA 890 
   
Infectious 
diseases 
MRSA 53 6.692 0.01108 0.67 (0.47-0.91) 
MSSA 149 
   
Medicine 
MRSA 1241 0.6192 0.8053 0.99 (0.91-1.07) 
MSSA 2944 
   
Obstetrics and 
gynaecology 
MRSA 9 15.09 0.00014 0.28 (0.12-0.56) 
MSSA 77 
   
Oncology 
MRSA 133 3.914 0.0495 0.82 (0.66-1.00) 
MSSA 386 
   
Orthopaedics 
MRSA 136 20.38 <0.001 0.64 (0.52-0.78) 
MSSA 496 
   
Paediatrics 
ICU 
MRSA 36 17.12 <0.001 0.48 (0.32-0.69) 
MSSA 179 
   
Paediatrics 
MRSA 16 94.3 <0.001 0.12 (0.07-0.20) 
MSSA 303 
   
Renal 
MRSA 526 4.557 0.03302 1.13 (1.01-1.26) 
MSSA 1131 
   
Surgery 
MRSA 499 34.45 <0.001 1.42 (1.26-1.60) 
MSSA 874 
   
OR = Odds Ratio, HDU/ICU = high dependency unit / intensive care unit 
Note: This table describes the risk of having MRSA in each specialty, e.g. what are the odds of having MRSA in 
A&E compared with the odds of having MSSA in A&E? 
 
3.3.3.3 Patient age and sex 
The mean age for MSSA was statistically lower than that for MRSA (58.1 years 
versus 67.8 years, p<0.0001) (Figure 3-8A, B, C). In addition, 3.4% of all MSSA 
bacteraemias occurred in individuals aged less than 1 year, while for all MRSA 
infections that figure was 1.0%. There was a statistically significant difference (albeit 
small) in the proportion of isolates from males versus females with 60.4% of MSSA 
isolates and 66.0% of MRSA isolates from males (p<0.0001) (Figure 3-8A, B, C). 
In investigating the relationship between the organism (either MSSA or MRSA) with 
patient age and sex; patient age did not differ with sex and vice versa (i.e. no 
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interaction was found to be significant with the model 
((𝑜𝑟𝑔𝑎𝑛𝑖𝑠𝑚 (𝑀𝑆𝑆𝐴 𝑜𝑟 𝑀𝑅𝑆𝐴) ~ 𝑎𝑔𝑒 +  𝑠𝑒𝑥 +  𝑎𝑔𝑒 ∗ 𝑠𝑒𝑥), (p>0.05)). The only 
variable that was univariately significant was age (i.e. as age advances, an individual 
is at an increased risk of MRSA, p<0.0001).  
Figure 3-8: Distribution of age and sex for (A) MSSA, (B) MRSA and (C) both MSSA and 













































































































































































While much of the information on whether an inpatient was fitted with an 
intravenous line or catheter at the time of bacteraemia was missing (records exist for 
24.0% of MSSA isolates, and 23.3% of MRSA isolates only); the data show that 
30.0% and 37.4% of MSSA and MRSA isolates respectively were associated with a 
patient who had a device. This difference was statistically significant between the 
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3.3.4 Multivariate analysis  
The result of the NMS analysis (Table 3-7, Figure 3-9A) was a three-dimensional 
solution that explained a total of 79.86% of the variation in the data. Additional 
dimensions provided no significant improvement in fit. The three axes comprised 
38.5%, 20.4% and 20.7% of the variation in the data respectively. The first axis, 
which was rotated to maximise the difference between MSSA and MRSA, described 
38.5% of variation in the data. Axes 2 and 3 separated the different specialties 
(Figure 9B). 
Overall there was considerable overlap between MSSA and MRSA with 
representatives in all specialties and in all three clones/clonal groups identified. The 
best separation of MSSA and MRSA was along NMS Axis 1 with MRSA to the right 
and MSSA to the left. As highlighted by the radiating lines on the joint plot (Figure 
3-9), MRSA was associated with older patients, longer antibiogram lengths, CC22 
clone and the specialty care of the elderly, and by contrast MSSA was associated 
with younger patients, shorter antibiogram lengths, non-CC22 and non-CC30 
‘others’ and hospital specialties paediatrics, and accident and emergency. 
MRPP was performed to test the null hypothesis of no difference between MSSA and 
MRSA. Results show (Table 3-7) that the null hypothesis of no difference between 
the groups can be rejected and the two groups occupy different regions of space as 
shown by the strong chance-correlated within-group agreement (A) and significance 
level (p<0.0001).  
Overall, the NMS and MRPP results show that MSSA and MRSA differ by a 
combination of patient age, antibiogram length, isolate clone, and hospital specialty. 
However, as aforementioned while MSSA and MRSA differ, there is some overlap. 
This means that some MRSA isolates are similar to MSSA isolates (given this 
combination and the data-reduction of these variables) and some MSSA isolates have 
attributes more alike that of MRSA.  
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Figure 3-9: Results of NMS – 2D ordination graphs (Axes 1 and 2) with joint plot with variables 






NMS differentiated two groups identified as MSSA (red polygon) and MRSA (blue polygon). ‘+’ indicated the 
centre point of a polygon. The polygons overlap meaning that the two groups share some characteristics. The 
black radiating lines indicate variables that are significantly associated with either group; for quantitative 
variables (i.e. age and antibiogram length), the longer the branch, and the stronger the association.  
Key: A_length = antibiogram length, specialties: CoE = Care of Elderly, A and E = accident and emergency 
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Table 3-7: Diagnostic results of NMS.  







Number of iterations 68 
Orthogonality , Axis pair 1 vs 2                                                       r 0.010 
% = 100(1- r
2
)                 100 
Orthogonality , Axis pair 1 vs 3                                                     r -0.147 
% = 100(1- r
2
)                 97.8 
Orthogonality , Axis pair 2 vs 3                                                       r -0.040 
% = 100(1- r
2




% of variation explained                                             Axis 1 38.5 
Axis 2 20.4 
Axis 3 20.7 
Total 79.6 
MRPP   







 <5, excellent, no prospect of misinterpretation; 5-10  good , no real risk of drawing false inferences; 
10-20 fair, provides a useable picture; >20 poor, dangerous to interpret; 35-40 random placement of 
samples (10) 
b
 better-than-random solution 
c
 chance-corrected within group agreement: a=1 all identical within group 
d
















3.4.1 MRSA bacteraemia decline 
The number of MRSA bacteraemia cases and the proportion of total SAB caused by 
MRSA have declined steadily in recent years in Scotland. These trends are attributed 
to a combination of strategies including government legislation on targets, 
surveillance and reporting, and interventions such as enhanced and intensive cleaning 
and disinfection, decolonisation programmes, heightened hygiene awareness with 
alcohol gels and hand washing, physical barriers and other novel approaches [11, 
148-152]. Ongoing action to remove MRSA from the hospital environment and 
particularly in high-risk specialties for MRSA, stands to not only reduce bacteria 
spread, risk of transmission between patients and therefore lower infection rates in 
the hospital, but it will also result in fewer discharged patients being colonised or 
infected. This could have a knock-on effect over time; gradually reducing the number 
of MRSA isolates spreading in the community and thus reducing the chance of 
colonised or infected individuals subsequently entering hospital.    
3.4.2 Sink-Source Model 
It would perhaps be predicted that such actions to eradicate MRSA as a public health 
problem would also have led to the reduction in MSSA cases but a decline was not 
observed and MSSA bacteraemia rates remain high. This could be explained by an 
ecological ‘sink-source’ model where a ‘sink’ population is only maintained by 
immigration from the ‘source’ (Figure 3-10) [165, 166]. Therefore the source which, 
in this context is the population of circulating MSSA in the community outside the 
hospital environment, is a self-sustaining reservoir from which isolates continually 
bombard or flow to the sink (i.e. hospital environment) with each colonised or 
infected patient, hospital visitor or member of hospital staff. Given that 
approximately one third of healthy individuals are asymptomatically colonised with 
S. aureus, this is highly plausible. Isolates could then potentially cause opportunistic 
community-acquired hospital-onset (CA-HO) infections in colonised hosts, could be 
spread to other susceptible hosts in the hospital to cause hospital-acquired 
colonisations or infections, or could be transferred to a surface of hospital furniture 
for example, where they would remain until spread to humans or removed by 
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cleaning or cell death. Without constant influx from the source, there is a high 
probability that the MSSA hospital population (i.e. the sink) would become extinct 
through stochastic events or, in ecological terms, habitat destruction [165]. For 
bacterial populations in hospitals, this destruction or removal could involve extensive 
cleaning or disinfection, or be the result of antimicrobial selection pressures or 
patient decolonisation. Owing to high selection pressures in hospitals, it is presumed 
that, given correct dosages, MSSA would be immediately destroyed when challenged 
with antimicrobials since the vast majority of isolates are susceptible to most 
antimicrobials in common usage. However, it is speculated that the MSSA 
population in hospitals can be maintained as it is constantly re-seeded with new wild-
type isolates from the community (i.e. source). Hospitals also remain a reservoir for 
at-risk individuals who are typically physically unwell, who may be 
immunocompromised or who may have had their skin barriers breached through 
operation or device. With this combination of a near-constant bacterial population 
and at-risk individuals; MSSA bacteraemias continue to occur. 
Figure 3-10: The ecological sink-source model as applied to MSSA and MRSA circulating 
isolates in community and hospital environments.  
 
 
The large red arrow between MSSA source and sink represents the constant and substantial flow of 
isolates, single red arrow between MSSA sink and source represents a lesser flow of isolates. The 
broken blue arrows between MRSA sink and source represents diminishing flow of isolates over time. 
The curly red and blue arrows represent circulation of MSSA and MRSA in the community and 
hospital setting. Over time, this would also diminish for MRSA. 
The Epidemiology of MRSA in Scotland 
65 
 
3.4.3 AMR in MSSA and MRSA 
In contrast to MSSA, antibiogram data showed that MRSA were commonly resistant 
to several antimicrobial classes. MRSA are likely better adapted to the hospital 
environment than MSSA and could therefore withstand hospital selection pressures. 
Harbouring many large and non-beneficial AMR genes in a low selection pressure 
environment has often been associated with reduced bacterial fitness, lessening the 
ability to spread [49]. On the other hand, in the hospital environment and under high 
selection pressures, resistance genes can be advantageous for MRSA and a 
population can be maintained since there is no shortage of potential hosts to colonise 
or infect.  
The MRSA population-level resistance to several antimicrobials (including 
erythromycin, clindamycin, kanamycin, tobramycin, neomycin, trimethoprim and 
tetracycline) fluctuated by about 10% over the study period. Fluctuations such as this 
can be caused by the frequent loss and gain or ‘shuffling’ of resistance genes carried 
on mobile genetic element (MGEs) which can be the result of multi-drug, 
intermittent and or changing antimicrobial usage with MGEs only becoming fixed in 
a population if they exhibit a selective advantage [34, 47]. It is assumed that once the 
selection pressure is switched off, then resistance will be lost as it is no longer 
advantageous to retain it and both mathematical and statistical modelling has shown 
that selection pressures can rapidly change the population-level of resistance over 
short time periods (within days or months) [127, 167-169]. However, co-selection of 
resistances due to genetic linkages of the resistance genes and compensatory 
mutations to counter the costs of carrying resistance genes, mean that resistance to an 
antimicrobial not currently in use may also be observed and may potentially take a 
long time to be lost [49]. This picture is further complicated since the cost of AMR 
can be a result of epistasis, environmental conditionals that affect fitness in different 
ways, or some mutations can be cost free [49]. Of note, this analysis showed that 
resistance to the antimicrobial mupirocin, which is of great interest since it is used to 
decolonise individuals harbouring MRSA, did not statistically increase over time. 
However, even when there are statistical differences and fluctuations in resistance 
levels, it is sometimes unclear what the biological implications are.    
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3.4.4 The community as a predominant source of MSSA and 
hospitals as a predominant source of MRSA 
While (especially) CC22 and CC30 MRSA may be well adapted to the hospital 
environment due to extended AMR, these clones may be less well adapted to the 
community environment than MSSA where the driving force of isolate reduction is 
the biological cost to the bacteria [49]. In the community where there are much lower 
selection pressures, it is assumed that MRSA isolates are burdened by large 
unnecessary resistance genes, e.g. are biologically less fit, and therefore spread less 
readily than MSSA. MRSA isolates would therefore be less likely to re-seed 
hospitals from the community ‘source’ (as is probable with MSSA) since it is 
hypothesised that MRSA cannot spread well in the community and moreover, with 
diminishing hospital colonisations and infections over time, fewer discharged 
infected or colonised patients re-enter the community. Therefore, it is unlikely that 
the community is the true ‘source’ and hospitals ‘sinks’ for MRSA isolates, but 
instead hospitals should be considered the ‘source’ and community the ‘sink’ for 
MRSA (Figure 3-10). However, with diminishing or in the absence of a constant 
flow of isolates from source-to-sink, the sink population cannot be sustained. With 
MRSA more at home in hospitals, it is therefore more likely to cause hospital-
acquired (i.e. infected in the hospital) than community–acquired infections 
(colonised or infected in the community), although community-acquired infections 
and infections that were hospital-acquired with a subsequent community onset, are 
also possible.   
Several epidemiological aspects point towards a predominant ‘community’ source 
for MSSA isolates and hospital source for MRSA. Firstly, in contrast to MRSA, the 
lack of resistance genes in the MSSA population suggests that MSSA is more 
adapted to a low selection pressure environment with penicillin resistance 
presumably exhibiting a current or historic selective advantage. Secondly, while both 
MSSA and MRSA occur in all hospital specialties, the data suggest that MSSA is 
more associated with accident and emergency, obstetrics and gynaecology, oncology, 
orthopaedics, and paediatrics than MRSA which are specialties that commonly serve 
outpatients and therefore (particularly accident and emergency) see a regular patient 
turnover. Many of the infections in these specialties could be community-associated 
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but with a hospital onset (CA-HO). This is often defined as a patient who is 
colonised or infected while in the community and whose infection develops and is 
diagnosed within 48 hours of admission. In contrast, MRSA is more associated with 
long-term care and high-risk patients in the specialties care of the elderly, high 
dependency units /intensive care units (HDU/ICU), and surgery. It is speculated that 
the majority of these infections would be hospital-associated, i.e. those that develop 
more than 48 hours post-admission. The specialties that were found to be more 
associated with MRSA in this thesis and also previously described as high risk for 
hospital-acquired infections including MRSA elsewhere [11, 170], are precisely the 
areas that have been subject to increased patient screening, intense cleaning and 
hygiene protocols in recent years. Therefore, this ‘niche’ for MRSA has been 
challenged and possibly destructed.  Thirdly, the abundance of non-CC22 / non-
CC30 ‘other’ clones in the MSSA population as compared with the hospital-
associated CC22 and CC30 clones again suggests that the community is a more 
common source for MSSA and the hospital a more common reservoir of MRSA. The 
NMS analysis described these differences well, but as was observed there is much 
overlap between the MSSA and MRSA populations and so the categorisation as 
highlighted by the NMS cannot be used as a tool to diagnose a bacteraemia patient. 
Therefore, microbiological analyses remain vital. 
3.4.5 Limitations 
There were several limitations in this study. While every effort was made to remove 
duplicated isolates from the same patient-visit, there may be further duplicates that 
were not excluded. For example, duplicates of patients who had a blood specimen 
taken on subsequent days during the same bacteraemia event, patients who had a 
blood specimen taken on the same day during the same bacteraemia event at two 
different locations (following hospital transfer), the same patient-event but with some 
laboratory or typing error in describing the isolate diagnostics or patient information, 
or some other reason. The unique patient identity number, community health index 
or ‘CHI’, is considered sensitive information and it was therefore removed before 
accessing these data which made accurately matching patients more challenging. In 
addition, there was missing information on specialty for 27.7% of MSSA isolates and 
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29.3% of MRSA isolates and furthermore, it cannot be confirmed that the specialty 
that the patient was in when the isolate was collected represented the specialty the 
patient was in when colonised or infected. This may be due to ‘boarding’ (within-
hospital movements) which is very common. In addition, not all hospital specialties 
are represented in the data which might indicate no cases or perhaps patients are 
moved when bacteraemia is suspected.  
3.4.6 To further this study 
To take this analysis further, it would be very useful to sequence the isolates 
discussed here using next generation sequencing (NGS) which would identify other 
genes of interest, e.g. other virulence determinants or heavy metal resistance 
determinants, as well as confirm spa type, AMR and toxin types. Bioinformatic and 
phylogenetic analyses could identify clusters and trace isolates as they move through 
and evolve in the hospital and community environments. If these data were 
combined, through large data linkage projects, to link data on patient demographic 
data, depravity scores, other disease statuses, number of hospital admissions, 
residency in care home, history of antimicrobial prescribing, history of surgery, 
disease outcomes/death for example; then a wide range of research question could be 
addressed.  
Similarly, to better understand the hospital and community dynamics of MRSA and 
MSSA populations, a screening study of individuals entering hospitals or a ‘capture-
recapture’ phylogenetic study to trace strains through the hospital and community 
environments and therefore test the source-sink hypothesis, may be interesting. The 
hypothesis could even be tested mathematically if, for example, the assumption that 
one third of all individuals entering the hospital are colonised is used and if certain 
information is available, e.g. the proportion of hospital arrivals that use alcohol gels 
to decolonise their hands, hospital cleaning rates, patient screening and 
decolonisation rates (which will vary between specialty), in-hospital patient-
movements (i.e. boarding), R0 for MSSA and MRSA, and potentially other factors.   
Furthermore, laboratory or modelling analyses may enable a more thorough 
understanding of the difference in fitness between MRSA and MSSA.  




For several decades, MRSA has been considered an important public health problem 
but the overall population-level burden has steadily decreased in recent years. On the 
other hand, MSSA continues to be a public health problem as it has always been and 
causes significantly more cases than MRSA. However, the difference is that MSSA 
more commonly causes shorter illnesses, lower individual-level burden, lower 
mortality rates and lower costs to the healthcare system than MRSA due to more 
extensive choices of successful drug treatments and perhaps other microbiological 
aspects of the bacterial populations that could not be shown here given the data 
availability (e.g. possible differences in virulence and pathogenicity).  
The results of this study suggest that there are epidemiological differences between 
MRSA and MSSA including antimicrobial resistance patterns and to some degree 
‘preferred’ niche. These differences may give some understanding as to why MRSA 
has declined but MSSA has persisted as a public health problem. Here, it is 
suggested that since MSSA is so abundant in the community (it is estimated that 
approximately one third of individuals are colonised with S. aureus) it will 
continuously bombard or re-infect the hospital environment via colonised or infected 
patients, members of staff or visitors. This is related to assumption that MRSA is 
more preventable than MSSA [171]. People shed MRSA and MSSA into the general 
environment [172] and the bacteria can survive on hospital items and furniture, 
survive in the environment including air, be passed by hands and spread to other 
people. Cleaning, antibacterial washes and antimicrobial use (if susceptible) will 
remove both MSSA and MRSA from people and the environment in hospitals, but 
MSSA will be replaced and re-introduced more quickly as it circulates in the 
community at higher levels.   
Screening and decolonisation of high-risk patients in high-risk specialties for MRSA 
may have had an important impact on MRSA declines. To reduce the number of 
MSSA bacteraemia cases in hospitals, it may also be important to begin screening 
and decolonising high-risk patients in high-risk specialties for MSSA. However, as 
with tackling MRSA, a multifactorial approach will likely be the way to reduce 
MSSA bacteraemia [127]. In addition, the importance of using alcohol gels to clean 
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hands on entry to hospitals for every visitor, staff member and patient should be 
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Antimicrobial resistance (AMR) is an historic, current and future issue associated 
with a range of microorganisms in a diversity of settings including hospitals, the 
community, livestock, the food chain and the environment [173]. The importance of 
this public health threat was recently highlighted in the WHO’s first global report on 
surveillance of antimicrobial resistance which advised that every country needed to 
do more to monitor the problem [18]. Since this publication, there has been much 
discussion on the possibility of a ‘post-antibiotic era’ and steps that could be taken to 
potentially mitigate this situation including an intergovernmental panel on AMR 
[22].  
Bacteria become resistant to antimicrobials as a result of point mutations in 
chromosomal genes, or through the acquisition of resistance gene-carrying mobile 
genetic elements [34]. Antimicrobial resistant mutants are selected for and survive in 
the presence of these drugs with resistance genes becoming fixed in populations 
when they show a strong selective advantage to the bacteria that outweighs any 
fitness cost [47]. Bacteria can be concurrently resistant to multiple antimicrobials and 
the proportion of a bacterial population that is resistant to any given substance is 
thought to reflect drug usage and selection pressures. For more background 
information on antimicrobial resistance in S. aureus, including selective pressures, 
molecular mechanisms of resistance, how MSSA becomes MRSA, see Chapter 1.1.2.  
Continued surveillance at the local, national and international levels can reveal the 
extent of AMR, and continued analysis of trends will indicate which antimicrobials 
are relevant and useful for the treatment or prevention of disease in particular 
situations or geographic regions. In the long run, this may highlight the need for 
better antibiotic stewardship, which in turn may help to reduce resistance rates and 
perhaps preserve the efficiency or longevity of these drugs.  Trends may also help to 
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evaluate the effectiveness of the UK Five Year Antimicrobial Resistance Strategy, 
which specifically focuses to; improve the knowledge and understanding of AMR; 
conserve and steward the effectiveness of existing treatments; and stimulate the 
development of new antibiotics, diagnostics and novel therapies [114].  
Staphylococcus aureus (S. aureus) is a universal coloniser of the skin that can cross 
skin and mucosal barriers to manifest as clinical disease. Following decades of 
widespread and intensive usage of topical, oral and intra-venous antimicrobials to 
treat S. aureus infections, AMR has become an established and ubiquitous problem 
in the treatment of infections caused by this microorganism. Resistance rates vary 
between countries, regions and even hospitals and this variation is thought to reflect 
drug usage and selection pressures. For more information on AMR in S. aureus, see 
Chapter 1.1.2.1, and for the history of AMR in S. aureus, see Chapter 1.1.2.2. 
Numerous clones of methicillin-resistant S. aureus (MRSA) circulate in the UK but 
two major epidemic clones have dominated in UK hospitals in recent decades 
namely EMRSA-15 (CC22, ST22 SCCmecIV) and EMRSA-16 (CC30, ST36 
SCCmecII) [131, 132]. Collectively, infections caused by these clones are reported to 
account for more than 85% of all MRSA infections [10, 126, 131, 133, 134]. As 
summarised by Wyllie et al [132], recent UK studies identified that these clones 
followed different epidemic curves. EMRSA-16 initially dominated the UK MRSA 
scene, peaked and then declined giving way to the rise and dominance of EMRSA-15 
[10, 126, 131, 133, 134]. For more information on the major UK clones and the 
Scottish perspective, see Chapter 1.1.7.2. 
The reasons behind this dominance shift and clone displacement are not established 
but it has been suggested that it could be linked to: increased fitness of EMRSA-15 
isolates which would enhance survival, spread and natural selection; interventions 
against MRSA that are particularly effective against EMRSA-16; microbial 
competition; and genetic differences  [135, 174]. In vitro studies have shown that 
EMRSA-15 isolates are fitter than EMRSA-16 isolates, evidenced by the ability of 
EMRSA-15 to grow independently in rich broth, competitiveness for nutrients in 
culture, and the ability to survive stress and desiccation [34, 174].   
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The objective of this study was to analyse temporal data of antimicrobial resistance 
for dominant clones in Scotland from 2003 to 2012 by examining resistance to 20 
individual antimicrobials, in particular, the proportion of clinical isolates with 
antimicrobial resistance and the diversity of resistance. An additional objective was 
to provide a comparison of clinical and non-clinical ‘screening’ isolates (as defined 
below). This was to determine if screening isolates are an appropriate proxy measure 
of clinical isolates that could identify the circulating clones and characteristics of 
those clones in the Scottish MRSA population.  
4.2 Materials and methods 
4.2.1 Data collection 
From 2003 to 2012, the Scottish MRSA reference laboratory (SMRSARL) collected 
MRSA isolates in the baseline survey ‘snapshot’. The programme was a volunteer 
referral system that requested diagnostic laboratories across Scotland to send all 
MRSA isolates received during a single specified week, four times per year, to 
SMRSARL. In this survey, MRSA isolated in hospitals and GP surgeries from all 
body sites, whether colonisation or infection, sent to any diagnostic laboratory for 
identification, were referred to the reference laboratory for further testing.  
Data from the snapshot database were divided into two time periods for the purpose 
of analysis: Time period A: 2003-2006 inclusive and Time period B: 2009-2012 
inclusive. Data collection was interrupted in 2007 and 2008, so data from this time 
frame were not included in this study. Isolates were designated as either clinical 
(wound swabs, blood, genital, respiratory or urine samples from infected individuals) 
or screening (nasal, throat, axilla and groin swabs (as previously described [10])). 
MRSA isolates from screening samples were analysed separately from clinical 
isolates. The two groups were compared to establish whether they differed in terms 
of antimicrobial resistance, and other epidemiological parameters discussed below, to 
determine if screening isolates were a useful representation of clinical isolates. While 
the main focus of this study was the similarities and differences between EMRSA-15 
and EMRSA-16, all other non-EMRSA-15 and non-EMRSA-16 clone types (herein 
collectively referred to as “others”) are discussed but no formal statistical analyses 
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were done on this group. Isolates were assigned to one of these three clonal ‘groups’ 
as per typing methods at the SMRSARL (see below). 
Table 4-1 shows the number of isolates and the percentage of total isolates 
represented by clones EMRSA-15, EMRSA-16 and non-EMRSA-15 and 
non-EMRSA-16 ‘others’ for each year and time period both clinical and screening 
isolates. There were totals of 1221 and 1055 clinical isolates in time periods A and B, 
respectively, and 467 and 1018 screening isolates in time periods A and B, 
respectively. Data collected included patient age, sex, NHS health board of origin, 
and specimen type (blood, genital, respiratory, wound, urine, and other). Isolates 
with specimen information missing were removed from the analysis (time period A: 
total = 99, of which, EMRSA-15 n=76, EMRSA-16 n= 21, others n= 2; time period 
B: total = 99, of which, EMRSA-15 n=134, EMRSA-16 n= 15, others n= 17). 
Table 4-1: Number of isolates and percentages of total isolates represented by clones by year for 























































EMRSA-15 266 220 205 288 250 281 191 157 1858 979 879 
EMRSA-16 62 44 51 57 32 22 19 11 298 214 84 
‘Others’ 4 10 3 11 15 17 24 36 120 28 92 
Total 332 274 259 356 297 320 234 204 2276 1221 1055 
Screening isolates 
EMRSA-15 60 73 105 121 152 308 225 150 1194 359 835 
EMRSA-16 22 22 17 24 24 40 19 7 175 85 90 
‘Others’ 2 4 9 8 7 22 32 32 116 23 93 
Total 84 99 131 153 183 370 276 189 1485 467 1018 
 
4.2.2 Isolate classification and antimicrobial testing  
Briefly, isolates received from diagnostic laboratories by the SMRSARL were 
confirmed as S. aureus using a latex slide agglutination test
 
(Staphytect Plus©), a 
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rapid agglutination test (PASTOREX© Staph-plus kit), a tube coagulase test, and a 
PCR testing for the nuc gene. PCR testing for the mec gene was carried out for 
identification of MRSA, and the Vitek®2 gram positive ID card for species-level 
organism identification. Details are fully described in Chapter 3.2.2. 
Isolates confirmed as S. aureus were typed as EMRSA-15, EMRSA-16 or ‘others’ 
following standard procedures at the SMRSARL using a combination of pulsed-field 
gel electrophoresis (PFGE), PCR ribotyping, biotyping (profiling based on a 
combination of isolate pigmentation, urease and tween tests), sequence typing (ST) 
(seldom carried out) and more recently, spa typing (seldom carried out in time period 
A).  
Antimicrobial testing was carried out using an automated method and following 
standard operating procedures for in vitro testing of bacterial susceptibility to 
antimicrobial agents using Vitek® sensitivity cards. Susceptibility to the following 
antimicrobials was tested consistently over the study period; ceferoxin/cefoxitin 
(Cx), chloramphenicol (Ch), ciprofloxacin (Cp), clindamycin (Cl), erythromycin 
(Er), fusidic acid (Fd), gentamicin (Gn), kanamycin (Km), linezolid (Lz), 
methicillin/oxacillin (Mt), mupirocin (high level) (Mp), neomycin (No), penicillin 
(Pn), rifampicin (Rf), streptomycin (St), sulphamethoxazole (Su), teicoplanin (Tc), 
tetracycline (Te), tobramycin (Tb), and trimethoprim (Tr). Resistance susceptibility 
to daptomycin (Dp), moxifloxacin (Mx), quinupristin (Qp), togamycin (Tg) and 
vancomycin (Va) was also tested for but not consistently over the whole study 
period. Therefore, these four antimicrobials were not included in the main analyses.  
Testing for the presence of Panton-Valentine Leukocidin toxin gene (pvl) and toxic 
shock syndrome toxin gene (tst) was carried out using polymerase chain reaction 
(PCR) as is standard procedure at SMRSARL. 
4.2.3 Data management and statistical analysis 
Unless otherwise stated all analyses refer to clinical isolates. 
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4.2.3.1 Background epidemiology  
The percentage of total isolates that were EMRSA-15, EMRSA-16 or ‘others’, by 
year and time period, were described. This confirmed EMRSA-15 as the dominant 
clone in the Scottish MRSA population. Differences in the percentage of isolates that 
were EMRSA-15 and EMRSA-16 across time periods were examined using a 
General Linear Model (GLM). Descriptive analyses of age, sex, clinical specimen 
(i.e. blood, genital, respiratory, swab or urine) and presence of toxin genes pvl and tst 
were also conducted. To investigate if a patient’s age (log transformed) varied by 
patient sex, clone, and/or time period, the following linear regression model was 
used: (log(𝑎𝑔𝑒) ~𝑠𝑒𝑥 ∗ 𝑐𝑙𝑜𝑛𝑒 ∗ 𝑡𝑖𝑚𝑒_𝑝𝑒𝑟𝑖𝑜𝑑). Associations between clinical 
specimen type and clone were examined using stratified 2𝑥2 tables. As a result of 
insufficient samples for time period A, the proportions of isolates that tested positive 
for the pvl or tst toxin genes were analysed for time period B only, and spa typing 
was also only available for time period B. Only descriptive analyses were conducted 
for ‘others’ as, especially in time period A, they were too few in number, and too 
heterogeneous, encompassing several MLST / spa-types.  
Unless otherwise stated, all analyses were carried out in R (version 3.1.2) [154]. 
Statistical significance was set at p<0.05. 
4.2.3.2 Antimicrobial Resistance  
4.2.3.2.1 Univariate analysis of single antimicrobials 
The percentage of clinical EMRSA-15, EMRSA-16 and ‘others’ resistant to 20 
antimicrobials was calculated for both time periods A and B. This information was 
displayed on radar charts. Pearson’s chi square tests or Fisher’s exact tests were used 
to assess the significance of changes in percentage over time for bacterial 
populations and time. The choice of Pearson’s chi square tests or Fisher’s exact tests 
was dependent on sample sizes; i.e. where ≤5 counts appeared in one box of the 2x2 
table, then the Fisher’s exact test was used, where all counts in the 2x2 table where 
>5, then the Pearson’s chi square test was used. Difference between clinical and 
screening isolates were plotted on radar charts and analysed by Pearson’s chi-square 
tests or Fisher’s exact tests.  
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4.2.3.2.2 Multivariate analysis using Nonmetric Multidimensional Scaling  
To further investigate differences between EMRSA-15 and EMRSA-16 isolates, a 
data reduction and nonparametric ordination technique called nonmetric 
multi-dimensional scaling (NMS) analysis was carried out. NMS is appropriate for 
data that are non-normal and does not have the assumption of linear relationships 
between variables that is common to other data reduction techniques. The analysis 
aims to visualise the level of dissimilarities between isolates in an N-dimensional 
space or scatterplot using a ranked distance matrix that was calculated with a 
Euclidian distance measure. The dimensionality of the plot was determined by 
plotting an inverse measure of fit (known as stress) to the number of dimensions with 
the optimal dimensionality being the number of dimensions with the lowest stress. 
This optimisation strategy aims to create a configuration which represents the 
smallest departure from monotonicity in the relationship between distance in the 
original space and that in the reduced ordination space. Five hundred iterations were 
used for each NMS run, using random starting coordinates. Several NMS runs were 
performed to ensure that the solution was stable and represented a configuration with 
the best possible fit. 
The NMS was performed using two matrices created from the data; matrix 1 and 
matrix 2. Information on antimicrobial resistance (binary (resistant versus not, 1/0)) 
for antimicrobials with variation greater than 5% (i.e. more than 5% of isolates 
resistant or more than 5% of isolates not resistant): including Cl, Cp, Er, Gn, Km, 
No, Tb, Te, Tr and removing Mt, Pn, Cx, Gn, Mp, Rf, Fd, Tc, Su, St, Lz, Ch) was 
included in matrix 1 and used to perform the NMS.  
To identify variables that were associated with either group of interest (i.e. EMRSA-
15, EMRSA-16), matrix 2 was superimposed on the ordination to create a joint plot 
(radiating lines). The direction of the lines indicates either a positive or negative 
relationship with an Axis and the variables of matrix 2, and (if the variable is 
continuous) the length shows the strength of the correlation on that axis. The 
ordination was rotated in order to ensure maximum separation of the groups of 
interest (EMRSA-15, EMRSA-16) along Axis 1. Variables in matrix 2 included 
information on antimicrobial resistance, antibiogram length (see below), isolate 
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pigmentation, urease test result, clinical specimen type, patient gender and age, NHS 
Health Board, year and time period. Multi-response Permutation Procedures (MRPP) 
analysis was performed to test the hypothesis of no difference between the two 
groups, EMRSA-15 and EMRSA-16, and the association of variables with either 
group. The NMS was performed in PC-ORD version 6.03 (MJM software Design, 
Gleneden Beach, OR). Scatterplots and 80% confidence ellipses were drawn to 
visualise the results.  
4.2.3.3 Antibiogram lengths 
An antibiogram is the combination or string of antimicrobials to which an isolate is 
resistant, e.g. if an isolate is resistant to penicillin, methicillin and erythromycin, the 
antibiogram is PnMtEr and the antibiogram length is 3. Antibiogram length is the 
total number of antimicrobials to which an isolate shows phenotypic resistance. 
Student’s t-tests were used to assess if there were significant differences in mean 
antibiogram lengths. A Student’s t-test was used, as the central limit theorem states 
that for large sample sizes (n>30, as a rule of thumb) the sample mean will be 
approximately normally distributed. Antibiogram length was also included in the 
aforementioned NMS analysis as an overlay from matrix 2.  
4.2.3.4 Antibiogram diversity  
Clinical and screening isolates were analysed separately. Four ecological diversity 
indices related to Rényi’s measures of generalised entropy were used to compare 
antibiogram diversity of EMRSA-15 and EMRSA-16 for both time periods A and B. 
This method, with specific reference to antimicrobial resistance, was described by 
Mather et al [175].  
The exponential of Rényi's entropy (Dα) estimates the effective number of species (or 
in this case, antibiograms) where α represents different weights of and adjusts for the 
number of antibiograms (richness) and relative abundances of antibiograms. Briefly, 
the diversity indices compared were: antibiogram richness (AR), a count of 
antibiograms (which ignores the relative abundance or weight of each antibiogram, 
e.g. rare and common antibiograms are considered equal), D0; Shannon entropy 
(SEn), the probability of any two isolates drawn at random from an infinitely large 
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population being the same antibiogram, log(D1); Simpson diversity (SD), the relative 
abundance of each antibiogram, 1/D2; and Berger-Parker (BP), the proportion of the 
most common antibiogram in the sample, 1/D∞. Owing to differences in sample sizes 
between EMRSA-15 isolates, EMRSA-16 isolates and time periods, resampling of 
99 isolates (this was the sample size of the smallest clinical subset, EMRSA-16 time 
period B) and 85 isolates (the sample size of the smallest screening subset, 
EMRSA-16 time period A) was carried out 1000 times (bootstrapped) within the 
other respective subsets. This sampling ‘with replacement’ method provided a mean 
and confidence intervals (CIs) for the diversity measures of EMRSA-15 in time 
periods A and B and of EMRSA-16 in time period A for clinical isolates, and same 
for diversity measures of EMRSA-15 in time periods A and B, and of EMRSA-16 in 
time period B for screening isolates. This allowed diversity measures of clones to be 
compared. This method was described by Mather et al [175]. This information is 
given in a table and in a diversity figure in which each index is represented along the 
x-axis and the effective number of antibiograms is on the y-axis. ‘Others’ were not 
included in this analysis since the sample sizes in time period A for clinical (n=28) 
and screening (n=23) isolates were the lowest of all clone-time period groups. 
Sampling with replacement using these low sample sizes would have resulted in 
wide, confidence intervals for the ‘other’ clones and uncertain conclusions. 
4.3 Results 
4.3.1 Background epidemiology of clinical isolates 
Over the study period, there were two major epidemic clones of MRSA in Scotland; 
EMRSA-15 (CC22, ST 22 SCCmecIV) and EMRSA-16 (CC30, ST36 SCCmecII). 
The number of EMRSA-15 isolates received over the course of the study was 4.6 
times higher than EMRSA-16 in time period A and 10.5 times higher in time period 
B (Table 4-2 and Figure 4-1). Together, EMRSA-15 and EMRSA-16 comprised 
97.7% of all clinical MRSA isolates in Scotland in time period A and 91.3% in time 
period B. Non-EMRSA-15 / non-EMRSA-16 spa types corresponding to sequence 
types including but not limited to ST1 (t127), ST5 (t002), ST8 (t008), ST80 (t044), 
ST88(t186), and ST239 (t037) made up the remainder. Appendix Table 1 lists all spa 
types associated with EMRSA-15, EMRSA-16 and ‘others’ for time period B. 
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The percentage of all isolates that were EMRSA-15 did not significantly change over 
time (p>0.05), while the percentage of isolates that were EMRSA-16 significantly 
decreased over time (p=0.002). The percentage of ‘others’ increased over time 
(p=0.01) from 1.2% in the first year of the study to 17.6% in the final year. While 
t002 was the most common spa type associated with ‘others’ (time period B, n=14), 
it was not possible to conclude whether this clone could emerge as the next ‘major’ 
clone as there was insufficient information from time period A. Figure 4-1 shows 
general trends and percentage of isolates that were EMRSA-15, EMRSA-16, and 
‘others’ by year.  
The mean patient ages for EMRSA-15 (71.2 years) for both time periods were the 
highest, followed by EMRSA-16 (66.8 years) and then ‘others’ (49.7 years) (Table 4-
3). There were significant differences in the mean age of patients between EMRSA-
15 and EMRSA-16 (p=0.01), EMRSA-15 and ‘others’ (p<0.001), and EMRSA-16 
and ‘others’ (p<0.01) for time period A, and between EMRSA-15 and EMRSA-16 
(p=0.02), EMRSA-15 and ‘others’ (p<0.0001), and EMRSA-16 and ‘others’ 
(p<0.0001) for time period B.  No clone differed in mean age between time periods 
(i.e. no difference between EMRSA-15 time period A versus B, p>0.05). The 
proportion of EMRSA-15 isolates from males was statistically significantly lower 
than that of EMRSA-16 for time period B (49.5% and 64.3% respectively, p=0.01) 
(Table 4-3). There were no other significant differences in the proportion of isolates 
from males between clones and time periods. In investigating the relationship 
between patient’s (log) age and sex, clone, and/or time periodlog(𝑎𝑔𝑒) ~𝑠𝑒𝑥 ∗
𝑐𝑙𝑜𝑛𝑒 ∗ 𝑡𝑖𝑚𝑒_𝑝𝑒𝑟𝑖𝑜𝑑), no interaction was found to be significant (p>0.05), 
indicating that there is no difference in the age with respect to sex, clone and time 
period.  
Table 4-4 lists the number of EMRSA-15, EMRSA-16 and ‘others’ from each 
clinical specimen for time periods A and B. Of all clinical EMRSA-15, EMRSA-16 
and ‘others’, the majority of specimens (68%, n=1552/2276) were from wound /skin 
swabs (other than for screening). Overall, urine and respiratory specimens comprised 
approximately 12% each and genital and blood comprised 4% of total isolates. After 
wound /skin swabs, the next most common known specimen type for EMRSA-15 
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time period A (13.9%) and B (14.2%) respectively was urine, for EMRSA-16 time 
period A (19.2%) and B (15.5%) was respiratory, and for ‘others’ time period A 
(10.7%) was respiratory and B (7.6%) was genital. There were no or marginal 
statistically significant differences in the proportions of each isolates from each 
clinical specimen for EMRSA-15 between time period A and B (p=0.05) and 
EMRSA-16 between time period A and B (p>0.05). There were statistically 
significant differences in the proportions of a clone from each clinical specimen 
between EMRSA-15 and EMRSA-16 for time period A (p<0.01) and time period B 
(p<0.0001). Blood specimens, which indicate the disease outcome with the highest 
morbidity and mortality, i.e. bacteraemia or bloodstream infections (BSI), comprised 
less than 5.2% of infections for each clone and time period but were highest for 
EMRSA-16 time period A (5.1%).  
Associations between specimen type and clone were examined using stratified 2x2 
tables (Table 4-4B). For all clinical specimen types except wound /skin swabs there 
was no difference across time frames (p>0.05) and therefore a common odds ratio 
was generated. Respiratory samples were 1.74 times more likely to be EMRSA-16 
than EMRSA-15 (p<0.0001). Urine and genital samples were more likely to be 
EMRSA-15 than EMRSA-16. Blood samples were equally likely to be EMRSA-15 
or EMRSA16 (p=1.0). There were differences across the time periods with respect to 
wound /skin swabs specimens. In time period A there was no difference between 
EMRSA-15 and EMRSA-16, however, in time period B wound /skin swabs 
specimens were almost 2x more likely to be EMRSA-16 than EMRSA-15 (odds ratio 
1.95 (CI: 1.11-3.61)).  
In time period A, only 1.6% and 0.2% of total clinical isolates were tested for the 
presence of the pvl and tst genes, however in time period B 98.7% of isolates were 
tested for both toxins. Therefore, only isolates from time period B are examined in 
terms of toxin genes. For EMRSA-15, EMRSA-16 and ‘others’, the percentages of 
isolates that were tested for pvl  presence were 98.6%, 97.6%, and 100%, and the 
percentage with the pvl gene present was 1.2%, 9.8%, and 19.6%. For EMRSA-15, 
EMRSA-16 and ‘others’, the percentages of isolates tested for tst presence were 
98.6%, 97.6%, and 100%, and the percentages with the tst gene present were 0.5%, 
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94.4%, and 4.3%. There were statistical differences in the proportions with pvl toxin 
and tst toxin with EMRSA-16 having higher proportions of both pvl and tst gene than 
EMRSA-15 (both p<0.0001), and higher odds of a pvl positive (odds ratio =0.1) or 
tst positive (odds ratio =0.0003) isolate being EMRSA-16 than EMRSA-15. 
Table 4-2: Percentages of clinical isolates represented by each clone type, by year and time 
period. 
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EMRSA-16 
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‘Others’ 
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Figure 4-1: The percentage of clinical MRSA isolates that represented EMRSA-15, 16, and 
‘others’ by year and time period. 
  
Time periods A and B are highlighted with parenthesis. 
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Table 4-3: Age and sex of individuals that clinical isolates were taken from. 
 Age Sex 
Clone and time 
period 


























































‘Missing’ indicates where there are missing data for individuals. The denominator used to calculate ‘Proportion 
Male’ was number of males + number of females with missing excluded. 
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SSTI = Skin and soft tissue infections 
 




4.3.2.1 Levels and patterns of AMR – Univariate analysis 
The percentage of EMRSA-15 (Figure 4-2A), EMRSA-16 (Figure 4-2B) and ‘others’ 
(Figure 4-2C) resistant to 20 consistently tested antimicrobials were compared for 
two time periods. All EMRSA-15 isolates were resistant to methicillin (by definition, 
all are MRSA) and penicillin (Figure 4-2A). Resistance to cefoxitin and 
ciprofloxacin significantly decreased in time period B from 99.3% to 96.8% 
(p<0.001) and 99.8% to 98.4% (p<0.01), respectively. Resistance significantly 
increased for clindamycin from 5.1% to 9.0% (p<0.01), kanamycin from 1.5% to 
7.7% (p<0.0001), trimethoprim from 14.9% to 20.4% (p<0.01), gentamicin from 
1.5% to 5.4% (p<0.0001), mupirocin from 0.3% to 1.8% (p<0.01) and tetracycline 
from 4.9% to 9.2% (p<0.001). Of the remaining antimicrobials, with the exception of 
erythromycin, resistance to all was less than 1.5% in time period A and less than 
2.5% in time period B. There were no significant differences between the time 
periods for any of these antimicrobials. 
All EMRSA-16 isolates were resistant to methicillin and penicillin (Figure 4-2B). In 
time period A, >90% of isolates were resistant to cefoxitin (100%), ciprofloxacin 
(100%), erythromycin (99.1%), and clindamycin (90.6%), and resistance to 
ciprofloxacin and erythromycin statistically significantly declined by 10.7% and 
8.5% respectively in the second time period (p<0.0001 and p<0.001). In time period 
A, between 80-90% of isolates were resistant to kanamycin (86.4%), tobramycin 
(85.1%) and neomycin (83.6%) but this fell to 63.1%, 71.2% and 57.5% respectively 
in the second time period (p<0.0001, p=0.01, and p<0.0001 respectively). The 
greatest increase in resistance was observed in the second time period for tetracycline 
which increased from 3.3% to 22.6% (p<0.0001). Resistance to trimethoprim 
(A=38.8%, B=42.9%), gentamicin (A=22.4%, B=29.8%) and mupirocin (A=16.4%, 
B=27.4%) was moderate in both time periods but did not significantly change. 
Resistance to all other antimicrobials was between 0% and 2.4% in time period A, 
and 0% and 4.8% in time period B and there were no significant differences between 
the time periods for any of these other antimicrobials.   
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Out of those 20 consistently tested antimicrobials, resistance to two antimicrobials 
declined and resistance to six antimicrobials increased among EMRSA-15, and 
resistance to five antimicrobials declined and to one antimicrobial increased among 
EMRSA-16. Some additional antimicrobials were also tested for (i.e. moxifloxacin, 
quinupristin, vancomycin, togamycin, and daptomycin) albeit not consistently across 
the study period. Resistance to moxifloxacin was only tested in time period A and for 
EMRSA-15 (n=711) and EMRSA-16 (n=152) isolates, 2.4% and 2.0% of isolates 
respectively were resistant. No isolates were resistant to quinupristin (EMRSA-15, 
time period A, n=711; EMRSA-16, time period A, n=152), vancomycin 
(EMRSA-15, time period B, n=879; EMRSA-16, time period B, n=84), or togamycin 
(EMRSA-15, time period B, n=879; EMRSA-16, time period B, n=84). Resistance to 
daptomycin was only tested in 2011 and 2012 for EMRSA-15 (n=166) and 
EMRSA-16 (n=11) isolates, no isolates were resistant. 
For non-EMRSA-15 / non-EMRSA-16 ‘others’, it is difficult to determine a pattern 
in resistance since the group contained several different clones (Figure 4-2C). Aside 
from resistance to mupirocin and chloroimphenicol, which slightly increased (but not 
significantly), resistance to all other antimicrobials declined or did not change 
between time periods A and B. Resistance to clindamycin fell by 23.8% (p<0.01), 
kanamycin by 29.2% (p=0.01), tobramycin by 30.1% (p<0.01), neomycin by 40.6% 
(p<0.001), trimethoprim by 31.2% (p<0.01), gentamicin by 22.7% (p=0.01), 
tetracycline by 22.7% (p=0.01), sulphamethoxazole by 40.7% (p<0.0001) and 
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Figure 4-2: Radar chart of antimicrobial resistance in (A) EMRSA-15, (B) EMRSA-16 and (C) 
‘others’ for time periods A and time period B. 
Percentages shown represent the percentage of each clone population with each time period that was resistant to 
each antimicrobial for time periods A and B. 
Orange / black asterisks indicate significant increase / decrease in resistance (significant if p≤0.05). 
The following abbreviations are used to indicate each antimicrobial; cefoxitin (Cx), chloramphenicol (Ch), 
ciprofloxacin (Cp), clindamycin (Cl), erythromycin (Er), fusidic acid (Fd), gentamicin (Gn), kanamycin (Km), 
linezolid (Lz), methicillin (Mt), mupirocin (Mp), neomycin (No), penicillin (Pn), rifampicin (Rf), streptomycin 
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4.3.2.2 Multivariate MDS analysis 
The result of the NMS analysis (Table 4-5, Figure 4-3A, B, C), which only included 
EMRSA-15 and EMRSA-16 isolates, was a two-dimensional solution that explained 
a total of 84.2% of the variation in the data. Additional dimensions provided only a 
slight (non-significant, p>0.05) improvement in fit. The first axis, shown on the joint 
plot and which was rotated to maximise the difference between EMRSA-15 and 
EMRSA-16, described 74.5% and Axis 2 only 9.7% of the variation in the data 
(Figure 3A).  
EMRSA-15 isolates were associated with a positive urease test, cream or white 
isolate pigmentation, shorter antibiogram lengths, urine and genital specimens, and 
sensitivity to clindamycin, erythromycin, kanamycin, neomycin and tobramycin on 
Axis 1. EMRSA-16 isolates were associated with a negative urease test, yellow 
isolate pigmentation, longer antibiogram lengths, respiratory specimens, the presence 
of tst toxin genes and resistance to kanamycin, neomycin, tobramycin, clindamycin, 
and erythromycin on Axis 1(Figure 3A). EMRSA-15 and EMRSA-16 also differed 
by resistance to trimethoprim and gentamycin on Axis 2 (Figure 3A). Isolate pigment 
and the urease test, which are used as diagnostic tools to broadly distinguish between 
EMRSA-15 and EMRSA-16 isolates, were shown to differentiate between the two 
groups effectively. Results from the NMS support and validate the results shown in 
Figure 2. 
In the analysis, a positive Tween test result, the presence of pvl toxin genes, patient 
age and sex, wound/skin swabs and blood specimens, and resistance to ciprofloxacin 
and tetracycline were common to both groups (i.e. EMRSA-15 and EMRSA-16). 
Although both groups (EMRSA-15 and EMRSA-16) shared some properties (as seen 
by overlapping confidence ellipses), the centroid points (as shown by a cross) for 
each group are distinct (Figure 3B). Furthermore, MRPP was performed to test the 
null hypothesis of no difference between EMRSA-15 and EMRSA-16 (p<0.0001). 
Results (Table 4-5) show that the null hypothesis can be rejected since the two 
groups occupy different regions of space as shown by the strong chance-correlated 
within-group agreement (A) and significance level (p). 
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Figure 3C shows EMRSA-15 and EMRSA-16 for both time periods. The close 
proximity of the centroids for EMRSA-15 for both time periods indicates that there is 
little change between the time periods, and in contrast the centroids for EMRSA-16 
for both time periods are more distant indicating change between the time periods. 
Furthermore, the confidence ellipse for EMRSA-16 time period B encompasses all 
other clone-time periods, again highlighting a diverse antibiogram and small sample 
size.  
 
Table 4-5: Results of NMS. 







Number of iterations 132 
Orthogonality , Axis pair 1 vs 2        
                                                                              r          0.0000 
                                                        % =100(1- r
2
) 100 







% of variation explained 
Axis 1 74.5 
Axis 2 9.7 
Total 84.2 
a
 <5, excellent, no prospect of misinterpretation; 5-10  good , no real risk of drawing false inferences; 
10-20 fair, provides a useable picture; >20 poor, dangerous to interpret; 35-40 random placement of 
samples (10) 
b
 better-than-random solution 
c
 chance-corrected within group agreement: a=1 all identical within group 
d
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Figure 4-3: Results of NMS – 2-dimentional ordination graphs.  
(A) EMRSA-15 versus EMRSA-16 with joint plot 
 
Key: A_length = antibiogram length, Antimicrobial abbreviations; ciprofloxacin (Cp), clindamycin (Cl), 
erythromycin (Er), gentamicin (Gn), kanamycin (Km), neomycin (No), tetracycline (Te), tobramycin (Tb), 
trimethoprim (Tr), toxin genes: pvl and tst, specimen types: blood, genital, respiratory, urine, wound/skin swab.  
(B) EMRSA-15 versus EMRSA-16 with confidence ellipses 
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(C) EMRSA-15 (time period A and B) versus EMRSA-16 (time period A and B) 
 
4.3.2.3 Antibiogram length 
Mean antibiogram length of EMRSA-15 was 5.0 in time period A and 5.2 in time 
period B (Table 4-6). Among clinical EMRSA-15 isolates, the antibiogram length 
was 5 or shorter among in 79.8% isolates from time period A and 73.2% from time 
period B. By contrast, 0.5% and 9.5% (time period A and time period B respectively) 
of EMRSA-16 isolates had an antibiogram length of 5 or below. The distribution of 
antibiogram lengths was strikingly different between the EMRSA-15 and 
EMRSA-16 populations (Figure 4-4A, Table 4-6). These results are consistent with 
those shown in Figure 4-2. Figures 4A and B show that the shortest and longest 
antibiogram lengths for each clone and for both time periods were not common (i.e. 
the maximum length of 10 occurs only once). 
The mean antibiogram lengths of EMRSA-15 and EMRSA-16 were significantly 
different (student’s t-test, time period A: p< 0.0001, time period B: p< 0.0001). The 
mean antibiogram lengths of EMRSA-15 in time period A and B were significantly 
different (increasing from a mean antibiogram length of 5.0 to 5.2, p<0.0001). The 
mean antibiogram lengths of EMRSA-16 in time period A and B decreased from a 
mean antibiogram length of 9.3 to 8.7 but this was not significantly different 
(p>0.05). A summary of the distribution of antibiogram lengths is given in Table 4-6. 
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The NMS analyses shown above (Figure 4-3) further highlight that antibiogram 
length is a key factor in discriminating between EMRSA-15 and EMRSA-16 
isolates. However, it cannot be used as a diagnostic tool since both clones can have 
wide, overlapping distributions of antibiogram length (Table 4-6). 
Table 4-6: Summary of antibiogram lengths of clinical isolates. 







Mean 3rd Qu. Max. 
EMRSA-15: A 2 4 5.0 5.0 5 10 
EMRSA-15: B 3 4 5.0 5.2 6 12 
EMRSA-16: A 5 9 9.0 9.3 10 13 
EMRSA-16: B 3 6 9.0 8.7 11 13 
‘Others’: A 3 5 7.0 8.4 13 14 























Figure 4-4: The frequency distributions of antibiogram length in time periods A and B. 
Distribution of frequencies for antibiogram lengths of (A)  EMRSA-15 isolates (red) and EMRSA-16 
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4.3.2.4 Antibiogram diversity 
Antibiogram diversity of EMRSA-15 and EMRSA-16 was compared within the two 
time periods by calculating four diversity indices; antibiogram richness (AR), 
Shannon entropy (SEn), Simpson diversity (SD) and Berger-Parker (BP). Due to 
differences in sample sizes, data were adjusted using EMRSA-16 time period B as 
the reference clone – time period since its sample size was the smallest, and re-
sampling in each of the other clone and time periods made indices comparable. This 
created measures of the expected diversity (rather than the observed). 
Each of the four diversity indices suggested that antibiogram diversity was higher 
among EMRSA-16 than EMRSA-15 within both time periods (Figure 4-5). In both 
clones, diversity was higher in time period B than time period A but not significantly 
so (p>0.05). Table 4-7 shows the mean measures of expected antibiogram diversity, 
adjusted for by sample size. Since the proportion of EMRSA-15 isolates resistant to 
individual antimicrobials and the mean antibiogram length of EMRSA-15 isolates 
were lower than for EMRSA-16 isolates (Figures 4-2, 4-3 and 4-4), it was expected 
that the antibiogram diversity of the EMRSA-15 population would be lower since 
fewer antimicrobial combinations were possible.  
The most common antibiogram (represented by the diversity index Berger-Parker) of 
EMRSA-15 isolates in both time periods was ‘PnMtCxErCp’ which represented 
49.0% and 38.0% in time periods A and B respectively. The dominance of this single 
antibiogram reflects the relative stability of antimicrobial resistance patterns for 
EMRSA-15 (the proportions resistant didn’t vary greatly over time as seen in Figure 
4-2 and 4-3, and the clone has similar mean antibiogram lengths for two time 
periods, Figure 4-4). This antibiogram of EMRSA-15 isolates was found once in the 
EMRSA-16 population in 2003. The most common antibiogram of EMRSA-16 in 
time period A was ‘PnMtCxErClCpKmNoTb’ which represented 33.0% of all 
EMRSA-16 isolates and ‘PnMtCxErClCp’ in time period B which represented 29.0% 
of all EMRSA-16 isolates (Table 4-7). This captures the reduction in the level of 
resistance to kanamycin, neomycin and tobramycin as seen in Figure 4-2. The lower 
Berger-Parker estimates for EMRSA-16 isolates indicate that the EMRSA-16 
population was dominated by a higher number of antibiograms than the EMRSA-15 
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population for both corresponding time periods. There were no EMRSA-15 isolates 
with the most common EMRSA-16 antibiogram in time period A, but the most 
common antibiogram of EMRSA-16 appeared every year in the EMRSA-15 
population in time period B. There were no isolates in either time period or either 
clone that were resistant to all 20 antimicrobials and only few (≤5) had antibiograms 
of the observed maximum length (Table 4-8, ‘others’ also shown). In time period A, 
three antibiograms were common to EMRSA-15 and EMRSA-16, and in time period 
B, four antibiograms were common to these two clones (Table 4-9).    



























































84 29* 2.84* 0.09* 0.29* PnMtCxErClCp 
*= reference clone-year and therefore no confidence intervals are given.  
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Figure 4-5: Expected diversity of antibiograms. 
Diversity of the effective number of antibiograms calculated by four different diversity indices. These 
indices occurs along the x-axis.  The solid curves (red, brown, blue, and black) represent diversity of 
EMRSA-15 and EMRSA-16 for both time periods. Shading around curves represents confidence 
intervals (no CIs for EMRSA-16 time period B as this was the reference clone-year). Key to diversity 
indices:  Antibiogram richness (AR), Shannon entropy (SEn), Simpson diversity (SD) and Berger-
Parker (BP). 
 










EMRSA-15: A 10 ‘PnMtCxErGnFdCpTrKmTb’ 2  
EMRSA-15: B 12 
‘PnMtCxErClGnCpTrTeMpKmTb’ 1 
‘PnMtCxErClGnFdCpTrTeMpKm’ 1 
EMRSA-16: A 13 
‘PnMtCxErClGnCpTrTeMpKmNoTb’ 6 
‘PnMtCxErClGnCpTrRfMpKmNoTb’ 1 




Others: A 14 ‘PnMtCxErGnCpTrSuTeKmStNoTb’ 3 
Others: B 11 
‘PnMtCxErClGnCpSuKmStTb’ 1      
‘PnMtCxErClGnCpTrMpKmTb’ 1      
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Table 4-9: Shared antibiograms between clones. 
Antibiograms of both EMRSA-15 and EMRSA-16 populations are listed with the number of 
observations (n) and the percentage of each clone (%). 
 
 
4.3.3 Clinical isolates versus screening isolates 
Overall, clinical and screening isolates were very similar. The screening isolates 
followed a similar pattern to the clinical isolates with EMRSA-15 being the 
dominant clone. Overall, EMRSA-15, EMRSA-16, and ‘others’ made up 80.4%, 
11.8% and 7.8% of all isolates, respectively. In time period A, EMRSA-15, EMRSA-
16, and ‘others’ made up 76.9%, 18.2% and 4.9% of all isolates, respectively, and 
82.0%, 8.8% and 9.2% of all isolates (respectively) in time period B (Table 4-10 and 
Figure 4-6). There was a significant difference in the percentages between clinical 
and screening isolates in time period A (p=0.01) but not time period B (p>0.05). 
There were no statistical differences in the age of patients from whom isolates were 
obtained between clinical and screening isolates within each clone and time period 
(p>0.05 in each case). There were no statistical differences in the sex of patients 
between clinical and screening isolates within each clone and time period (p>0.05 in 
each case) except in time period A (p<0.01) when the proportion of isolates from 
males which were EMRSA-16 was higher in screening samples (73.5%) compared 
with clinical samples (56.1%).  
 EMRSA-15 EMRSA-16 
Time 
period 
Antibiogram n % n % 
A 
‘PnMtCxErClCp’ 41 4.7 20 9.3 
‘PnMtCxErClCpTr’ 7 0.8 2 0.9 
‘PnMtCxErCp’ 477 54.3 1 0.5 
B 
‘PnMtCx’ 8 0.9 7 8.3 
‘PnMtCxErClCp’ 44 5.0 16 19.0 
‘PnMtCxErClGnCpTrKm’ 1 0.1 1 1.2 
‘PnMtCxErClGnCpTrTeMpKmTb’ 1 0.1 1 7.1 
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For EMRSA-15, EMRSA-16 and ‘others’ in time period B, the percentage of 
screening isolates with the pvl gene present was 0.36%, 2.2%, and 12.9%, 
respectively, and the percentage of screening isolates with the tst gene was 0.12%, 
87.8% and 5.4%, respectively. There was no difference between clinical and 
screening isolates for either toxin (p>0.05). 
There was a statistical difference between the antimicrobial resistances of screening 
and clinical isolates for: trimethoprim (EMRSA-15 time period A, p<0.0001 
resistance in screening isolates higher, EMRSA-16 time period A, p<0.02, resistance 
in clinical isolates higher), clindamycin (EMRSA-15 time period B, p<0.002, 
resistance in clinical isolates higher), kanamycin (EMRSA-15 time period B, 
p<0.002, resistance in clinical isolates higher), mupirocin (EMRSA-16 time period 
A, p<0.0001, resistance in screening isolates higher), and ciprofloxacin (EMRSA-16 
time period B, p<0.01, resistance in screening isolates higher)(see Figure 4-7 A, B 
and C)). There were no differences in the proportion resistant between screening or 
clinical isolates for any other antimicrobials, for any clone or time period (p>0.05).  
There were statistically significant differences in the mean antibiogram lengths 
(Table 4-6 and 4-11) between screening (mean length, time period A= 5.15; time 
period B=4.98) and clinical (mean length, time period A= 4.99; time period B=5.20) 
EMRSA-15 isolates (time period A, p = 0.01, and time period B, p<0.001). For 
EMRSA-16 isolates, there was no statistically significant difference between the 
mean antibiogram lengths of screening (mean length, time period A= 9.17; time 
period B=8.45) and clinical (mean length, time period A= 9.30; time period B=8.70) 
isolates (time period A, p>0.05, and time period B, p>0.05).  
As was seen with clinical isolates, the antibiogram diversity of EMRSA-16 among 
screening isolates was higher than that among EMRSA-15 isolates but the difference 
was not significantly different (Figure 4-8, Table 4-12). There was no difference 
between EMRSA-15 isolates between time periods. Owing to the re-sampling 
methods (i.e. bootstrapping) and restrictions of small sample sizes, CIs around 
EMRSA-16 were narrow. EMRSA-16 in time period B was the reference for this 
analysis so no CIs were generated. The most common antibiograms for clinical 
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isolates were the same as those for screening isolates and, again, there were no 
isolates that were resistant to all antimicrobials.  
Differences between clinical and screening isolates are summarised in Table 4-13. 
Table 4-10: Number of isolates and percentages represented by each clone type by year 
(screening isolates only). 
 





Total isolates 84 99 131 153 183 370 276 189 1485 467 1018 
Percentage 
EMRSA-15 
71.4 73.7 80.2 79.1 83.1 83.2 81.5 79.4 80.4 76.9 82.0 
Percentage 
EMRSA-16 
26.2 22.2 13 15.7 13.1 10.8 6.9 3.7 11.8 18.2 8.8 
Percentage 
‘Others’ 
2.4 4 6.9 5.2 3.8 5.9 11.6 16.9 7.8 4.9 9.1 
 
Figure 4-6: The percentage of isolates that were EMRSA-15, 16, and ‘others’ by year (screening 
isolates only). 
 
Time periods A and B are highlighted with parenthesis. 
 
A B 
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Figure 4-7: Radar chart of antimicrobial resistance of clinical and screening isolates for time 
period A and B: (A) EMRSA-15 (B) EMRSA-16, and (C) ‘others’. 
 
Asterisks denote statistical differences in the proportion resistant between clinical and screening isolates. 
Radar charts show the percentage of a) EMRSA-15, b) EMRSA-16, and c) ‘others’ that were resistant to each 
antimicrobial for time period A and B. The following abbreviations are used to indicate each antimicrobial; 
cefoxitin (Cx), chloramphenicol (Ch), ciprofloxacin (Cp), clindamycin (Cl), erythromycin (Er), fusidic acid (Fd), 
gentamicin (Gn), kanamycin (Km), linezolid (Lz), methicillin (Mt), mupirocin (Mp), neomycin (No), penicillin 
(Pn), rifampicin (Rf), streptomycin (St), sulphamethoxazole (Su), teicoplanin (Tc), tetracycline (Te), tobramycin 










*period A only 
*period A only 
*period A only 












*period A only 
*period A and B 
*period B only 
*period 
A only 
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Table 4-11: Summary of antibiogram lengths of screening isolates only. 
Clone and time period Min. 1st Qu. Median Mean 3rd Qu. Max. 
EMRSA-15: A 3 5 5 5.15 6 9 
EMRSA-15: B 2 4 5 5.0 5 11 
EMRSA-16: A 5 8 9 9.2 10 13 
EMRSA-16: B 3 6 9 8.5 10.6 13 
‘Others’: A 3 4 5 6.2 10 10 
‘Others’: B 3 4 4 4.8 6 11 
 
 
Table 4-12: Mean measures (with 2.5, 97.5% CI) of antibiogram diversity adjusted by sample 
size. 









































































Figure 4-8: Expected diversity of antibiograms of screening isolates.  
 
Figure illustrates diversity in the effective number of antibiograms as calculated by four different indices. 
These indices occur along the x-axis. The solid curves (red, brown, blue, and black) represent diversity of 
EMRSA-15 and EMRSA-16 for both time periods. Shading around curves represents confidence intervals 
(no CIs for ‘EMRSA-16 time period B as this was the reference clone-year). Key to diversity indices:  
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Table 4-13: Differences between clinical and screening isolates summarised. 
 
* Only antimicrobials with statistically significant differences between EMRSA-15 and EMRSA-16 are shown 
 
 Clinical Screening Significant difference? 
Dominant clone EMRSA-15 EMRSA-15 N/A 
Clone   
A: p=0.01, B: p>0.05 
% EMRSA-15 A: 79.9, B: 83.0 A: 76.9, B: 82.0 
% EMRSA-16 A: 17.8, B:8.1 A: 18.2, B: 8.8 
% ‘Others’ A: 2.3, B: 8.9 A: 4.9, B: 9.1 
Mean age    
EMRSA-15 A: 70.8, B: 71.2 A: 71.3, B: 72.2 A: p>0.05,  B: p>0.05 
EMRSA-16 A: 67.5, B: 66.2 A: 64.3, B: 70.8 A: p>0.05,  B: p>0.05 
‘Others’ A: 51.8, B: 49.3 A: 56.2, B: 64.0 A: p>0.05,  B: p>0.05 
% Male    
EMRSA-15 A:49.6, B: 49.5 A: 50.6, B: 50.4 A: p>0.05,  B: p>0.05 
EMRSA-16 A: 56.1, B: 64.3 A: 73.5, B: 52.2 A: p<0.01,  B: p>0.05 
‘Others’ A: 64.3, B: 48.3 A:52.2, B: 52.7 A: p>0.05,  B: p>0.05 
pvl toxin - % positive    
EMRSA-15 B: 1.2 B: 0.36 B: p>0.05 
EMRSA-16 B: 9.8 B: 2.2 B: p>0.05 
‘Others’ B: 19.6 B: 12.9 B: p>0.05 
tst toxin - % positive    
EMRSA-15 B: 0.5 B: 0.12 B: p>0.05 
EMRSA-16 B: 94.4 B: 87.8 B: p>0.05 





EMRSA-15 A:4.99, B: 5.20 A: 5.15, B: 4.98 A: p<0.01,  B: p<0.001 
EMRSA-16 A: 9.30, B: 8.70 A: 9.17, B:8.45 A: p>0.05,  B: p>0.05 
Antimicrobial 
resistance* 
   
EMRSA-15    
Cl B: 9.0 B: 5.0 B: p<0.002 
Km B: 7.7 B:4.8 B: p<0.002 
Tr A: 14.9 A: 26.0 A: p<0.0001 
EMRSA-16    
Cp B: 89.3 B: 93.3 B: p<0.01 
Mp A: 16.4 A: 20.0 A: p<0.0001 
Tr A: 38.8 A:23.6 A: p<0.02 
Antibiogram diversity    
 





   
A:  PnMtCxErCp,  
B:  PnMtCxErCp 
A:  PnMtCxErCp,  





B:  PnMtCxErClCp 
A: PnMtCxErClCp 
KmNoTb 
B:  PnMtCxErClCp 
N/A 




4.4.1 Clone dominance and differences 
EMRSA-15 and EMRSA-16 have been the two most dominant MRSA clones over 
the past decade. EMRSA-15 remains by far the most common with the number of 
EMRSA-16 isolates declining. There is no indication yet of an emerging sequence 
type from the ‘others’ group that could potentially be the next major clone. However, 
in a 16-year surveillance study of MRSA isolates in NHS Grampian, increases in the 
number of community strains, in particular CC5, was recently reported [119]. 
Results in this chapter show that EMRSA-15 and EMRSA-16 populations differ in 
terms of the level and pattern of antimicrobial resistance, their antibiogram lengths 
and (to a lesser extent) antibiogram diversity. As is likely true for all bacteria, but 
particularly at times of dominance and latterly decline; MRSA has both benefitted 
from and been hindered by antimicrobial resistance. 
There have been some changes in the MRSA antibiogram over time. While this 
largely has to do with EMRSA-16 isolates losing antibiotic resistance determinants 
(predominantly losing resistance to kanamycin, tobramycin and neomycin), the data 
imply that this also has to do with clones changing in frequency.  
4.4.2 Selecting for AMR 
Mutants containing genes for antimicrobial resistance are selected when isolates are 
under selection pressure, and genes only become fixed in a population when they 
give a strong selective advantage to the bacteria which outweighs any fitness cost 
[47].  Previous studies have shown that there is often a fitness cost and reduced 
growth rate associated with resistance, and the harbouring of mobile genetic 
elements (MGEs) with drug resistance genes, and especially if the resistances are not 
beneficial such as would be the case in a low selection pressure environment [48-50]. 
Furthermore, if resistance does carry a fitness cost, resistance tends to be eliminated 
once the selective pressure is removed [50]. This is not a straightforward issue since 
the effect of resistance on fitness can differ depending on environmental conditions, 
and can be altered by compensatory mutations or epistasis, and some mutations may 
be cost free [49]. In simple terms, it might be argued that EMRSA-15 isolates are not 
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burdened by large unnecessary resistance genes and are therefore biologically fitter, 
and spread more readily between people, patients, visitors, hospital staff and the 
hospital environment (including furniture, floors and air), as well as in the non-
hospital environment. 
In contrast, EMRSA-16 isolates tend to harbour resistance genes to a larger number 
of antimicrobials. It could be suggested that so many large genes hinder the clone, 
reducing its ability to readily spread from person-to-person at a rate faster than it is 
removed in order to sustain the population (although there are likely several other 
factors influencing spread of the clone). Isolates can be removed from the 
environment by cleaning as well as by natural bacterial death, and in humans and 
animals by the immune system, antimicrobials, antibacterials or by radiation. If 
bacteria are not replaced by new isolates of the same clone (e.g. from colonised or 
infected hospital staff, visitors, patients or through air conditioning systems) or 
dispersed through the hospital population and environment faster than the rate of 
removal, then the number of isolates of that clone will diminish over time (as 
observed). Of course, it is possible that low levels of bacteria will continue to remain 
since cleaning is not always 100% effective, antimicrobials not always taken 
correctly, or due to antimicrobial resistance. 
Since differences in levels and patterns of resistance to a single antimicrobial most 
likely reflect current (at the time of sample isolation) or historical antimicrobial 
selective pressures, it is reasonable to infer that EMRSA-16 isolates exist(ed) in a 
niche of high antimicrobial usage. Furthermore, it has previously been proposed that 
EMRSA-16 may be particularly well adapted to the hospital environment [135]. 
Specifically, the niche occupied may be intensive care units or care of the elderly 
specialties in major hospitals for example, which in recent years have been subject to 
targeted interventions and hygiene policies and practices [105]. This targeting of 
particular specialties could have caused the observed impact on the EMRSA-16 
population.  
Unlike the EMRSA-15 population, the level and pattern of resistance to several 
antimicrobials changed in the EMRSA-16 population by time period B. This ‘gene 
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shuffling’, in which the resistance to ciprofloxacin, erythromycin and 
aminoglycosides fell, and resistance to tetracycline increased, could be a result of 
adaptation to survive in changing environments or selection pressures. MGEs are key 
in the adaptation to new niches [47], and gene shuffling indicates frequent transfer 
and loss of MGEs carrying resistance genes. Looking specifically at the proportion of 
EMRSA-15 clinical isolates resistant to different antimicrobials per individual year 
of time period B, there was evidence for increase in resistance to trimethoprim, 
tetracycline, and to a lesser extent gentamicin, with resistance to kanamycin and 
clindamycin fluctuating but increasing overall. It has been suggested (personal 
communication with Giles Edwards, former director of the Scottish MRSA 
Reference Laboratory and consultant microbiologist) that a subset of EMRSA-15 
isolates have adapted to fill the vacating niche of EMRSA-16 isolates and have hence 
taken on traits which would have been common to the EMRSA-16 clone in order to 
survive there. However, there are several questions surrounding this hypothesis, such 
as why EMRSA-16 would not survive but EMRSA-15 could. This may be due to the 
rate at which EMRSA-15 spreads and is replaced; that it is being removed as 
EMRSA-16 would be (e.g. by cleaning and antimicrobials) but it is replaced faster 
than it is removed. 
4.4.3 Co-resistance 
Although antimicrobial drug use selects for resistant mutants, resistance can also be 
acquired in the absence of selection pressure by co-resistance where one gene 
confers resistance to multiple antimicrobial classes. For example, erythromycin 
resistance is conferred by the msrA gene (carried on MGE) as well as the erm genes 
(ermA, ermB, ermC, ermT, also MGE) which also confer resistance to clindamycin 
[51]. In addition, clindamycin resistance in Staphylococcus species can be either 
constitutive (meaning that isolates will display the resistant phenotype under routine 
screening conditions) or inducible (isolates display resistance phenotype only in the 
presence of erythromycin and clindamycin). Therefore, isolates with the inducible 
phenotype will appear to be erythromycin resistant and clindamycin sensitive when 
not tested in the presence of each other [52]. The presented results have only 
included isolates with constitutive resistance only. If inducible resistance had also 
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been included, for time period A, the proportion of EMRSA-15 isolates resistant to 
clindamycin would have increased from 5.4% to 21.8%, and for EMRSA-16 isolates 
from 90.2% to 94.7%. There was no inducible resistance recorded for time period B 
for either clone. Inducible resistance becomes particularly important when deciding 
on the most appropriate treatment regimens for patients.  
Co-resistance is also conferred for aminoglycosides kanamycin, tobramycin and 
neomycin due to acquisition of any one of the genes aadD, aacA-aphD, ant4 [176, 
177]. These genes are carried on large MGEs together with heavy metal resistance 
genes and penicillinase [33] and it has been suggested that having this large plasmid 
may be negatively associated with the survival capacity of the bacteria. This may 
have contributed to the reduction of the proportion resistant to all three 
antimicrobials in the second time period for EMRSA-16 isolates. Gentamicin is also 
an aminoglycoside that confers resistance through acquisition of the aacA-aphD gene 
only.  
In addition, bacterial species can acquire resistance to heavy metals. This is 
important not only since bacteria can grow in the presence of these materials, but 
also because the genes for heavy metal resistance can be linked to genes for AMR. 
Furthermore, research suggests that resistance to antimicrobial metals may be a 
driver of AMR [43]. For example, a cluster of metal resistance determinants can exist 
on the SCCmec element, closely linking it to the mecA gene and β-lactam resistance 
[43]. Resistance to antiseptics (i.e. chemical applied to skin or living tissue that kills 
or inhibits the growth of microorganisms, e.g. alcohol gels, surgical hand scrubs etc) 
is also possible and there is some suggestion that this can lead to reduced 
antimicrobial susceptibility by intrinsic or acquired mechanisms of resistance [45].  
4.4.4 Mupirocin 
The use of the topical antimicrobial mupirocin has greatly increased in recent years 
since it emerged that nasal decolonisation of patients and healthcare workers 
dramatically decreases the risk of S.aureus nosocomial spread and infection [109]. 
Hence, any increase in resistance would be of great clinical interest. Resistance 
statistically increased for EMRSA-15 with high-level mupirocin resistance gained 
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through acquisition of the mupA and mupB genes which are carried on MGEs [51]. 
Of further interest, mupA can also confer resistance to gentamicin, tetracycline, and 
trimethoprim as well as mupirocin [178]. 
4.4.5 Clinical versus screening isolates  
Table 4-13 highlights that there were very few differences in the pattern of resistance 
between clinical and screening isolates, which is in agreement with previous research 
[10, 56]. This suggests that it is the colonising strains that go on to be clinically 
important and therefore, this furthers the argument for decolonising hospital 
admissions to prevent re-seeding of hospitals and hospital outbreaks, and especially 
hospitalised patients pre-surgery to prevent infection. However, even if patients are 
screened and found not to be colonised, they may still go on to develop a clinical 
episode since the bacteria may be acquired in hospital (i.e. hospital-acquired 
infection) or due to a false negative result.  
It also suggests that screening isolates can be analysed in order to identify trends in 
clinical isolates such as the emergence of new spa types or increasing resistances.  
4.4.6 Non-EMRSA-15 / non-EMRSA-16 ‘others’   
The ‘others’ are a group of non-EMRSA-15 / non-EMRSA-16 isolates of several 
different sequence types (ST) and spa types and therefore this group was not 
expected to behave in a predictable manner. The levels of resistance varied and 
antibiogram lengths changed for both clinical and screening isolates between the two 
time periods, which could suggest a shift in clone dominance within the group. 
Unfortunately, this could not be investigated as sequence and spa typing was rarely 
carried out in time period A. 
4.4.7 Limitations 
There were further limitations of the data and assumptions made to carry out these 
analyses.  
Firstly, it is difficult to say whether all ‘screening’ isolates were removed from the 
database of ‘clinical’ isolates. The definition of ‘screening’ isolates (as used by [10]) 
was: any nasal, throat, axilla or groin swabs from which bacteria were grown. The 
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major assumption here was that specimen types listed as ‘skin swabs’ and swabs 
from various body sites were indeed wound and skin and soft tissue infections, i.e. 
true infections rather than screens. While removing screening isolates results in slight 
changes in the percentages of isolates that are EMRSA-15, EMRSA-16 and ‘others’, 
and despite the fact that there were some statistically significant differences in the 
percentages resistant to different antimicrobials, this limitation made very little 
difference to the overall results.  
Secondly, antibiogram length was described in this study given resistance to 20 
consistently tested antimicrobials. Resistance to untested antimicrobials could 
theoretically have been possible which could have resulted in longer maximum 
length antibiograms. This said, the twenty consistently tested antimicrobials were 
considered to be most relevant for MRSA (personal communication with Giles 
Edwards) and it is unlikely that the overall picture of resistance would have been 
altered by including further antimicrobials in the analyses.  
Thirdly, the snapshot database is a volunteer referral system and while cooperation 
and adherence was very good, some isolates for some years may have been missed.  
Lastly, this chapter suggests that there is a link between survival and dominance of 
EMRSA-15 isolates and, conversely, the decline of EMRSA-16 isolates with the 
level and pattern of antimicrobial resistance, antibiogram length and diversity. 
However, there may be several other influences on survival that could not be 
explained by these data, for example, the fact that EMRSA-15 and EMRSA-16 
isolates also differ genetically and have different SCCmec types [134]. Experimental 
investigation may be helpful to further understand the impact of these differences. 
4.4.8 How this builds on previous publications 
Previously, MRSA strain distribution and  antimicrobial resistance patterns in NHS 
Grampian (northeastern Scotland) originating from patients attending GP surgeries 
and hospitals over a 5 year period (from 2003 – 2007) were described [10]. The 
study described the proportions of each strain type from different clinical specimens 
(e.g. blood, urine, swab) with EMRSA-15 the most common strain in each category. 
The authors also found a shift in the relative rates of epidemic strains with an 
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increase in community-associated strains, and in addition they reported no difference 
in antibiotic resistance between clinical and screening isolates. 
The findings of this chapter agree with those of NHS Grampian but this chapter 
covers a longer, more recent, time period, is Scotland-wide and gives a more detailed 
comparison of strain types, describing AMR, antibiogram length and diversity. 
4.5 Conclusion 
EMRSA-15 isolates were dominant throughout this study. Historically, clones have 
dominated, declined and then been replaced by another clone, and although this 
looks unlikely to happen to EMRSA-15 isolates in the short-term, it appears to have 
already happened to EMRSA-16. However, there is no clear single sequence type or 
clonal complex emerging from the ‘others’ group at present. 
The diversity of antibiograms was found to be wide which could reflect frequent loss 
and transfer of resistance genes between isolates [33]. However, it could also be 
suggested that EMRSA-15 and EMRSA-16 populations do not share a spatial niche 
as distinct resistance patterns were observed. The levels and patterns of resistance are 
likely reflective of selective pressures within these spatial (and also temporal) niches 
which may vary due to the clinical usage, the volume consumed, and the method of 
administering in addition to the method of gaining resistance. 
There are several antimicrobials to which the resistance in the population remains 
very low and therefore they are still available for treatment of MRSA infections 
caused by EMRSA-15. The main pattern of resistance and most common 
antibiogram in the EMRSA-15 population remained stable throughout this study but 
NHS Scotland must remain vigilant. This is especially important if EMRSA-15 
isolates do move into the vacating niche of EMRSA-16 isolates and become more 
multi-drug resistant. Furthermore, NHS Scotland must continue to monitor the multi-
resistances of EMRSA-16 isolates since treating these now apparently rare infections 
could become more challenging.  
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Chapter 5: Antimicrobial prescribing and its 
relationship with antimicrobial resistance in MRSA 
 
5.1 Background 
Since their introduction into general clinical usage, antimicrobials have greatly 
contributed to the improvement of health and to increasing life expectancies globally 
[17]. However, with the rise of antimicrobial resistance (AMR) and since only two 
new classes of drugs have been introduced since the 1970s [20], there is great 
concern that we could be entering a post-antibiotic era where successful and 
powerful drugs of the past will no longer be effective. To address this, there have 
been calls for improved antimicrobial stewardship to better regulate drug usage, as 
well as improved surveillance, monitoring and regulation [20-22] (for more 
background information on antimicrobial stewardship, see Chapter 1.1.4.2.4).  
A better understanding of prescribing rates may provide an appreciation of the 
effects of population-level antimicrobial usage on antimicrobial resistance and the 
epidemiology of infectious diseases. For methicillin-resistant Staphylococcus aureus 
(MRSA), there have been several studies that have investigated this effect. In a time-
series analysis, the delay (after varying lag periods) in the effect of prescribing levels 
of several antimicrobial classes in a hospital in NHS Grampian and its association 
with the proportion of total S. aureus that was MRSA (%MRSA) was captured [126]. 
Also in NHS Grampian was a case-control study of two hospitals which found 
prescribing rates of macrolides and quinolones to be significantly and positively 
associated with an increase in %MRSA [127]. However, in a study of MRSA isolates 
in a single London hospital, the correlation between prescribing and antimicrobial 
resistance was reported to be strongest with ciprofloxacin and cephalosporin [34]. 
There was also an  association between antimicrobial use in the previous 12 months 
and the %MRSA isolates from non-clinical colonised individuals in England [179]; a 
strong association between antimicrobial usage within the previous 6 months and 
MRSA infection in a community-acquired MRSA outbreak in rural Alaska [180]; 
and, likewise, a strong association of antimicrobial usage within the previous 12 
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months and nasal colonisation in Taiwanese children [181]. In contrast there was no 
association found between prescribing and skin infections in two studies [182, 183] 
and in a meta-analysis that included those two and the Alaskan study, the odds ratio 
was close to 1 [184].  
The work in this chapter was intended as a pilot study to inform a larger analysis 
looking at trends and associations between prescribing and resistance levels for a 
greater number of antimicrobials and several pathogens. Therefore, the overall 
purpose was to test methods, and describe pitfalls of using such data and carrying out 
such a study. This is discussed at the end of the chapter. The specific aims of this 
chapter were two-fold. Firstly, to examine spatial and temporal trends in Scottish 
primary and secondary care prescribing rates. This included the use of the 
multivariate ordination technique, principal component analysis (PCA). Secondly, to 
investigate whether there were associations between primary or secondary care 




5.2.1.1 Scottish prescribing data 
5.2.1.1.1 Measurement of prescribing 
The international standard which the WHO recommends for comparing antimicrobial 
usage is the metric daily defined doses (DDD), defined as the assumed average 
maintenance dose per day for a drug used for its main indication in adults [185]. This 
is therefore a proxy measure for the average number of patients exposed to the drug 
in question each day. Prescribing rates per 1000 population (by quarter and HB) were 
calculated using population data as the denominator and number of DDD as the 
numerator. 
5.2.1.1.2 Prescribing databases 
Two datasets containing information on antimicrobial prescribing were received 
from Information Services Division (ISD), NHS Scotland.  
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The first dataset was extracted from the Prescribing Information System for Scotland 
(PRISM) database and contained information on antimicrobial prescribing in primary 
care, i.e. dispensed from community pharmacies, measured in DDD with variables 
including: antimicrobial name and group, NHS Health Board (HB), drug 
formulation, year (financial year, starting 1
st
 April 2004/05 - 2011/12 inclusive) and 
quarter (1=March, April, May; 2=June, July, August; 3=September, October, 
November; 4=December, January, February). HB boundaries were reconfigured in 
2007: NHS Argyll and Clyde was broken up and part-absorbed into what was 
previously NHS Greater Glasgow and subsequently NHS Greater Glasgow and 
Clyde, and NHS Highlands. The PRISM database contains information from pre- and 
post-reconfiguration but the database only uses the new HB names and boundaries. 
Pharmacies in regions where the boundaries changed were re-assigned to reflect the 
new HBs by ISD prior to releasing the data.  
The second dataset was taken from the Hospital Medicines Utilisation Database 
(HMUD) and contained information on antimicrobial prescribing in secondary care 
measured by DDD and again with information on: antimicrobial name and group, 
HB, drug formulation, year (financial year 2007/08 – 2011/12 inclusive) and quarter. 
Herein, when years are discussed, the year represents the beginning of a financial 
year. i.e. 2007 represents financial year 2007/08. HMUD also reflects new HB 
boundaries. 
5.2.1.1.3 NHS Health Boards 
Data collection was incomplete for some HBs. Therefore only seven HBs with 
consistently the most complete reporting to HMUD could be included in this study. 
The HBs included were: NHS Ayrshire and Arran, NHS Fife, NHS Forth Valley, 
NHS Greater Glasgow and Clyde, NHS Grampian, NHS Lanarkshire and NHS 
Lothian. This was applied to both the primary and secondary prescribing datasets to 
allow for direct comparison. Approximately 81% of annual prescribing in primary 
care and between 56-72% of annual prescribing in secondary care was in these seven 
HBs, and the same HBs contain approximately 80% of the total Scottish population. 
Hence these HBs were considered a good representation of prescribing in Scotland.  




Fourteen antimicrobials were initially selected for this study. These were: 
chloramphenicol (Ch), ciprofloxacin (Cp), clindamycin (Cl), erythromycin (Er), 
fusidic acid (Fd), gentamicin (Gn), linezolid (Lz), neomycin (No), rifampicin (Rf), 
streptomycin (St), teicoplanin (Tc), tetracycline (Te), tobramycin (Tb), and 
trimethoprim (Tr).  These were selected since they represent classes of antimicrobials 
that are relevant to S. aureus infections (personal communication with Dr Giles 
Edwards, former infectious diseases consultant in NHS Greater Glasgow and Clyde, 
and former director of the Scottish MRSA Reference Laboratory). Initial 
investigation of general patterns showed that six antimicrobials, ciprofloxacin, 
clindamycin, erythromycin, gentamicin, tetracycline and trimethoprim, had the 
highest prescribing rates in primary and secondary care when rates from both 
primary and secondary care were combined and ranked. These six antimicrobials 
became the focus of further analyses. Combined they accounted for between 16-22% 
of total annual primary prescribing (between 97-99% of the 14 antibiotics initially 
selected) and between 13-19% of total annual secondary prescribing (between 93-
95% of the 14 antimicrobials initially selected).  
5.2.1.2 Scottish population data 
Mid-year population estimates at 1) HB-level and 2) the national-level were obtained 
from the General Register Office for Scotland website for the years 2004 – 2011 
inclusive.  
5.2.1.3 Scottish resistance data 
Data on the proportion of MRSA isolates resistant to the six different antimicrobials 
(ciprofloxacin, clindamycin, erythromycin, gentamycin, tetracycline and 
trimethoprim) were extracted from the Scottish MRSA reference laboratory 
(SMRSARL) database. Specifically, this included information on MRSA isolates that 
had caused bacteraemia, by quarter and HB for the years 2003-2012. This 
information was collected by the SMRSARL for contributing to the EARS network 
(European Antimicrobial Resistance Surveillance Network). The proportion resistant 
to an antimicrobial was calculated as the number of isolates (for a given quarter, year 
and HB) that were resistant as the numerator, and the total number of MRSA isolates 
The Epidemiology of MRSA in Scotland 
116 
 
(for the corresponding quarter, year and HB) as the denominator. Herein, ‘the 
proportion of MRSA isolates that were resistant’ shall be referred to as the 
‘proportion resistant’. 
5.2.2 Descriptive and statistical analysis  
All statistical analyses were done using R (version 3.1.2) [154]. 
5.2.2.1 General Scottish trends 
General patterns of 14 antimicrobials prescribed in either primary or secondary care 
were first described. Then descriptive analyses of six antimicrobials (ciprofloxacin, 
clindamycin, erythromycin, gentamycin, tetracycline and trimethoprim) were 
conducted.  
Temporal trends of prescribing rates in primary care for financial years 2004/05 - 
2011/12 and secondary care for financial years 2007/08 – 2011/12, measured by the 
number of DDDs per 1000 population, were examined using regression analysis 
(exploring linear, quadratic or cubic where appropriate). Spatial trends in primary 
and secondary care prescribing rates, i.e. number of DDDs per 1000 population, 
between HBs were examined using a one-way analysis of variance (ANOVA). The 
reference HB for each model was the one with the highest estimate of prescribing 
rate. To identify where the statistical differences between HBs lay, a post-hoc 
multiple comparisons testing using Tukey’s test was carried out. One of the outputs 
from this analysis is that HBs are grouped together based on mean prescribing rates, 
and HBs with statistically different rates are placed in different groups. Groups are 
assigned letters to easily identify different groups. Thus, HBs in the same group do 
not have statistically different means, and hence will be assigned the same letter. In 
addition, any interaction between year and HB was also investigated using the 
model; 𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔_𝑟𝑎𝑡𝑒 ~𝐻𝐵 + 𝑌𝑒𝑎𝑟 + 𝐻𝐵 ∗ 𝑌𝑒𝑎𝑟.  
Level of statistical significance for all models was set at p≤0.05. Skewed variables 
were first log-transformed to normalise the data and where necessary the log of x+1 
was taken to avoid problems taking the log of 0: primary care data (𝑙𝑜𝑔10(𝐷𝐷𝐷)) 
for ciprofloxacin, clindamycin, erythromycin, tetracycline and trimethoprim, and 
(𝑙𝑜𝑔10(𝐷𝐷𝐷 + 1)) for gentamycin; secondary care data (𝑙𝑜𝑔10(𝐷𝐷𝐷)) for 
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ciprofloxacin, erythromycin, gentamycin and trimethoprim, and (𝑙𝑜𝑔10(𝐷𝐷𝐷 + 1)) 
for clindamycin.  
5.2.2.2 Principal Component Analysis (PCA)  
Principal component analysis (PCA), the multivariate ordination technique that 
reduces the dimensionality of a dataset while largely maintaining the variation [186], 
was used to examine relationships between prescribing of selected antimicrobials 
over space and time. A PCA reduces the dimensionality of a dataset by identifying 
directions (axis) along which data have the greatest distance or variation. This 
distance is represented by loading scores. PCA therefore creates new variables called 
principle components that can be plotted in order to visualise similarities and 
differences between groups, in this case prescribing rates between and within 
primary and secondary care. 
The first PCA was based on the combined primary and secondary care prescribing 
rate (DDD per 1000 population) of ciprofloxacin, clindamycin, erythromycin, 
gentamycin, tetracycline and trimethoprim (transforming variables were appropriate 
and aforementioned). Following preliminary runs of the analysis, two outliers (1= 
secondary data from the 4th quarter, 2011 from NHS Greater Glasgow and Clyde; 2= 
secondary data from the 4th quarter, 2011 from NHS Lothian) were removed since 
data for both were further than two standard deviations from the mean, suggesting 
that data from this quarter were not complete. 
To find variables associated with different groups in a PCA, a second matrix with 
additional data is superimposed on the ordination to create a joint plot (radiating 
lines). The direction of the lines indicates either a positive or negative relationship 
with an axis and the variables of the second matrix, and the length shows the strength 
of the correlation on that axis. The ordination was rotated in order to show the 
strongest correlations along axis 1. Variables in the second matrix included 
information on NHS Health Board, year, quarter, season (quarters 2/3 = 
spring/summer and quarters 3/4= autumn/winter), and the proportion of antimicrobial 
resistance (to ciprofloxacin, clindamycin, erythromycin, gentamycin, tetracycline and 
trimethoprim) in the MRSA population. Multi-response permutation procedures 
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(MRPP) analysis was performed to test the hypothesis of no difference between 
groups.  
Two additional PCAs were run on primary care prescribing data only and secondary 
care prescribing data only. Joint plots were also plotted to visualise within-group 
differences over years and between HBs. MRPP carried out to test for no difference 
over time, and between HBs. All PCA were performed in PC-ORD version 6.03 
(MJM software Design, Gleneden Beach, OR).  
 
5.2.2.3 Associations between prescribing and MRSA antimicrobial resistance 
Associations between the prescribing rate in both primary and secondary care and the 
proportion of the MRSA population resistant to the six different antimicrobials 
(ciprofloxacin, clindamycin, erythromycin, gentamycin, tetracycline and 
trimethoprim) were investigated using linear regression analyses. This would capture 
any association between prescribing and resistance in the same quarter (t0). To 
capture any possible delay or lag in the effect that prescribing had on resistance 
trends, resistance data were also staggered so that they represented a delay of one 
quarter (t1), two quarters (t2), and so on until six quarters (t6) (with one quarter 
being three months). In these univariate analyses, the proportion resistant to each 
antimicrobial in each time period (t1, t2 etc.) were the dependent variables, and 
prescribing rate (in either primary or secondary care) the independent or explanatory 
variable. Resistance data for each antimicrobial were log transformed (log10(X+1)) to 
normalise the data.  
In a multivariate analysis, the proportion of isolates resistant to each antimicrobial at 
t0 was the dependent variables, and prescribing rates (both primary and secondary 
care), HB and year the independent variables. Correlation analyses were conducted 
to check that no two variables were strongly correlated (correlation coefficient >0.8). 
A backward elimination approach was applied and statistical significance set at 
p≤0.05. The akaike information criterion (AIC) and quantile-quantile-plots were used 
to compare nested models, and p-values and adjusted R
2
 values to compare non-
nested models. The robustness of final models was tested by applying a forward 
stepwise approach and examining the diagnostic statistics, and the stability of the 
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final models was also checked by removing variables one at a time and assessing the 
effect of the remaining variables. The final models were deemed to be both robust 
and stable. They were then run using the staggered resistance data that represented 
lag period t1-t6 as the independent variable. 
 
5.3 Results 
5.3.1 General patterns 
Among the 14 antimicrobials initially investigated, the three most commonly 
prescribed from primary healthcare sources over the entire study period were 
erythromycin, trimethoprim and ciprofloxacin (Figure 5-1A). Among the 14 
antimicrobials initially investigated that were prescribed from secondary healthcare 
sources, ciprofloxacin and trimethoprim were also high (Figure 5-1B). In secondary 
care, moderate rates of prescribing (between 10-50 DDDs per 1000 population) were 
also observed for erythromycin, gentamycin and clindamycin, and low rates of 
prescribing (below 10 DDDs per 1000 population) for all other selected antibiotics 
(Figure 5-1B).  
Despite being the two most commonly prescribed antibiotics in secondary care in 
this study, the rate of prescribing of ciprofloxacin and trimethoprim for the years 
2007 – 2011 was between 2.4 - 3 and 8.1 - 8.7 times lower than that seen in primary 
prescribing for both respective antibiotics (Table 5-1). Prescribing rates were 
between 6.2-6.8 times higher in primary care for the 14 antimicrobials combined, and 
between 6.5- 7.0 times higher in primary care for the 6 selected antimicrobials 
combined. The difference between prescribing in primary and secondary prescribing 
was largest for erythromycin (28 - 38 times higher in primary care) and tetracycline 
(24-44 times higher in primary care). Prescribing was consistently higher in 
secondary care for clindamycin and gentamycin (Table 5-1). The range reflects 
variation in prescribing rates over years. 
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Figure 5-1: Antibiotic prescribing rate per 1000 population, by year, in (1A) primary and (1B) 
secondary care. Raw data (i.e. no transformations) with HB and quarter collapsed. 
A) Primary care prescribing 
 
B) Secondary care prescribing 
  
Antimicrobial abbreviations: Ch, chloramphenicol; Cp, ciprofloxacin; Cl, clindamycin; Er, erythromycin; Fd, 
fusidic acid; Gn, gentamicin; Lz, linezolid; No, neomycin; Rf, rifampicin; St, streptomycin; Tc, teicoplanin; Te, 
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2007 0.8 2.4 28.1 0.06 29.9 8.7 
2008 0.7 2.7 31.4 0.05 24.4 8.1 
2009 0.7 2.9 33.3 0.03 29.1 8.2 
2010 0.8 2.7 35.9 0.02 37.6 8.1 
2011 0.8 3 38.3 0.02 44 8.4 
i.e. Primary prescribing of erythromycin was 28.1 times higher than in secondary care in 2007. 
 
5.3.1.1 PCA results – differences between primary and secondary prescribing 
A PCA was conducted on combined primary and secondary care prescribing data 
showed differences between the two groups (MRPP = chance-corrected within-group 
agreement, A = 0.84, p<0.0001). There was only one significant axis (p=0.001) that 
had an Eigenvector value over 1 and that explained 78.5% of total variation in the 
data (Table 5-2). Loading scores, which indicate where the main differences in the 
data lie, were highest for ciprofloxacin, erythromycin, and gentamycin, closely 
followed by clindamycin and trimethoprim (Figure 5-2). Axis 1, representing 78.5% 
of total variation, distinguished primary care which was characterised by high levels 
of ciprofloxacin, erythromycin, tetracycline and trimethoprim prescribing and low 
levels of gentamycin prescribing, from prescribing in secondary care which had low 
levels of ciprofloxacin, erythromycin, tetracycline and trimethoprim, and high levels 
of gentamycin prescribing. Clindamycin was prescribed in both primary and 
secondary care as represented by the second (non-significant) axis which explained 
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of Var. Minimum Average Maximum p-value 
Primary and secondary data combined 
1 4.65 1.09 1.21 1.36 0.001 77.58 77.58 
2 0.94 1.03 1.11 1.21 1 15.69 93.27 
3 0.2 0.95 1.03 1.11 1 3.33 96.6 
4 0.14 0.88 0.96 1.03 1 2.28 98.88 
5 0.05 0.78 0.89 0.99 1 0.82 99.7 
6 0.02 0.66 0.81 0.92 1 0.3 100 
 
Cum.% of Var. : Cumulative percentage of variance 
% of Variance : Percentage of variance 
 
 
Figure 5-2: PCA loading values for combined primary and secondary care prescribing data. 
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Figure 5-3: PCA – Joint plot showing differences in prescribing between primary and secondary 
care.  
 
Radiating lines were superimposed on the ordination to create a joint plot which identifies variables associated 
with either group. The direction of a line indicates either a positive or negative relationship with an axis and the 
variables of the secondary matrix, and the length shows the strength of the correlation on that axis. The ordination 
was rotated in order to show the strongest correlations along axis 1. Antibiotic abbreviations: Cl, clindamycin; 
Cp, ciprofloxacin; Er, erythromycin; Gn, gentamycin; Te, tetracycline; Tr, trimethoprim. Polygons were drawn 
around the outermost data points to distinguish each group (primary care and secondary care). 
 
5.3.2 Trends  
5.3.2.1 Temporal trends in prescribing 
5.3.2.1.1 Regression analyses 
In primary care, the prescribing rates of ciprofloxacin (p<0.001), gentamicin 
(p=0.01), and tetracycline (p<0.001) statistically declined over the study period 
(Table 5-3A). Despite being statistically significant, the adjusted R
2
 values were 
consistently low suggesting the model explained very little of variation in the data. 
The cubic regression model for ciprofloxacin (p>0.05) described the data better than 
the linear and quadratic models. The linear model was the best fitting for gentamicin, 
and there were no statistical differences between any of the three regression models 
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for tetracycline (p>0.05). Primary care prescribing of clindamycin (p=0.0002) and 
trimethoprim (p<0.0001) increased over the study period, with the linear regression 
providing the best fitting models for clindamycin, and either the linear or quadratic 
models being best fitting for trimethoprim with no difference between the two 
(p>0.05). There was no change in the primary care prescribing rates of erythromycin. 
Figure 5-4A shows primary prescribing data over time with regression fitted. 
In secondary care, the prescribing rates of ciprofloxacin (p<0.0001), clindamycin 
(p=0.02), erythromycin (p=0.001), and tetracycline (p<0.01) statistically declined 
over the study period (Table 5-3B). As with the primary care data, adjusted R
2
 values 
were consistently low. There were no statistical differences between the three 
regression models for ciprofloxacin, clindamycin and tetracycline (each p>0.05), but 
either the linear or quadratic regressions best described erythromycin prescribing.  
The prescribing rates for gentamicin (<0.0001) and trimethoprim (p<0.01) 
statistically increased over time with there being no difference between the three 
regressions for gentamicin (p>0.05) and with the linear regression providing the best 
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Table 5-3: Model outputs from regression analyses of temporal changes in antimicrobial 
prescribing in (A) primary and (B) secondary care.  
All years and health boards combined. In the model column, for the best model for each antimicrobial 
is in bold and italicised; where there was no difference between models, more than one is in bold. 
A) Primary care prescribing 




Y -0.01 0.003 0.06 . 0.01  
Y*Y -0.001 0.0004 0.002 ** 0.04 ↓ 
Y*Y*Y -0.0002 0.00004 0.00008 *** 0.07 ↓ 
Clindamycin’ 
Y 0.02 0.005 0.0002 *** 0.06 ↑ 
Y*Y 0.002 0.001 0.01 ** 0.03 ↑ 
Y*Y*Y 0.0001 0.0001 0.04 * 0.02 ↑ 
Erythromycin’ 
Y -0.002 0.002 0.25  0.001  
Y*Y -0.0002 0.0002 0.23  0.002  
Y*Y*Y -0.00003 0.00002 0.22  0.002  
Gentamicin’’ 
Y -0.004 0.001 0.01 ** 0.03 ↓ 
Y*Y -0.0004 0.0002 0.02 * 0.02 ↓ 
Y*Y*Y -0.00004 0.00002 0.04 * 0.02 ↓ 
Tetracycline’ 
Y -0.01 0.004 0.0004 *** 0.05 ↓ 
Y*Y -0.002 0.0005 0.0004 *** 0.05 ↓ 
Y*Y*Y -0.0002 0.0001 0.0006 *** 0.05 ↓ 
Trimethoprim’ 
Y 4.1 0.3 <0.0001 *** 0.40 ↑ 
Y*Y 0.4 0.04 <0.0001 *** 0.40 ↑ 
Y*Y*Y 0.005 0.0005 <0.0001 *** 0.38 ↑ 
’ data log transformed 
” data log(x+1) transformed 
Sig: Significant = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 1 = ‘ ’  
Trend indicates direction of change if regression is significant (↑ = increase, ↓ = decrease) 
SE = standard error 
Adj. R2 = adjusted R2 
Model:  linear regression (Y) Primary_DDD_rate ~ Year 
quadratic regression (Y*Y) Primary_DDD_rate ~ Year*Year 
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B) Secondary care prescribing 




Y -0.05 0.01 <0.0001 *** 0.26 ↓ 
Y*Y -0.01 0.001 <0.0001 *** 0.24 ↓ 
Y*Y*Y -0.001 0.0002 <0.0001 *** 0.22 ↓ 
Clindamycin’ 
Y -0.02 0.01 0.02 * 0.03 ↓ 
Y*Y -0.003 0.001 0.02 * 0.03 ↓ 
Y*Y*Y -0.001 0.0003 0.03 * 0.03 ↓ 
Erythromycin’ 
Y -0.05 0.01 0.0009 *** 0.07 ↓ 
Y*Y -0.01 0.002 0.0006 *** 0.07 ↓ 
Y*Y*Y -0.001 0.0004 0.001 ** 0.07 ↓ 
Gentamicin’ 
Y 0.09 0.01 <0.0001 *** 0.2 ↑ 
Y*Y 0.01 0.002 <0.0001 *** 0.18 ↑ 
Y*Y*Y 0.002 0.0005 <0.0001 *** 0.15 ↑ 
Tetracycline 
Y -0.02 0.01 0.01 ** 0.04 ↓ 
Y*Y -0.004 0.001 0.01 ** 0.05 ↓ 
Y*Y*Y -0.001 0.0003 0.005 ** 0.05 ↓ 
Trimethoprim’ 
Y 0.02 0.01 0.01 ** 0.04 ↑ 
Y*Y 0.004 0.002 0.02 * 0.03 ↑ 
Y*Y*Y 0.001 0.0003 0.03 * 0.03 ↑ 
’ data log transformed 
” data log(x+1) transformed 
Sig: Significant = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 1 = ‘ ’  
Trend indicates direction of change if regression is significant (↑ = increase, ↓ = decrease) 
SE = standard error 
Adj. R = adjusted R2 
Model:  linear regression (Y) lm(Primary_DDD_rate ~ Year) 
quadratic regression (Y*Y) lm(Primary_DDD_rate ~ Year*Year) 
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Figure 5-4: Plots of regression models fitted to data showing prescribing rates over time in (A) 
primary and (B) secondary care. 
(A)  
 
x-axis year: 1 = 2004/05, 2 = 2005/06, 3 = 2006/07, 4 = 2007/08, 5 = 2008/09, 6 = 2009/10, 7 = 
2010/11, 8 = 2011/2012 
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5.3.2.2 PCA results– Differences over time 
A PCA of primary care prescribing data showed differences in prescribing over time 
(MRPP, p<0.0001). There were two significant axes (p=0.001) with eigenvector 
values over 1.0 which explained 53% of total variation in the data (Table 5-4). While 
the eigenvector value for a third axis was close to 1.0, it was not significant and 
therefore not described. The loading scores (Figure 5-5A), which indicate where the 
main differences in the data lie, were highest in Axis 1 for tetracycline followed by 
ciprofloxacin, and Axis 2 for ciprofloxacin and erythromycin. The joint plot (Figure 
5-6Ai) appears to show a shift from left to right along Axis 1 which explains 29.0% 
of the total variation and represents a reduction in tetracycline prescribing and an 
increase in trimethoprim and clindamycin prescribing over time. This is consistent 
with the above regression analyses. Axis 2, which explains 24.0% of the variation in 
the data, is associated with gentamycin and ciprofloxacin prescribing. The ellipse 
plot also indicates a shift over time (Figure 5-6Aii). 
A further PCA was carried out on secondary care prescribing data and also showed 
there to be differences in prescribing over time (MRPP, p<0.0001). There were two 
significant axes (p=0.001) with eigenvector values over 1 which explained 65.5% of 
total variation in the data (Table 5-4). The loading scores (Figure 5-5B) were highest 
in Axis 1 for ciprofloxacin, clindamycin and gentamicin, and Axis 2 for 
trimethoprim, erythromycin and again gentamicin. The joint plot (Figure 5-6Bi) 
appears to show a shift from left to right along Axis 1 (34.0% of the total variation) 
which distinguished between high levels of ciprofloxacin and clindamycin 
prescribing which declined over time, and low levels of gentamycin prescribing 
which increased over time. Axis 2 (31.5% of the variation) separated erythromycin 
which declined and trimethoprim that increased over time. Again, this is consistent 
with the above regression analyses.  The ellipse plot also indicates a shift over time 
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of Var. Minimum Average Maximum p-value 
(A) Primary 
1 2.07 1.11 1.29 1.61 0.001 28.64 28.64 
2 1.83 0.99 1.15 1.32 0.001 23.71 52.35 
3 0.98 0.91 1.04 1.15 0.962 16.05 68.4 
4 0.64 0.79 0.94 1.05 1 13.45 81.85 
5 0.33 0.7 0.84 0.95 1 10.88 92.72 
6 0.15 0.58 0.73 0.9 1 7.28 100 
(B) Secondary 
1 2.07 1.11 1.29 1.61 0.001 34.53 34.53 
2 1.83 0.99 1.15 1.32 0.001 30.57 65.09 
3 0.98 0.91 1.04 1.15 0.962 16.28 81.38 
4 0.64 0.79 0.94 1.05 1 10.68 92.05 
5 0.33 0.7 0.84 0.95 1 5.46 97.51 
6 0.15 0.58 0.73 0.9 1 2.49 100 
Cum.% of Var. : Cumulative percentage of variance 
% of Variance : Percentage of variance 
 
















































Figure 5-6: PCA - Differences over time in (A) primary and (B) secondary care prescribing.  
i – The joint plots show radiating lines that were superimposed on the ordination to identify variables 
associated with the grouping variable (i.e. year). The direction of a line indicates either a positive or 
negative relationship with an axis and the variables of the secondary matrix, and the length shows the 
strength of the correlation on that axis. Crosses indicate the centroid of the polygon which joins the 
outer data points for each group. The ordination was rotated in order to show the strongest correlations 
along axis 1.   
ii – The confidence ellipses show with 95% confidence where data in ordination space lie. Crosses 
indicate central points of ellipses. Data points removed to make it easier to see the patterns 











Antimicrobial abbreviations: Cl, clindamycin; Cp, ciprofloxacin; Er, erythromycin; Gn, gentamycin; Te, 
tetracycline; Tr, trimethoprim. 
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5.3.2.3 Trends in prescribing between NHS Health Boards 
5.3.2.3.1 ANOVA and post-hoc Tukey analyses 
ANOVA analyses showed that for each of the six antimicrobials, i.e. clindamycin, 
ciprofloxacin, erythromycin, gentamycin, tetracycline, and trimethoprim, there were 
differences between HBs (p<0.0001) in prescribing rates in both primary and 
secondary care (Tables 5-5A and 5-5B).  
Post-hoc Tukey analyses showed pairwise differences in prescribing rates between 
HBs (Tables 5-5A and 5-5B). Each letter represents different groups of HB where 
the prescribing rates were similar. No one HB was consistently high across all 
antimicrobials examined. For each antimicrobial, there are several different 
groupings with tetracycline prescribing in primary care having the fewest (3 groups) 
meaning lower heterogeneity in prescribing rates. In secondary care, ciprofloxacin 
had the fewest number of groupings (three groups), while both gentamicin and 
trimethoprim had the highest number (6 groups). Figure 5-7A and 5-7B shows the 
between-HB differences in prescribing means for both primary and secondary care 
respectively. These interval plots also show for which pairs of HBs the prescribing 
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Table 5-5: Results of ANOVA and post-hoc Tukey analysis in (A) primary and (B) secondary 
care showing the mean, standard deviation (SD), minimum and maximum prescribing rates 
(DDD per 1000 population) and HB groupings.  
(A) 
HB Mean Minimum SD Maximum Grouping§ 
Ciprofloxacin’ ANOVA - p<0.0001 
AA 1.75 1.55 0.08 1.86 c 
FI 1.81 1.75 0.04 1.88 b 
FV 1.92 1.74 0.07 2.05 a 
GC 1.75 1.64 0.04 1.82 c 
GR 1.78 1.49 0.14 1.92 bc 
LA 1.75 1.65 0.05 1.84 c 
LO 1.62 1.51 0.06 1.72 d 
Clindamycin’ ANOVA p<0.0001 
AA 0.23 -0.06 0.11 0.47 cd 
FI 0.32 0.07 0.12 0.5 bc 
FV 0.51 0.31 0.09 0.73 a 
GC 0.37 0.16 0.09 0.5 b 
GR 0.32 0.07 0.11 0.56 bc 
LA 0.22 -0.14 0.18 0.57 d 
LO 0.58 0.35 0.1 0.71 a 
Erythromycin’ ANOVA p<0.0001 
AA 2.24 2.13 0.06 2.34 a 
FI 2.2 2.11 0.04 2.27 b 
FV 2.2 2.11 0.03 2.24 b 
GC 2.21 2.16 0.03 2.27 ab 
GR 2.15 2.07 0.05 2.25 c 
LA 2.18 2.12 0.04 2.24 b 
LO 2.24 2.15 0.04 2.3 a 
Gentamycin’’ ANOVA p<0.0001 
AA 0.04 0.0004 0.04 0.16 c 
FI 0.12 0.04 0.07 0.32 a 
FV 0.06 0.003 0.03 0.15 bc 
GC 0.12 0.08 0.02 0.17 a 
GR 0.08 0.003 0.05 0.18 b 
LA 0.08 0.03 0.02 0.12 b 
LO 0.08 0.03 0.02 0.12 b 
Tetracycline’ ANOVA p<0.0001 
AA 0.66 0.56 0.06 0.76 c 
FI 0.73 0.54 0.09 0.9 c 
FV 0.67 0.45 0.13 0.89 c 
GC 0.84 0.75 0.03 0.91 b 
GR 0.96 0.84 0.06 1.08 a 
LA 0.88 0.7 0.13 1.14 b 
LO 0.69 0.51 0.11 0.87 c 
Trimethoprim ANOVA p<0.0001 
AA 130.36 120.71 7.62 148.76 ab 
FI 131.42 112.41 11.28 147.4 a 
FV 118.35 106.07 8 140.54 cd 
GC 121.7 105.26 10.28 139.61 bc 
GR 128.28 117.3 6.74 143.89 abc 
LA 109.61 79.94 23.34 145.96 d 
LO 111.88 95.81 9.27 127.21 d 
 




HB Mean Minimum SD Maximum Grouping§ 
Ciprofloxacin’ ANOVA - p<0.0001 
AA 29.37 22.27 6.37 39.09 a 
FI 16.36 12.64 2.96 22.66 c 
FV 16.97 13.04 2.23 20.78 c 
GC 21.55 12.51 7.6 34.85 b 
GR 23.26 15.68 2.89 27.61 b 
LA 15.58 12.23 2.51 21.69 c 
LO 25 18.16 4.17 30.9 a 
Clindamycin’ ANOVA p<0.0001 
AA 0.68 0.44 0.15 0.91 a 
FI 0.34 0.06 0.14 0.69 d 
FV 0.43 0.22 0.2 0.77 cd 
GC 0.37 0.13 0.19 0.72 d 
GR 0.6 0.4 0.08 0.75 ab 
LA 0.54 0.37 0.08 0.64 bc 
LO 0.62 0.54 0.05 0.71 ab 
Erythromycin’ ANOVA p<0.0001 
AA 1.12 0.99 0.09 1.27 a 
FI 0.54 0.29 0.14 0.77 d 
FV 0.49 0.29 0.12 0.74 c 
GC 0.91 0.81 0.06 1.02 b 
GR 0.86 0.69 0.1 1.03 b 
LA 0.69 0.51 0.08 0.83 c 
LO 0.51 0.34 0.09 0.64 d 
Gentamycin’ ANOVA p<0.0001 
AA 0.54 0.36 0.13 0.74 de 
FI 0.51 0.36 0.09 0.67 e 
FV 0.69 0.31 0.32 1.09 cd 
GC 0.81 0.58 0.16 1 bc 
GR 1.07 0.85 0.14 1.21 a 
LA 0.97 0.5 0.26 1.24 ab 
LO 0.59 0.49 0.06 0.73 de 
Tetracycline’ ANOVA p<0.0001 
AA -1.09 -1.73 0.57 0 c 
FI -0.68 -1.23 0.37 0 a 
FV -0.8 -1.63 0.42 0 abc 
GC -0.52 -1.14 0.27 -0.11 a  
GR -0.73 -1.31 0.27 -0.26 ab 
LA -0.73 -1.61 0.33 -0.21 ab 
LO -1.05 -1.39 0.18 -0.76 bc 
Trimethoprim ANOVA p<0.0001 
AA 15.1 12.38 2.25 20.6 c 
FI 11.21 6.71 1.84 13.17 d 
FV 9 7.47 1.48 12.99 e 
GC 21.97 17.53 1.9 25.27 a 
GR 17.81 14.36 2.18 21.8 b 
LA 18.96 13.71 3.22 23.3 b 
LO 9.34 7.02 1.25 11.14 de 
’ data log transformed; ” data log(x+1) transformed; HB abbreviations: AA = NHS Ayrshire and Arran, FI = NHS 
Fife, FV = NHS Forth Valley, GR = NHS Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS 
Lanarkshire, LO = NHS Lothian; §Groupings: HBs with statistically different rates will be placed in different 
groups. Groups are assigned letters to easily identify different groups. Thus, HBs in the same group do not have 
statistically different means or %MRSA, and hence will be assigned the same letter. 




Figure 5-7: Results of post-hoc Tukey analysis showing differences in prescribing rates between 














x-axis = Differences in mean levels of Daily Defined Doses (DDD) per 1000 population. y-axis: Pairwise HB 
comparisons; HB abbreviations: AA = NHS Ayrshire and Arran, FI = NHS Fife, FV = NHS Forth Valley, GR = 
NHS Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS Lanarkshire, LO = NHS Lothian. 
Antimicrobial abbreviations: Cl, clindamycin; Cp, ciprofloxacin; Er, erythromycin; Gn, gentamycin; Te, 
tetracycline; Tr, trimethoprim. 
 
Cp Cl  
Te Tr 
Gn Er 
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5.3.2.4 PCA results– differences between HBs 
In the two aforementioned PCAs of primary care and secondary care prescribing 
rates, differences between HBs was also investigated. In both primary and secondary 
care, there were differences in prescribing rates between HBs (MRPP, p<0.0001).  
The results from the PCA for primary care, as visualised in the joint plot (Figure 5-
8Ai), largely agree with those from the ANOVA and Tukey analyses, for example 
prescribing of ciprofloxacin was highest in NHS Forth Valley, NHS Fife, and NHS 
Grampian, clindamycin highest in NHS Lothian and NHS Forth Valley, and 
gentamicin highest in NHS Fife, NHS Greater Glasgow and Clyde and NHS 
Grampian. Results from the PCA for secondary care, as visualised in the joint plot 
(Figure 5-8Bi), were also largely similar to the ANOVA and Tukey analyses: NHS 
Ayrshire and Arran had the highest rates of prescribing of ciprofloxacin, clindamycin 
and erythromycin, NHS Greater Glasgow and Clyde had high rates of prescribing of 
erythromycin, gentamicin and trimethoprim, and both NHS Fife and NHS Forth 
Valley had comparably low rates of prescribing of all antimicrobials other than 
tetracycline. Figures 5-8Aii and 5-8Bii show the confidence ellipses for HBs on the 
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Figure 5-8: PCA – between HBs in (A) primary care and (B) secondary care prescribing.  
i –Joint plots show radiating lines that were superimposed on the ordination to identify variables 
associated with the grouping variable (i.e. year). Line direction indicates either a positive or negative 
relationship with an axis and the variables of the secondary matrix, and the length shows the strength 
of correlation on that axis. Crosses indicate the centroid of the polygon. The ordination was rotated to 
show the strongest correlations along axis 1.  
ii –Confidence ellipses, with 95% confidence limits, show the location of the data points in ordination 
space lie. Crosses indicate central points of ellipses. 
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HB abbreviations: AA = NHS Ayrshire and Arran, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS 
Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS Lanarkshire, LO = NHS Lothian.  
Antimicrobial abbreviations: Cl, clindamycin; Cp, ciprofloxacin; Er, erythromycin; Gn, gentamycin; Te, 
tetracycline; Tr, trimethoprim. 
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5.3.2.5 Trends in prescribing by NHS Health Boards over time 
Prescribing rates were further investigated using the model 
(𝑚𝑜𝑑 < − 𝑙𝑚(𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 ~ 𝐻𝐵 +  𝑌𝑒𝑎𝑟 +  𝐻𝐵 ∗ 𝑌𝑒𝑎𝑟)) to determine if there 
were differences in prescribing rates in each NHS HB over time. Model outputs are 
given in Appendix Table 2A (primary care) and Appendix Table 2B (secondary 
care). There were significant interactions between HB and year in both primary and 
secondary care indicating differences in prescribing in each HB over time for each 
antimicrobial (p<0.0001) except tetracycline in secondary care (p>0.05). An additive 
model (𝑚𝑜𝑑 < − 𝑙𝑚(𝑝𝑟𝑒𝑠𝑐𝑟𝑖𝑏𝑖𝑛𝑔 𝑟𝑎𝑡𝑒 ~ 𝐻𝐵 +  𝑌𝑒𝑎𝑟)) for tetracycline in secondary 
care was not significant (p>0.05). Thus, prescribing rates over time differed between 
HBs. Differences in prescribing rates between HBs for primary care are plotted in 



















The Epidemiology of MRSA in Scotland 
142 
 




HB abbreviations: AA = NHS Ayrshire and Arran, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS 
Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS Lanarkshire, LO = NHS Lothian.  
Antimicrobial abbreviations: Cl, clindamycin; Cp, ciprofloxacin; Er, erythromycin; Gn, gentamycin; Te, 










































































































































































HB abbreviations: AA = NHS Ayrshire and Arran, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS 
Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS Lanarkshire, LO = NHS Lothian.  
Antimicrobial abbreviations: Cl, clindamycin; Cp, ciprofloxacin; Er, erythromycin; Gn, gentamycin; Te, 
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5.3.3 The association between prescribing rates and resistance 
5.3.3.1 Univariate analyses 
Associations between prescribing rates and antimicrobial resistance were examined 
using univariate analysis with prescribing rates as the independent variables and the 
proportion resistant at t0 and each time lag (t1–t6) as the dependent variables. Model 
outputs for primary care are shown in Appendix Tables 3A and for secondary care in 
Appendix Tables 3B. Prescribing rates were positively associated with the concurrent 
proportion resistant (t0), and also at each time lag (t1 – t6) for clindamycin and 
gentamicin in primary care, and for gentamicin and trimethoprim in secondary care. 
Primary care prescribing rates of trimethoprim were positively associated with 
trimethoprim resistance in t0 and t1. No other associations were found (p>0.05).   
5.3.3.2 Multivariate analyses 
In a multivariate analysis, the proportions of isolates resistant to each antimicrobial at 
t0 were the dependent variables, and prescribing rates (both primary and secondary 
care), HB and year were the independent variables. When a significant model was 
identified, it was then run using staggered resistance data representing lag period t1-
t6 as the independent variable. Significant associations between prescribing and 
resistance were only found for clindamycin, gentamycin and tetracycline.  
The best fitting model to describe clindamycin resistance was an additive model 
including the variables primary care prescribing, year and NHS HB (Table 5-6). This 
model was positive and significant (p<0.0001) at t0 and each time lag (t1-t6). This 
model was significant albeit with low adjusted R
2
 values. The best fitting model to 
describe gentamicin resistance included primary care prescribing and secondary care 
prescribing with an interaction term (Table 5-6). This model was positive and 
significant (p<0.0001) at t0 and each time lag (t1-t6) but with low adjusted R
2
 values. 
The best fitting model to describe trimethoprim resistance included secondary care 
prescribing only (Table 5-6) and this was positive and significant (p<0.0001) at t0 
and each time lag (t1-t6).  
In the two aforementioned PCAs; antibiotic resistance data was included as an 
overlay in matrix 2. Prescribing and resistance data represented concurrent years (i.e. 
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t0). The joint plots (primary care by years - Figure 5-10Ai, primary care by HB – 
Figure 5-10Aii; secondary care by years - Figure 5-10Bi, secondary care by HB – 
Figure 5-10Bii) show weak associations, particularly for secondary care in which 
resistance and prescribing of erythromycin, gentamycin, tetracycline and 
trimethoprim were on radiating lines in similar directions that occupied proximal 
ordination spaces (Figure 5-10Bi). This is also the case for gentamycin and 
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Table 5-6: Results of multivariate analysis for clindamycin, gentamycin and trimethoprim –











Clindamycin resistance ~ primary prescribing rate (Pr) + Year (Y) + HB 
t0 Pr 0.23 0.07 0.002 ** 0.18 <0.0001 
 Y -0.01 0.01 0.005 **   
 HB 0.03 0.01 <0.0001 ***   
t1 Pr 0.27 0.08 0.0005 *** 0.19 <0.0001 
 Y -0.01 0.01 0.01 *   
 HB 0.03 0.01 <0.0001 ***   
t2 Pr 0.26 0.07 0.0006 *** 0.23 <0.0001 
 Y -0.02 0.01 0.004 **   
 HB 0.03 0.01 <0.0001 ***   
t3 Pr 0.24 0.07 0.002 ** 0.23 <0.0001 
 Y -0.01 0.01 0.01 *   
 HB 0.03 0.01 <0.0001 ***   
t4 Pr 0.22 0.08 0.004 ** 0.23 <0.0001 
 Y -0.01 0.01 0.04 *   
 HB 0.03 0.01 <0.0001 ***   
t5 Pr 0.16 0.08 0.03 * 0.23 <0.0001 
 Y -0.01 0.01 0.13    
 HB 0.04 0.01 <0.0001 ***   
t6 Pr 0.13 0.08 0.1 . 0.22 <0.0001 
 Y -0.01 0.01 0.37    
 HB 0.04 0.01 <0.0001 ***   
Gentamicin resistance ~ primary prescribing rate (Pr) * secondary prescribing rate (Sec) 
t0 Pr 0.71 0.19 0.0002 *** 0.29 <0.0001 
 Sec 0.14 0.03 <0.0001 ***   
t1 Pr 0.46 0.19 0.02 * 0.25 <0.0001 
 Sec 0.15 0.03 <0.0001 ***   
t2 Pr 0.46 0.18 0.01 * 0.21 <0.0001 
 Sec 0.12 0.03 <0.0001 ***   
t3 Pr 0.44 0.19 0.02 * 0.18 <0.0001 
 Sec 0.12 0.03 <0.0001 ***   
t4 Pr 0.39 0.19 0.04 * 0.15 <0.0001 
 Sec 0.11 0.03 0.0002 ***   
t5 Pr 0.46 0.19 0.02 * 0.17 <0.0001 
 Sec 0.11 0.03 0.0001 ***   
t6 Pr 0.56 0.19 0.004 ** 0.18 <0.0001 
Trimethoprim resistance ~ secondary prescribing rate (Sec) 
t0 Sec 0.02 0.0038 <0.0001 *** 0.15 <0.0001 
t1 Sec 0.02 0.0036 <0.0001 *** 0.14 <0.0001 
t2 Sec 0.01 0.0038 0.0006 *** 0.08 0.0006 
t3 Sec 0.01 0.0037 0.0009 *** 0.08 0.0009 
t4 Sec 0.01 0.0037 0.0003 *** 0.09 0.0003 
t5 Sec 0.01 0.0037 <0.0001 *** 0.11 <0.0001 
t6 Sec 0.02 0.0036 <0.0001 *** 0.13 <0.0001 
Sig.: Significant = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 1 = ‘ ’  
SE:  standard error; Adj. R2 : adjusted R2; Var. p-value: variable 
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Figure 5-10: PCA – the previously shown joint plots for (A) primary care prescribing (i) over 
years and (ii) NHS Health Boards and for (B) secondary care prescribing (i) over years and (ii) 
NHS Health Boards with additional information on AMR superimposed. 
(Ai)       
 










HB abbreviations: AA = NHS Ayrshire and Arran, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS 
Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS Lanarkshire, LO = NHS Lothian.  
Antimicrobial abbreviations: Cl, clindamycin; Cp, ciprofloxacin; Er, erythromycin; Gn, gentamycin; Te, 
tetracycline; Tr, trimethoprim. 
Resistance in MRSA population to each antimicrobial: r_CpMRSA, Cp; r_ClMRSA, Cl; r_ErMRSA, Er; 








5.4.1 The volume of prescribing in primary and secondary care 
Despite concerns of over-prescribing of antimicrobials and the threat of the 
post-antibiotic era, prescribing rates of several antimicrobials increased over this 
study period. Primary care prescribing was far higher than that in secondary care, 
although this differed between antimicrobials. This agrees with other studies reported 
in the literature: in the UK in 2005, approximately 80% of all antibiotics were 
prescribed by GPs, most of which were for respiratory infections [187]. Similarly, for 
the period 2009-2010 in the Netherlands, 80% of prescribing occurred in primary 
care [188].It is difficult to reduce antimicrobial consumption [127], particularly when 
the burden of bacterial disease remains high, and where patients expect to be treated 
with drugs and therefore there is pressure on medical professionals to prescribe 
[189].  
5.4.2 Spatial differences 
This study also found that, for all antimicrobials studied, the rate of prescribing 
differed between Health Boards. This could suggest spatial variation in prescribing 
policies and implementation of those policies. It may also reflect the different 
hospital types or specialties within those HBs with prescribing pressures differing 
between locations to meet the needs of infections or conditions particular to those 
hospitals or specialties. It may also reflect a variation in demographics, e.g. age, sex, 
ethnicities, or other social characteristics of an HB, e.g. low social economic status, 
or high rates of drug abuse. 
5.4.3 AMR and prescribing 
It is presumed that in high antimicrobial selection pressure environments, i.e. where 
there is high levels of antimicrobial prescribing and consumption, it would be a 
selective advantage for bacteria to be resistant to those drugs, and hence it would also 
be expected that with intensifying usage resistance would also increase [48-50]. In 
this study, significant positive associations between prescribing and resistance were 
found for gentamicin and trimethoprim in both primary and secondary care, and 
clindamycin in primary care only. For clindamycin and gentamycin, resistance was 
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seen concurrently with prescribing but was also detectable up to 18 months later (6 
quarters). In a meta-analysis of the effect of prescribing on resistance in different 
bacterial populations, there was strong evidence of associations which were strongest 
in the month directly after prescribing, but detectable up to 12 months after 
prescribing [184]. The association between prescribing of several antimicrobial 
classes and an observed change in the proportion of S. aureus that was MRSA in an 
Aberdeen hospital was seen for each drug class within 7 months, (only 1 month delay 
described for macrolides, penicillins with extended spectrum, and third-generation 
cephalosporins) [126].  
Although trimethoprim resistance was strongly linked to hospital use, clindamycin 
resistance was a response to primary healthcare prescribing and gentamicin 
resistance to both primary and secondary care. Other antimicrobials resistances were 
not clearly linked to either primary or secondary care prescribing. This may imply 
that clindamycin resistance is being imported into hospitals on MRSAs, MSSAs or 
some other route. In Chapter 4 of this thesis, it was noted that levels of clindamycin 
resistance remained high over the study period (2003-06, 2008-2012) in the 
healthcare-associated and nursing home-associated EMRSA-16 clone but levels of 
resistance increased from low to moderate levels in non-EMRSA-15 and non-
EMRSA-16 ‘other’ clones. Additionally, the proportion of ‘others’ resistant to 
trimethoprim also increased over the study period of Chapter 4. Since the 
antibiograms of EMRSA-15s and EMRSA-16s remained relatively stable (Chapter 
4), and the ‘others’ group seemed to be expanding, it is possible that the associations 
between prescribing and resistance in this Chapter may apply to the ‘others’ clonal 
group only. Owing to small sample sizes, this could not be accurately tested. 
The multivariate models showed significant positive associations between resistance 
and prescribing in both primary and secondary care. This is an important finding as it 
might be assumed that since MRSA bacteraemia is primarily a hospital acquired 
infection, only stewardship in secondary care settings is important, but this study 
suggests otherwise, e.g. that stewardship in all settings is important. This is 
something that could be investigated further. However, model outputs showed low 
adjusted R
2
 values meaning that while these were the best fitting models to describe 
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the data given the available variables, there may have been other variables which 
influenced the level of clindamycin, gentamycin and trimethoprim resistance. These 
variables are discussed below. 
The lack of association between resistance and prescribing for other antimicrobials 
could be due to fixed resistances in bacterial population which might have resulted 
from historic prescribing, or maintained due to compensatory mutations diminishing 
or cancelling any fitness cost to the bacteria [49]. It is thought not to be beneficial to 
harbour resistance genes against drugs which are not in current use since resistance 
can carry a fitness cost. Thus, resistance tends to be eliminated once the selective 
pressure is removed [50]. Alternatively, it may be that resistance to one antimicrobial 
is genetically linked to another resulting in resistance to an antimicrobial that is not 
currently in use. Examples of such co-resistance include the acquisition of any of the 
erm genes (ermA, ermB, ermC, ermT, carried on mobile genetic elements (MGEs)) 
which confer resistance to both erythromycin and clindamycin [51], and acquisition 
of any one of the genes aadD, aacA-aphD, ant4 (again MGEs) which confer 
resistance to aminoglycosides kanamycin, tobramycin and neomycin [176, 177].  
5.4.4 Limitations 
There were several limitations to this study. These limitations would be important 
issues to consider in a subsequent, larger study involving additional antimicrobials 
and pathogens. Incomplete data for both primary and secondary prescribing meant 
that this study was restricted to using seven HBs with the most complete data. 
Furthermore, only hospitals which used compatible pharmacy administration 
systems, e.g. Ascribe RX® Pharmacy System, were capable of electronically 
submitting data to HMUD which may have introduced bias and led to important 
trends in other HBs being missed. However, the HBs selected represent 
approximately 80% of the Scottish population and so the most significant trends 
were likely identified.  
Only 14 antimicrobials were initially selected to look at general patterns, and 6 
antimicrobials for further analysis. This may have led to missed trends and means 
that this study cannot give estimates of total antibiotic usage. However, the selected 
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antibiotics represent those in common clinical usage and that are important for 
MRSA treatment and resistance. A disadvantage of both primary and secondary 
prescribing data is that they represent only a proxy for antibiotic usage. Primary 
prescribing data represent all prescriptions that are dispensed by community 
pharmacies, but not necessarily used or taken by the patient, and secondary 
prescribing data represent drugs dispensed from hospital pharmacies to different 
hospital departments and, again, not necessarily administered to patients. While these 
prescribing datasets represent only a proxy measure for antibiotic usage; this was the 
best data available for researching population-level prescribing trends in Scotland at 
the time of the analysis.  
No prescribing information was available for topical agents or items without 
associated DDDs. This included mupirocin, the use of which is thought to have 
greatly increased in the past few years to treat MRSA skin infections and nasal 
colonisations since it emerged that nasal decolonisation of patients and healthcare 
workers dramatically decreases the risk of S. aureus nosocomial spread and infection 
[109]. Perhaps an additional constraint of this study is that results cannot be applied 
at the individual-level since this was a population-based study that cannot adjust for 
individual level doses or characteristics [189].  
 
5.5 Conclusion 
This study serves as a pilot study for a much larger analysis examining trends and 
associations between prescribing and resistance for a greater number of 
antimicrobials and pathogens. As a stand-alone project, sound methods were 
developed for investigating spatial and temporal trends, and associations between 
prescribing and resistance for MRSA. There are several potential public health 
messages arising from this study.  
Firstly, it was found that antibiotic usage of several antimicrobials increased and the 
rate of this increase should be monitored to prevent extreme over-use and drugs 
potentially becoming obsolete.  
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Secondly, the rate of prescribing of different antimicrobials differed between HBs 
and over years which could be due to several factors but likely mirrors differing HB-
specific prescribing guidelines but also represents a lack of consistency in treatment. 
Thirdly, resistance was found to be associated with prescribing rates for three 
antimicrobials over this study period, although there are also likely to be other 
factors contributing to resistance (for example historic prescribing).  
Secondly, the rate of antimicrobial prescribing differed between HBs and over years. 
This could be due to several factors but likely mirrors differing HB-specific 
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Chapter 6: A hospital-level risk factor analysis of 
Staphylococcus aureus bacteraemia in Scotland 
 
6.1 Background  
Healthcare-associated infections (HAIs) have been an unwanted aspect of healthcare 
systems for several decades. Staphylococcus aureus (S. aureus) is a common HAI 
which results in a spectrum of clinical conditions ranging from mild and often 
self-limiting skin and soft tissue infections to more serious illnesses including 
bacteraemia, pneumonia and toxic shock syndrome. Despite representing only a 
proportion of all symptomatic S. aureus infections, S. aureus bacteraemia (SAB) 
contributes globally to a considerable and disproportionate disease burden owing to 
their high associated mortality rates from life-threatening complications such as 
infective endocarditis and metastatic infections [158]. Therefore, SAB is considered 
a serious disease outcome of S. aureus infection and of high clinical importance. 
Furthermore, when methicillin-resistant S. aureus (MRSA) is the causative agent of 
bacteraemia, the risk of treatment failure and mortality is greater, and associated 
costs of managing these patients are higher than patients with bacteraemia caused by 
methicillin-sensitive S. aureus (MSSA) bacteraemia [10-12].      
To design successful and targeted intervention programmes, risk factor analyses are 
often carried out to identify behaviours and characteristics associated with 
transmission, morbidity and mortality. Many studies on risk factors for S. aureus and 
MRSA infections including SAB have been performed at the patient-level, 
identifying characteristics such as previous hospitalisation, recent antimicrobial 
therapy, indwelling vascular devices, prior invasive or surgical procedures, often 
within risk groups such as the elderly and those with underlying health conditions 
[53, 60]. For more information on risk factors, see Chapter 1.1.3. 
However, these patient-level characteristics do not fully explain observed 
heterogeneity in the number of bacteraemia cases between hospitals. Therefore, 
hospital-level risk factors must also be considered, for example, hospital size, 
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hospital connectedness where hospitals are connected through shared patients, and 
hospital type (for examples of these risk factors in the literature, see Chapter 1.1.3.5).  
Controlling the spread of MRSA depends on knowledge of where the bulk of disease 
burden lies and understanding why infections occur where they do.  Therefore, the 
aim of this study was to determine whether hospital connectivity, type and size 
significantly influence hospital-level MRSA morbidity rates in mainland Scottish 
hospitals. The approach was twofold: firstly to identify risk factors for the presence 
of MRSA bacteraemia in all Scottish mainland hospitals, and, secondly, to identify 
risk factors for high rates of MRSA bacteraemia for General hospitals only.  
6.2 Methods 
6.2.1 Hospital selection 
Initially all 264 facilities listed in the financial year 2007/08 Information Services 
Division (ISD) Scotland cost book reports (R020 and R020LS) were considered 
[190]. For analysis, a hospital was defined as a secondary healthcare facility with at 
least one inpatient per year and with at least one hospital specialty (previously known 
as departments). These facilities were scrutinised and those with a facility index 
other than ‘H’ (for hospital) were excluded. The excluded facility indices were: 
residential homes (index R), nursing homes (index V), GP surgeries and health 
centres (index B), clinics (index C), prisons (index P) and others. Within facility 
index H, dental hospitals, clinics (hospital- and non-hospital clinics), closed 
locations, day hospitals, the NHS National Waiting Times Centre (Golden Jubilee 
national hospital), Clydebank, Glasgow, and the State hospital, Carstairs, South 
Lanarkshire, and a further 3 hospitals were excluded since their function and costs 
were considered not comparable to other hospitals included in the study. In addition, 
island Health Boards; NHS Orkney, NHS Shetland and NHS Western Isles were also 
excluded since they are considered to contain atypical hospitals. Therefore the study 
included hospitals from the Scottish mainland only. This resulted in 198 National 
Health Service (NHS) hospitals being included in the study for the financial year 
2007/08, and 66 facilities being excluded. All hospitals in Scotland and the number 
of MRSA bacteraemia cases are shown in Figure 6-1. 
The Epidemiology of MRSA in Scotland 
156 
 
6.2.2 Data collection 
6.2.2.1 Case data 
MSSA and MRSA bacteraemia case data by hospital for the financial years 2006/07 
– 2010/11 (5 years) were received from Health Protection Scotland (HPS). The 
financial year 2007/08 (6 April 2007 – 5 April 2008) was chosen as the study year 
because at the time it was the only year for which data were available for all risk 
factors (hospital size, type and connectivity). While the study period was only one 
year, size (measured in occupied bed days (OBDs)) did not vary considerably from 
year to year (See Appendix Figure 1A), and size (measured in metres squared) and 
hospital type did not change over the five year period. While this study only used 
data from a single year, hospitals that had MRSA bacteraemia cases, i.e. were MRSA 
‘positive’, tended to remain positive over the five-year period; and hospitals that did 
not have any MRSA bacteraemia cases, i.e. were MRSA negative, tended to remain 
negative over the five-year period (Appendix Table 4). Almost 90% of hospitals had 
the same status (either MRSA bacteraemia positive or negative) over the five years 
(financial years 2006/07 to 2010/11 inclusive) for which data were available. There 
were three hospitals that were only positive for the year of this study. All models 
were run with and without these hospitals with no change in the results.  
6.2.2.2 MSSA agreement with MRSA: justification for MRSA data only 
This study focuses on MRSA bacteraemia only. However, the justification for not 
including MSSA bacteraemia was scrutinised by testing the agreement between 
MSSA and MRSA data. The association between the presence of MRSA and MSSA 
for all hospitals was examined for the financial year 2007/08 (chi-square test) and 
across all years for which data were available (2006/07 – 2010/11, n=5 years) (Table 
6-1). The analysis across financial years was performed using a stratified 2x2 
analysis which calculates the Breslow Day statistic. This tests the null hypothesis that 
there is no difference between MSSA and MRSA where p≤0.05, i.e. just as likely to 
have one or the other, and the relationship between MSSA and MRSA is the same 
across all years (homogeneity of odds).  
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6.2.2.3 Risk factors 
Data regarding potential risk factors were obtained from ISD for each hospital for the 
financial year 2007/08 (a full list of variables in Appendix Table 5). As the aim was 
to test specific hypotheses regarding the effect of hospital size, type and connectivity; 
the majority of the data that were obtained represented different measures of those 
characteristics. Other measures including average occupancy rate, total number of 
whole time equivalent (medical and dentistry, nursing and midwifery, domestic, and 
support services) staff, patient-staff ratios (number of patients to medical and 
dentistry, nursing and midwifery, domestic, and support services staff), and cleaning 
by hospital size were considered (Appendix Table 5). 
6.2.2.3.1 Hospital size 
Measures of size included occupied bed days (OBD), surface area (m
2
), average 
staffed beds, total inpatients discharged, total staff members and others (Appendix 
Table 5). 
6.2.2.3.2 Hospital type 
Within the ISD database, Scottish hospitals are grouped into the following 
categories: Category A (General (mainly acute) including Teaching (A1), large 
General (A2), General (A3), and Sick children’s (A4)); Category B (Long stay), 
Category C (Mental); Category D (psychiatry of learning difficulties); Category E 
(Maternity); and Category J (Community). Information on the presence and absence 
of 46 specialties was also acquired (Appendix Table 5).  
6.2.2.3.3 Connectivity 
To quantify movements of patients between hospitals, patient admission data were 
obtained from ISD. Patient admission data covered all admissions to healthcare 
facilities in Scotland for the calendar year 2007 (1 January – 31 December 2007). 
From this dataset movements were extracted for patients between hospitals either as 
direct transfers, i.e. from one hospital directly to another hospital, or as indirect 
transfers, i.e. when a patient was discharged from one hospital into the community 
and subsequently, within the period covered by the data, admitted to another hospital. 
From these data, a movement matrix was derived for all connected hospitals in 
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Scotland [191] and then various summary measures of hospital connectivity 
generated (Table 6-2).  
6.2.3 Descriptive and statistical analyses  
All statistical analyses were carried out in R (version 3.1.2) [154]. 
6.2.3.1 Descriptive analyses 
Descriptive analyses were conducted to summarise hospital characteristics and the 
number of cases per hospital for both MSSA and MRSA. Descriptive analyses of 
potential hospital-level risk factors were also done. Several variables were log10(x+1) 
transformed to correct for non-normal distribution of the data and others were 
categorised. A full list of all 39 explanatory variables is shown in Appendix Table 5. 
Hospital connectivity variables were examined as both continuous and categorical 
variables. Cut-off levels of connectivity variables were determined using receiver 
operating characteristic (ROC) curve analysis [14], above which hospitals were 
considered positive for MRSA bacteraemia. The cut-off chosen was one that 
maximized the sum of the sensitivity and specificity. Confidence intervals (CIs, 25th 
and 75th percentiles) for the cut-off values were generated from 10,000 bootstrap 
simulations. The presence of a hospital specialty (n=46) and the association with 
MRSA cases was investigated using Chi-square or Fisher’s exact tests where 
appropriate. Specialties that were statistically significant in this univariate screening 
were included in a nonmetric multi-dimensional scaling (NMS) analysis. Data 
regarding hospital specialties was summarised using NMS to reduce the number of 
variables. The NMS was performed in PC-ORD version 6.08 (MJM software Design, 
Gleneden Beach, OR) using the 36 specialties that were sufficiently represented 
across all hospitals, i.e. present in at least 5% of the hospitals, so 10 specialties were 
excluded from this analysis. Multi-response Permutation Procedures (MRPP) 
analysis [15] was used a posteriori to test the hypothesis of no difference between 
hospital status (presence/absence of MRSA bacteraemia) and hospital type (Category 
A, B, C, D, E, J). The association between the presence of a specialty within a 
hospital and the number of MRSA bacteraemia cases was examined for each of the 
46 hospital specialties using Chi-square or Fisher’s exact where appropriate. Odds 
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ratios (OR) are given for specialties with statistically significant Chi-square tests 
(Table 6-3). 
6.2.3.2 Regression analyses 
For both the univariate and multivariate analyses, two models were considered. 
Model 1 was a logistic regression model with binomial distribution fitted to 
presence-absence data for all hospitals (n=198) to identify risk factors for having 
cases versus not. Model 2 was a generalised linear model with a Poisson distribution 
fitted to count data, offset by the logarithm of OBD, to identify risk factors 
associated with higher rates of MRSA bacteraemia in General (Category A) hospitals 
only (n=38).  
Before undertaking the multivariate analysis, each variable was examined 
individually in a univariate analysis. Correlational analyses were performed to look 
for correlations between explanatory variables and matrices were constructed to 
screen for confounders. Correlation was considered strong if the coefficient was 
>0.8, moderate if >0.5 and <0.8, and weak if below 0.5. Correlation coefficients of 
size and connectivity variables are shown in screening matrices in Appendix Figure 
2A (size) and 2B (connectivity). There were strong correlations between several 
different potential measures of size (Appendix Figure 2A) and connectivity 
(Appendix Figure 2B). Variables that were statistically significant in a univariate 
analysis (p<0.05) and not highly correlated to other variables were taken forward to 
the multivariate statistical analysis. A p<0.05 screening level was chosen as there 
were many variables that were significant in the univariate analysis. This is not 
surprising given that these variables were chosen a prioir as possible risk factors.  
A backward elimination approach was applied in the multivariate analysis. Statistical 
significance was set at p≤0.05. Likelihood-ratio tests and the akaike information 
criterion (AIC) were used to select the most parsimonious model. The robustness of 
the final model was tested by applying a forward stepwise approach and examining 
the diagnostic statistics. The stability of the final model was also checked by 
removing the variables in the model and assessing the effect of the remaining 
variables. The final models were deemed to be both robust and stable.  




6.3.1 General epidemiology 
6.3.1.1 Hospitals Summary 
There were a total of 1,018,597 inpatients discharged from 198 hospitals (range 1 to 
75159 inpatients, median = 338 inpatients per hospital) in Scotland over the financial 
year 2007/08, representing a total of 7,506,822 occupied bed days (OBD) (range 990 
to 322500 OBDs, median =12170OBDs per hospital). The size of hospitals 
(measured in m
2
) ranged from 100 to 15200 m
2 
(median = 3621), the number of 
specialties per hospital ranged from 1 to 29 (median = 2), the proportion of 
specialties per hospital that were acute ranged from 0 – 1 (median = 0.5) and the 
average occupancy rate per hospital ranged from 28.6 - 97.3% (median = 78.2%). 
Thirty-eight hospitals in our study were classed as General hospitals (mainly acute), 
52 as long-stay hospitals, 34 as mental hospitals, 13 as psychiatry of learning 
disabilities hospitals, 3 as maternity hospitals, and 58 as community hospitals. 
6.3.1.2 Cases 
From the 198 hospitals included in this study, the majority (n=152, 77%) reported no 
MRSA bacteraemia cases (Figure 6-1). The remaining 46 hospitals reported 662 
MRSA bacteraemia cases in total (range 0 to 72 MRSA cases at the hospital-level). 
From these 662 cases, 47 cases died from all-cause mortality within 30 days, giving a 
30-day case-fatality ratio of 7.1%. MRSA bacteraemia occurred in 0.06% of all 
inpatients in Scotland. 
During the study year, MRSA was the causative agent of 36.6% of all 
Staphylococcus aureus bacteraemia (SAB) infections although this varied between 
NHS Health Boards. The highest percentage of total SAB due to MRSA in NHS 
Lanarkshire (43.7%, n=126), and the lowest percentages in NHS Borders (24.0%, 
n=25), and NHS Dumfries and Galloway (23.7%, n=38). MSSA and MRSA 
bacteraemia co-occurred in the same 39 hospitals.  
Of the 198 hospitals included in this study, the majority (n=149, 75%) reported no 
MSSA bacteraemia cases. The remaining 49 hospitals reported 1147 MSSA 
bacteraemia cases in total (range 0 to 108). Of these 1147 cases, 51 died from all-
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cause mortality within 30 days, giving a 30-day case-fatality ratio of 4.4%. MSSA 
bacteraemia occurred in 0.11% of all inpatients in Scotland. 
Figure 6-1: Map of mainland Scotland with NHS Health Boards.  
Circles show the 198 hospitals included in this study for financial year 2007/08. Each circle represents 
one hospital. Number of cases per hospital is continuous (ranging from 0-72) and the size of circle 
represents the number of cases with increasing number of cases illustrated by increasingly larger 




6.3.1.3 MSSA agreement with MRSA - Justification for MRSA data only 
There was a significant association between MSSA and MRSA for financial year 
2007/08 (chi square test: 124.5, p<0.001) and this was consistent for all financial 
years for which data was available (Breslow Day Statistic, 2.969, p=0.5642). 
Hospital’s that were positive for MRSA were 101.3 (95%CI = 59.44-179.8) times 
more likely to be positive for MSSA. The data are shown in Table 6-1. Owing to the 
substantial and significant agreement in the data, MRSA herein is the focus of the 
study. 
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Table 6-1: Number of hospitals that were positive or negative for MRSA and MSSA. 
 MSSA 
Year 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 
MRSA N P N P N P N P N P 
P 8 34 6 40 3 37 2 37 4 33 
N 146 10 143 9 148 9 140 13 129 14 
P, positive for MSSA/MRSA; N, negative for MSSA/MRSA.  
For the financial year 2006/07 to 2010/11. Total 198 hospitals, 5 financial years. 
 
 
6.3.2 Univariate analysis of risk factors 
Model outputs from the univariate regression analyses are shown in Appendix Table 
6 (Model 1) and Appendix Table 7 (Model 2). Several measures of hospital size (size 
(m
2
), average number of staffed beds, OBDs, total patients discharged) were found to 
be statistically significant predictors for the presence of MRSA bacteraemia cases 
(model 1, p<0.0001) and number of cases in General hospitals (model 2, p<0.0001). 
Figure 6-2 shows the distribution of MRSA bacteraemia cases with respect to 
hospital size. Hospitals were ranked by size, as measured by occupied bed days. 
Several proxy measures of size were highly and positively correlated with correlation 
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Figure 6-2: Number of MRSA bacteraemia cases for the 198 hospitals included in this study. 
Hospitals were arranged by increasing size (represented by number of occupied bed days (OBD)). 
 
 
Hospital connectivity, both as a continuous or as a threshold variable, was 
statistically significant with both models (Appendix Tables 6 and 7). Table 2 shows 
the best cut-off levels for the connectivity measures identified using ROC curve 
analysis. For all cut-offs found, hospitals above the threshold were at significantly 
increased risk for the presence of MRSA bacteraemia (Table 6-2). Several measures 
of connectivity were also highly and positively correlated with correlation 






































Hospital Rank (Smallest to Largest)  
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Table 6-2: Summary of hospital connectivity measures. 








Total number of patients moving to 
this hospital from other hospitals 
adjusted by number of staffed beds 
3.61 3.26-4.09 <0.001 
In-degree 
Number of hospitals that 
transferred patients to this hospital 
[11] 
11 6-25 <0.001 
Out-
degree 
Number of hospitals that receive 
patients from this hospital [11] 
8 8-12 <0.001 
Closeness 
centrality 
Normalised measure of centrality 
of a node in a network based on the 
mean length of all shortest paths 
from that node to every other 





afrom 10,000 bootstrap simulations 
bFisher's exact test 
Hospital type was an important factor. In regression analyses with model 1; being a 
General hospital (p<0.0001), having increased number of specialties (p<0.0001), and 
having a higher proportion of specialties that were acute (p<0.0001) were risk factors 
for the presence of MRSA bacteraemia. In the regression analyses with model 2; 
being a Teaching hospital (p<0.0001), having increased number of specialties 
(p<0.0001), and having a higher proportion of specialties that were acute (p<0.0001) 
were risk factors for increasing MRSA bacteraemia rates.  
Table 6-3 lists all specialties included in the NMS. It also lists results of univariate 
screening using Chi-square or Fisher’s exact where appropriate and providing OR for 
specialties that with statistically significant Chi-square or Fisher’s exact tests. The 
univariate screening of specialties was carried out prior to the NMS analysis and to 
aid selection of variables for the NMS analysis. Several specialties had an increased 
risk of MRSA (OR>1, and significant p-values (p≤0.05) were positively associated 
with MRSA). Hospitals with intensive care units (ICUs) were identified as having 
the highest significant odds of MRSA bacteraemia compared to hospitals without 
ICUs (OR = 196 (95%CI = 28.0-8096)). Hospitals with the specialties Geriatric 
Psychiatry, Learning Disabilities and General Practice were at a lower risk of MRSA 
(OR<1, i.e. protective against MRSA).  




Table 6-3: List of 46 hospital specialties and association with hospital-level MRSA bacteraemia 
Results of univariate screening using Chi-square or Fisher’s exact where appropriate and OR (for 
specialties that with statistically significant Chi-square tests and no cells where n=0). Specialties in 







𝒙𝟐 p OR (95%CI) 
Accident and Emergency 11 10 24.0 <0.001 41.9 (5.52-1832) 
Acute other 46 1 1.26 0.412 - 
Adolescent psychiatry 46 0 0.398 1.00 - 
Burns 11 9 17.98 <0.001 18.24 (3.50-177) 
Cardiac Surgery 46 5 13.25 0.001 - 
Cardiology 16 15 39.9 <0.001 73.1 (10.2-3095) 
Child psychiatry 46 1 2.81 0.232 - 
Clinical genetics 46 3 7.66 0.012 - 
Communicable Diseases 6 6 16.2 0.0001 - 
Coronary Care Unit 19 19 59.4 <0.001 - 
Dermatology 12 11 27.05 <0.001 47.46 (6.36-2055) 
Ear Nose Throat 19 17 42.46 <0.001 44.0 (9.38-401) 
Gastroenterology 13 11 23.65 <0.001 23.6 (4.73-223) 
General Medicine 38 32 101.9 <0.001 171.4 (35.7-1533) 
General Practice 69 5 15.2 <0.001 0.168 (0.049-0.461) 
General psychiatry 41 10 0.0389 1.00 - 
Geriatric Assessment 48 36 95.21 <0.001 42 (15.49-117) 
Geriatric long stay 77 14 1.802 0.227 - 
Geriatric Psychiatry 70 8 8.46 0.0045 0.306 (0.116-0.728) 
General Surgery 38 32 92.87 <0.001 84.57 (24.1-359) 
Gynaecology 21 20 57.34 <0.001 116 (16.6-4844) 
High Dependency Unit 26 24 67.7 <0.001 81.8 (17.7-734) 
Haematology 26 25 76.6 <0.001 180 (25.7-7425) 
Intensive Care Unit 27 26 80.7 <0.001 196 (28.0-8096) 
Learning Disabilities 18 1 3.48 0.079 0.177 (0.004-1.197) 
Medical other 18 11 15.93 0.003 6.51 (2.103-21.08) 
Medical Paediatrics 17 14 29.59 <0.001 21.7 (5.50-122) 
Nephrology 11 11 31.7 <0.001 - 
Neurology 11 10 24.0 <0.001 41.9 (5.52-832) 
Neurosurgery 46 4 7.46 0.011 14.4 (1.35-713) 
Obstetrics GP 12 3 0.129 1.00 - 
Obstetrics Specialist 21 17 35.97 <0.001 21.7 (6.3-92.9) 
Ophthalmology 20 18 45.84 <0.001 48.2 (10.3-438) 
Oncology* 11 10 24.01 <0.001 41.9 (5.52-1832) 
Oral surgery 17 15 35.9 <0.001 36.3 (7.65-334) 
Orthopaedics 32 29 83.7 <0.001 84.7 (21.9-459) 
Paediatrics 17 14 30.15 <0.001 22.4 (5.66-12.6) 
Rehabilitation Medicine 16 11 20.2 <0.001 9.24 (2.71-35.6) 
Respiratory medicine 15 14 36.56 <0.001 66.06 (9.18-2811) 
Rheumatology 11 9 17.98 <0.001 18.2 (3.50-177) 
Special Care Baby Unit 46 12 23.7 <0.001 17.5 (4.32-100) 
Spinal paralysis 46 1 2.81 0.232 - 
Surgical paediatrics 46 3 3.56 0.083 - 
Vascular surgery 9 9 25.3 <0.001 - 
Thoracic 46 5 13.3 0.001 - 
Urology 20 20 63.2 <0.001 - 
Young Chronic Sick 9 6 8.326 0.006 7.45 (1.493-47.4) 
‘*’: includes medical and clinical oncology; ‘-’: OR could not be calculated as 1 cell contained a zero, OR = Odds 
Ratio, x2=Chi square 
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6.3.3 Multivariate analysis of risk factors 
6.3.3.1 NMS results 
The NMS aimed to describe differences between hospitals with MRSA bacteraemia 
versus those that did not, based on presence of specialties for the 198 hospitals 
included in this study. The result of the NMS analysis was a two-dimensional 
solution that explained a total of 83.9% of the variation in the data. Additional 
dimensions provided no significant improvement in fit. The first axis, which was 
rotated to maximise the difference between hospitals with and without MRSA, 
explained 78.7% of the variation.  
MRPP was performed to test the null hypothesis of no difference between hospitals 
with MRSA versus those without. The null hypothesis of no difference between the 
groups can be rejected and the two groups occupy different regions of space as 
shown by the strong chance-correlated within-group agreement (A) and significance 
level (p<0.0001).  
Progression along NMS Axis 1 was associated with an increasing number of MRSA 
bacteraemia cases, increasing hospital size (OBD) and an increasing number of 
specialties (Figure 6-3).  
Three significantly (MRPP, p<0.001) different hospital groups were identified, 
distributed along NMS Axis 1 (Figure 6-3), namely: Teaching, General (no 
teaching), and “Other”. The “Other” group corresponded  to the ISD hospitals 
designated categories B, C, D, E, J. Hospitals designated “Other” were at lower risk 
of MRSA than General Hospitals with no Teaching (Categories A2, A3, A4) which 
in turn had a lower risk than Teaching hospitals (Category A1). There was some 
overlap between the three groups meaning that there were some hospitals with 
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Figure 6-3: Nonmetric multidimensional scaling (NMS) of the specialties (n=36) for the 198 
hospitals included in this study. 
Two significant axes explain a total of 83.9% of the variation in the data with NMS axis 1 explaining 
78.7%, representing an increasing number of MRSA cases, increasing hospital size (OBD), and an 
increasing number of total specialties (from left to right along NMS Axis 1). 80% confidence ellipses 
drawn to designate significant groups based on hospital type as defined by Information Services 
Division (ISD): Teaching (Category A1; n=6, red points), General, no teaching (Category A2, A3, A4; 
n=32, grey points) and Other (Categories B, C, D, E, J; n=160, blue points). 
 
 
6.3.3.2 Model 1 - Risk factors for presence of MRSA bacteraemia cases (n=198 
hospitals).  
Results (Figure 6-5) showed that the probability of a hospital having at least one 
MRSA bacteraemia case increased with hospital size (log10OBD) but only for 
hospitals that exceeded the threshold for the connectivity variable outdegree 
(interaction: log10OBD x outdegree threshold, p=0.0009)). Hospitals above the 
threshold were statistically significantly (i.e. p≤0.05) at greater risk (OR (95%CI): 
309 (13-7213)) for having at least one MRSA bacteraemia case than hospitals below 
the threshold (OR (95%CI): 0.40 (0.042-3.92)), regardless of their size (Figure 6-5).  
 
 
General (no teaching) 
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Figure 6-4: Probability of a hospital having at least one case of MRSA bacteraemia. 
For hospitals above (red line, n=56) and below (blue line, n=142) the Outdegree threshold (Table 6-1). 
 
 
6.3.3.3 Model 2 - Risk factors for higher rates of MRSA bacteraemia (n=38 
hospitals).  
After adjusting for size (model included an offset for OBD); results showed (Table 6-
4) that the total number of patients transferred (proxy measure of connectivity), being 
a teaching hospital and the ratio of patients-to-domestic staff were all significant 
predictors of the level of MRSA bacteraemia in General hospitals. However, the 
significant effects of the total number of patients transferred varied depending on 
whether the General hospital was Teaching or non-Teaching (interaction, p=0.005). 
In General, non-Teaching hospitals, the rate of MRSA bacteraemia increased with 
the total number of patients transferred (p<0.001). Whereas, for General, teaching 
hospitals the number of patient transfers, which is already high, had no significant 
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Table 6-4: Risk factors for higher rates of MRSA bacteraemia in General Scottish mainland 
hospitals (n=38). 
Variable Estimate (SE) p-value Risk Ratio (95% CI)
a
 
Total patients transferred 
(log10) 
1.73 (0.332) 0.0682 1.69 (0.962-2.97) 
Teaching hospital 10.21 (2.18) <0.001 27134 (377-1954565) 
Ratio of patients to domestic 
staff 
0.253 (0.060) <0.001 1.29 (1.14-1.45) 
Total patients transferred 
(log10) 








aRisk ratio and 95% confidence intervals estimated using the modified Poisson Regression approach [24]. 
 
6.4 Discussion 
In this study, data on MRSA bacteraemia were obtained for all Scottish mainland 
hospitals, defined as a secondary healthcare facility with at least one inpatient per 
year and with at least one hospital specialty. Only 23% of the hospitals examined in 
this study reported at least one case of MRSA bacteraemia. This proportion was 
small however; the hospital definition included long stay, mental and community 
hospitals which were typically small facilities, providing very few specialties. 
Generally, hospitals that reported at least one case of MRSA bacteraemia over the 
study period were large hospitals. However, even large hospitals rarely had large 
numbers of reported MRSA bacteraemia cases unless they were also well connected 
to the wider hospital network. For all connectivity measures generated in this study, 
there seemed to be a cut-off below which a hospital had no or lower than expected 
MRSA bacteraemia cases from a model that included size alone. Although further 
testing would be required, such a measure is highly useful in identifying hospitals at 
high risk for MRSA bacteraemia (and potentially other HAIs) as it could help focus 
surveillance efforts at a national level. Hospital connectivity was also a significant 
risk factor in the level of MRSA bacteraemia observed in General hospitals thus 
providing further evidence that size alone cannot fully predict a hospital’s MRSA 
bacteraemia status.  
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6.4.1 Well-connected hospitals and transfer patients 
Since well-connected hospitals receive large volumes of transfer patients from 
several other facilities; a hospital’s level of connectivity is important in disease 
transmission. Previous studies have shown that transfer patients have a 
comparatively higher risk of nosocomial infection than non-transferred patients 
owing to different  demographics, health status at time of transfer (often acutely 
unwell and critical) and other patient-level risk characteristics [100]. Compared with 
non-transfer patients, transfer patients have also spent an increased length of time in 
the healthcare network and therefore have had increased chance of pathogen 
exposure, carriage or infection, and opportunities to seed and spread infections in 
their new hospitals.  
6.4.2 Hospital type 
When examining hospital type; Teaching hospitals were highlighted as having a 
large number of MRSA bacteraemia cases. Teaching hospitals are large, well 
connected and have a high number of specialties and teasing apart the effect of 
connectivity, size and hospital type is not easy. As all Teaching hospitals were well 
connected, there was no additional effect of further increasing connectivity. By 
comparison, increasing connectivity in non-teaching hospitals, led to significant 
increases in MRSA bacteraemia. Well-connected hospitals (which also tend to be 
large and Teaching hospital) are also more likely to generate cases in both the in-
coming transfer population as well as the rest of the hospital population (who also 
have patient-level risk factors for bacteraemia). With a higher proportion of 
specialties that are acute, well-connected hospitals tend to have the capacity to carry 
out specialist, complex or high-risk procedures on often acutely physically unwell 
individuals, who may be infectious, immune-compromised and high-risk for 
bacteraemia. For the same reasons, these hospitals will also receive the most acutely 
unwell emergency cases direct from the community increasing the at-risk hospital 
population and introducing new potential sources of infection.  
 
 




6.4.3.1 Community versus hospital acquired bacteraemia 
Unfortunately, a restriction of the data meant that acute hospital admissions with 
bacteraemia and cases that developed bacteraemia during their stay in hospital (i.e. 
hospital-associated versus community-associated cases) could not be distinguished. 
In a 3-year study of admissions to a large general hospital in NHS Lanarkshire, 
26.6% of all SAB cases and 18.8% of all MRSA bacteraemia cases were acute 
admissions, and the majority (81%) of acute admissions with MRSA bacteraemia 
were admitted from nursing homes and had been transferred from another hospital or 
had been an inpatient within the previous 6 months [192]. Similarly, in a five year 
study of bacteraemia trends in a teaching hospital in NHS Grampian, 44% of MSSA 
and 62% of MRSA bacteraemia were considered hospital-associated (defined as 
occurring  >48 hours after admission or ≤14 days from discharge) [9]. While this 
may not reflect the picture across all Scottish hospitals, bias could be introduced into 
this dataset since acute cases occurring in the community (including nursing homes) 
may be more likely to attend hospitals with accident and emergency departments. 
This would therefore increase the counts of bacteraemia cases for those hospitals.  
6.4.3.2 Direct and indirect hospital transfers 
Measures of connectivity in this study were estimated from referral data for both 
direct and indirect hospital-to-hospital transfers of patients in both directions 
regardless of bacteraemia status. Indirect transfers were those where the patient 
returns to the community or non-hospital-facility (i.e. nursing home) for a given 
period before being readmitted. In the case of the Scottish transfer network for the 
financial year 2007/08, approximately 15% of readmissions occurred within 7 days 
of discharge, 40% of cases were readmitted within 30 days, and 70% within 90 days. 
Pathogen carriage and infection can be very long lasting months or even years [193]. 
As a result, indirect transfers could lead to transmission on subsequent admissions 
(and therefore the source of the colonisation or infection not being the same the 
hospital where the bacteraemia was counted as occurring). Robotham et al [194] also 
suggested that readmissions to hospitals from the community were a critical 
consideration for control of HAIs to be successful.  
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6.4.3.3 Important caveats 
This study has some further limitations that must be considered. The definition of a 
hospital was intended to capture facilities with overnight patients receiving medical 
care. Nursing homes, for example, were excluded since not all patients would receive 
medical care, the demographics and risk factors of patients would likely differ from 
true hospitals, and nursing homes operate in a different way to hospitals. Despite 
this, the incidence of colonisation and all-type infection, i.e. outcomes other than 
bacteraemia, and level of transmission within nursing homes and to hospitals is 
expected to be high. Nursing homes are thought to harbour a vast number of 
Staphylococcus aureus colonisation and infections and therefore are thought to be an 
important reservoir for hospital infections [195-198]. 
 It is also expected that since bacteraemia is a notifiable condition, the number of 
cases would not be affected by substantial underreporting. It is acknowledged that by 
only studying the disease outcome bacteraemia may have influenced our results since 
severe outcomes tend to be associated with riskier procedures, certain hospital 
specialties and certain hospital categories. It is also accepted that MSSA and MRSA 
colonisation and other disease outcomes of S. aureus infection, such as wound 
infections, are likely occur in a significant proportion of hospitals throughout 
Scotland.  
It is an important finding that high patient-to-staff ratios were also identified as a risk 
factor for higher levels of MRSA bacteraemia. Patient-to-staff ratio of domestic 
workers was used as a proxy measure for the ratio of patients to cleaning staff. 
Hospital cleaning remains a vital strategy for effective infection control which was 
highlighted by this small but significant risk from our model. This result, however, 
supports the previously reported effect of heightened hygiene awareness and 
enhanced cleaning on reducing the number of new infections and microbial 
contamination of the hospital [148, 151, 172, 199].    
6.4.3.4 Unavailable information 
There were a number of potential risk-factors that data were not available for 
analysis. There was no access to universal data on within-hospital movements known 
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as ‘boarding’.  Boarding, where patients are moved to other wards to accommodate 
influxes of new patients or to more appropriate wards or specialties which may be of 
greater benefit to the patient [200], is thought to increase the risk of infection 
transmission. In addition, referrals (including both direct and indirect transfers) from 
outside Scotland were not considered. As suggested by Ciccolini et al [201], a 
regional approach, for example a UK-wide study, may be more appropriate than a 
Scotland only study as some patients are transferred across these borders. 
Unfortunately, the full repertoire of variables was not available for all hospitals 
elsewhere in the UK and the interconnectedness of hospitals in Scotland with 
elsewhere in the UK was not known. Data on the composition or demography of 
patients, such as mean age, sex, or proportion belonging to certain religions, 
ethnicities and social groups at different hospitals was also lacking. Such 
demographic mixes could differ between hospitals and since groups may have 
different patient-population-based risk-factors for bacteraemia; hospital demography 
could have contributed to hospital-level differences. Data on antibiotic usage are 
currently unavailable at the hospital-level. The number of daily defined dose (DDDs) 
per antibiotic would very likely be an important risk factor for MRSA although it 
would perhaps correlate with hospital size or the proportion of specialties that are 
acute. There was also no measure of universal hospital-level infection control or 
policy data to include in the study.  
 
6.5 Conclusion 
This is the first Scotland-wide study utilizing hospital-level characteristics to 
examine differences in MRSA bacteraemia morbidity among hospitals. This study 
showed that 23% of Scottish mainland hospitals reported cases of MRSA 
bacteraemia. Effort to reduce MRSA transmission and the number of bacteraemia 
cases should therefore be focused on large, well-connected hospitals. Further 
research should be conducted with respect to reducing the ratio of patients to 
domestic staff as a means of reducing the levels of MRSA bacteraemia infections, 
especially in teaching hospitals where the levels are very high. 
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Health Protection Scotland (HPS) and Scottish Government prioritise the 
implementation of effective infection control measures to reduce the spread of 
pathogens in nosocomial settings. MRSA bacteraemia may be considered as a 
marker for the ability to contain transmission of important pathogens in healthcare 
settings. Programmes that prevent MRSA bacteraemia transmission will likely be 
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Chapter 7: Thesis conclusion 
7.1 Main conclusions from chapters 
7.1.1 Chapter 2 – MSSA and MRSA morbidity and mortality trends 
MSSA bacteraemia rates did not significantly decline over time while total S. aureus 
and MRSA bacteraemia rates did. Government targets to reduce bacteraemia cases 
by 30% of the 2005/2006 levels were met for total SAB and targets were exceeded 
by the 2010 deadline with rates remaining low thereafter. However, this was due to a 
disproportionate reduction in MRSA SAB which reached 30% of the 2005/2006 
levels by 2010. MSSA did not decline to 30% of the 2005/2006 levels. In addition, 
there were no changes in mortality rates where the primary, secondary or combined 
cause of death was MSSA, however where MRSA was the primary, secondary and 
combined cause of death, mortality rates significantly declined over time. There were 
no significant declines in case-fatality ratio for either MSSA or MRSA. 
7.1.2 Chapter 3 – MRSA declines while MSSA remains a public 
health concern 
In this chapter, 11 years of microbiological and epidemiological data for isolates 
causing MSSA and MRSA bacteraemia in Scotland were examined. The main 
differences between MSSA and MRSA were: (1) antimicrobial resistance, with 
MRSA being multi-drug resistant and having longer antibiograms, (2) clone, with 
MRSA more associated with CC22, which includes the hospital-associated sequence 
type ST22, and MSSA with non-CC22 and non-CC30 ‘other’ clones, (3) patient age, 
with MRSA associated with older patients, and (4) hospital specialties with MRSA 
associated with care of elderly, high dependency units /intensive care units, renal and 
surgery, and MSSA with accident and emergency, infectious diseases, obstetrics and 
gynaecology, orthopaedics, paediatrics and paediatrics ICU.  
These data suggest that the natural niche of MRSA is in the hospital and for MSSA it 
is in the community, i.e. outside the healthcare environment. The ‘sink-source’ 
model was used to illustrate this. While MRSA has declined, which is likely a result 
of targeted interventions such as screening, decolonisation and cleaning, MSSA has 
not and it remains a public health concern. It is suggested that since one third of all 
The Epidemiology of MRSA in Scotland 
176 
 
patients, visitors and staff are commonly colonised, MSSA constantly enters the 
hospital from the community at a rate faster than it can be removed.  
7.1.3 Chapter 4 - Antimicrobial resistance of MRSA 
Using 8 years of data, antimicrobial resistance was described for MRSA. 
Specifically, resistance to 20 individual antimicrobials, antibiogram length and 
antibiogram diversity for clinical isolates and non-clinical ‘screening’ isolates were 
compared for EMRSA-15 (CC22, ST22 SCCmecIV) and EMRSA-16 (CC30, 
ST36SCCmecII) isolates. EMRSA-15 was by far the most dominant MRSA clone in 
Scotland. EMRSA-16 declined significantly, and non-EMRSA-15/non-EMRSA-16 
‘other’ clones are causing an increasing number of infections. EMRSA-16 was 
resistant to a larger number of antimicrobials than EMRSA-15, typically 9 compared 
with 5, and although resistance varied for EMRSA-16 over the study period, 
resistance remained stable for EMRSA-15. There was little difference between 
clinical and screening MRSA isolates. 
7.1.4 Chapter 5 - Antimicrobial prescribing and its association with 
MRSA epidemiology 
This chapter describes as a pilot study for a much larger analysis looking at trends 
and associations between prescribing and resistance for a greater number of 
antimicrobials and pathogens. As a stand-alone project, a sound methodology was 
developed for investigating spatial and temporal trends in Scottish primary and 
secondary care prescribing rates and associations between prescribing and resistance 
in MRSA. Analyses of antimicrobial prescribing showed that rates of several drugs 
increased from 2003 to 2013. Primary care prescribing was in general far higher than 
that in secondary care, although this differed between antimicrobials. Significant 
positive associations between prescribing and resistance rates were found for 
gentamicin and trimethoprim in both primary and secondary care, and clindamycin in 
primary care only. 
7.1.5 Chapter 6 - A hospital-level risk factor analysis of MRSA  
The aim of this study was to explore the hypotheses that hospital size, hospital 
connectivity and hospital category have an effect on the hospital-level incidences of 
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MRSA in mainland Scottish hospitals. In Scotland, size was not the only significant 
risk factor identified for the presence and rate of MRSA bacteraemia. The probability 
of a hospital having at least one case of MRSA bacteraemia increased with hospital 
size only if the hospital exceeded a certain level of connectivity. Higher levels of 
MRSA bacteraemia were associated with the large, highly connected teaching 
hospitals with high ratios of patients to domestic staff. A hospital’s level of 
connectedness within a network may be a better measure of a hospital’s risk of 
MRSA bacteraemia than size. 
7.2 Key policy implications  
There are several potential implications of this work.  
This thesis highlights the need to investigate case-fatality ratios further and to find a 
way to reduce deaths of cases. This could impact policy since it could become the 
evidence behind a government target, e.g. to reduce CFR to 70% of that in 2015 etc. 
It may also impact funding in this area to provide more resources for the 
development of bedside rapid testing for timely and appropriate treatment of patients. 
Further down the line, it could become routine policy to test patients with suspected 
bacteraemia using a bedside rapid test. 
If the sink-source model of MSSA and MRSA is verified and found to be accurate, 
then there should be more effort to reduce MSSA traffic into hospitals. This could 
impact policy and lead to MSSA screening and decolonisation for high-risk patients 
entering high-risk specialties for MSSA. 
This thesis highlights the extent of multi-drug resistance of MRSA although this is 
largely stable for the most common clone, EMRSA-15. The ‘snapshot’ programme 
provides invaluable insight into resistance of MRSA and it is important that this 
programme is maintained. Surveillance of MRSA through the ‘snapshot’ and EARS 
databases should remain a priority as potential policy implications can arise from 
monitoring trends. In the future, this may highlight which ‘other’ clones will become 
clinically important and to which antimicrobials resistance is developing.  
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This thesis describes levels of AMR in MSSA and MRSA. This has potential policy 
implications since it could lead to the review of antimicrobial prescribing practices. 
This thesis has shown that prescribing is associated with resistance at the Health 
Board level. It should be emphasised, and could become a key educational and 
training point, that resistance can be tackled locally in GP surgeries and hospitals by 
prudent use of antimicrobials and antibiotic stewardship.  
To further reduce MRSA and potentially other hospital-associated infections; large, 
highly connected teaching hospitals with high ratios of patients to domestic staff 
could be identified and targeted for more extensive health protection activities such 
as screening all patients, extra cleaning, and heightened surveillance. Since 
connectivity is a measure of how connected hospitals are in terms of shared patients, 
screening and decolonising patients prior to transfer might be another policy 
recommendation to reduce MRSA in the healthcare environment. 
This thesis used several large public health databases. These are valuable sources of 
public health information and the continued practice of collecting, compiling, 
analysis and distributing data should be maintained. The experience of this PhD was 
that there are often missing data, or no available data on some factor that would have 
been interesting to investigate. Therefore, it is suggested that there is a policy for 
when new major databases are being planned; a consultation with potential users of 
the database takes place. In addition, owing to legislation surrounding release of data 
(particularly surrounding confidentiality of patient information), the time between 
requesting data and acquiring it can often be lengthy and the process often unclear. 
During this PhD, successful collaborations were formed between the holders of data 
and me. For future collaborations, there needs to be more explicit guidelines on 
standard practice and protocol for requesting and clearing data for quick release 
from, for example, the Scottish Government, ISD or HPS.  
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7.3 Questions unanswered by this thesis 
There are several questions that resulted from this body of work, or that arose during 
this PhD which could not be answered due to time constraints, data or other resource 
limitations. Below are listed some of these questions. 
1. How to reduce MSSA bacteraemia? 
Screening and decolonisation of high-risk patients in high-risk specialties for MRSA 
has had an important impact on MRSA declines. To reduce the number of MSSA 
bacteraemia cases in hospitals, it may also be important to begin screening and 
decolonising high-risk patients in high-risk specialties for MSSA. However, as with 
tackling MRSA, a multifactorial approach will likely be the way to reduce MSSA 
bacteraemia. For example, decolonisation of patients prior to transfer may reduce 
hospital-level infections in the patients’ next hospital. In addition, the importance of 
using alcohol gels to clean hands, and potentially further activities, on entry to 
hospitals for every visitor, staff member and patient should be more strongly 
advocated.  
2. How to reduce case-fatality ratios for SAB?  
There needs to be a better understanding of factors that contribute to a case going on 
to succumb to the infection. One factor may be that the length of response time 
between patients becoming ill, being diagnosed and receiving appropriate treatment 
is too long. A potential strategy would be to lessen the response time which will 
likely require the development of real-time or bedside diagnostics.  
3. Which resistances carry the highest fitness costs?  
Answering this question would likely require laboratory experiments to determine if 
some resistance genes affect the spread and growth of bacteria more than others, or if 
a fitness cost is instead due to a certain combination of resistance genes, or if it’s a 
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4. What caused EMRSA-16 to decline?  
It is speculated that EMRSA-16 declined due to a specific focus on cleaning, 
screening and decolonisation of people and the hospital environment in high-risk 
specialties that was perhaps the natural niche for EMRSA-16. Furthermore, it is 
speculated that the multi-drug resistances of EMRSA-16 carried too high a fitness 
cost and negatively affected the bacteria’s ability to spread. Laboratory experiments 
may help to answer this question. 
5. Is there a subset of EMRSA-15 that will fill the EMRSA-16 vacated niche?  
If it is indeed true that EMRSA-16 had a ‘niche’ in the hospital and that it was 
eliminated from it, will EMRSA-15 or a different clone expand to fill that niche? If 
so, will it take on characteristics, such as certain resistances, to enable them to 
survive in that niche? This seems unlikely since if EMRSA-16 could not survive 
there, another clone would also meet the same challenges.  
6. How frequently do MSSA and MRSA enter a hospital and spread?  
This would require screening patients, visitors, staff and the hospital environment 
and perhaps a capture-recapture design. It could help to confirm the sink-source 
model.   
7. How can the sink-source model be confirmed? 
A screening study of individuals entering hospitals or a ‘capture-recapture’ 
phylogenetic study to trace strains through the hospital and community environments 
could test the source-sink hypothesis. It could also perhaps be tested mathematically. 
8. How important are nursing homes for MRSA and MSSA in Scotland? 
Nursing homes are thought to be a source of MSSA and MRSA infection but it is not 
known how they fit in to the sink-source model and it is not known how much 
bacteraemia is attributable to Scottish nursing homes. Screening studies may show 
this. In addition, the level of connectivity or the connectivity network of nursing 
homes to hospitals could also be an important risk factor for hospital-level infections. 
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9. How do hospital level risk factors apply to other diseases? 
It is expected that size, connectivity and hospital type will be important hospital-level 
risk factors for other hospital-associate infections but it would be interesting to apply 
data of other diseases to confirm this. 
10. How have private cleaning contracts affected MRSA, SAB and other HAI? 
Private cleaning contracts in some hospitals became more common in the last 
decade. It would be an important finding if this was found to be a hospital-level or 
patient-level risk factor for infection.  
7.4 Research recommendations for the future 
Below are listed some research recommendations for the future. 
Large data linkage projects to link data on isolates from SMRSARL, or cases, or 
deaths due to MRSA, with other data would enable the study of a number of wider 
research questions. The data requested would be specific to the research questions, 
e.g. patient demographic data, depravity scores, other disease statuses, number of 
hospital admissions, residency in care home, history of antimicrobial prescribing, 
history of surgery, disease outcomes/death etc. Data, if available, can be acquired 
through ISD with the linkage process taking up to one year. Furthermore, the isolates 
could be whole genome sequenced (WGS) with bioinformatic and phylogenetic 
analyses conducted which could identify clinically-relevant clusters and a wide range 
of genetic determinants including AMR and virulence genes, help to understand 
strain evolution, as well as elicit any associations between isolate and variables from 
the linked datasets. 
A field study in hospitals and the community to investigate MRSA and MSSA 
transmission by collecting information and taking swabs from staff / patients / 
visitors / environment at several time points.  This study would provide information 
on the proportion of admissions and discharges that were colonised or infected, help 
to understand the role of staff / patients / visitors / environment in transmission, and 
provide molecular epidemiology information such as levels of AMR and diversity of 
strains and how this related to patient outcome (infection type, death etc.) or 
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specialty.  It would also help to test the ‘sink-source’ model and the rate of strain 
removal. Isolates could also be whole genome sequenced and phylogenetic studies 
conducted to ‘follow’ isolates at hospital admission, through the hospital setting and 
back into the community (as per the sink source model) and provide insight into 
(AMR) gene acquisition and loss. 
Develop mathematical models that test different strategies to tackle AMR. For 
example, (a) models that can provide estimates of a threshold of drug prescribing, 
above which, AMR develops, or (b) models suggesting how best to rotate 
antimicrobials to prevent resistance developing, or (c) developing early warning 
systems. 
Develop tools to reduce CFR, for example, bedside diagnostics to ascertain the 
pathogen and any AMR for more timely and appropriate treatment of patients. 
7.5 Data limitations 
In every chapter, there were limitations surrounding data. The large, public health 
databases used in this thesis were often collected for purposes other than the analyses 
described here.  
The largest database used was that from the SMRSARL. In its entirety, the full 
database contained 240 columns of information for more than 120,000 isolates 
spanning 17 years. It is an unparalleled source of S. aureus information with many of 
the original isolates still existing in storage at the laboratory. However, the full 
database did not represent a single baseline study, instead including information of 
all isolates processed by the Reference Laboratory which included special studies, 
sub-projects, research, as well as testing for the EARS, snapshot and pathfinders 
studies described in this thesis and routine testing. Therefore, for Chapters 3, 4 and 5 
of this thesis, the EARS and snapshot sub-databases were extracted from this full 
database and analysed. However, these extracts had many missing and irrelevant data 
(for purpose of this thesis anyway) and as a result, only a small number of variables 
could be used for analyses in this thesis. It would have been useful and interesting to 
have had information on whether an isolate was from a hospital-associated or 
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community-associate case, information on antiseptic resistance and heavy metal 
resistance, a greater number of demographic variables, and others that could 
potentially be addressed through a data linkage study. 
The primary and secondary care prescribing databases used in Chapter 5were also 
very large and incomplete with many data missing for certain time periods or 
regions. As a result, only 7 NHS Health Boards and 6 antimicrobials were examined. 
In addition, no information of prescribing was available for topical agents or items 
without associated DDDs. This included mupirocin, which is used in the 
decolonisation of colonised individuals. 
The data used in Chapter 6, the hospital-level risk factor analysis, also had a number 
of issues including highly correlated variables and the fact that it was difficult to 
tease apart many variables as they were often closely related. Furthermore, there 
were a number of potential risk-factors that data were not available for and which 
could have potentially widened the scope of this chapter too. 
7.6 Methodological critique 
The descriptive and analytical methods used in this thesis are standard statistical 
methods that are appropriate for the types of data used and questions addressed. 
Analyses were discussed with a statistician either prior to being carried out or during 
the results stage.  
Methods included: Pearson’s Chi square and Fisher’s exact tests to test for 
independence and/or association, t-tests to test for differences in means in continuous 
variables, ANOVA with Bonferroni or Tukey corrections to test for differences in 
means between categories, PCA and MDS as techniques to reduce the number of 
variables and visualise data, diversity plots, and modelling to investigate trends in 
space and time.  
A risk factor analyses was carried out in Chapter 6 again using standard methods 
beginning with normalising data, checking for correlations, screening variables, and 
then building and validating the model using a backwards and forwards stepwise 
process.   
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To test if there were any statistical differences between HBs in terms of rates, 
analysis of variance (ANOVA) analyses where conducted, and to describe where 
those statistical differences were, Bonferroni or Tukey analyses were carried out. In 
the quarterly national surveillance reports by HPS [153], the funnel plots are used to 
illustrate the rate as well as identify any HB outliers (with rates above or below what 
would be expected). This is a useful way of depicting this information although it 
does not give any indication of any statistical differences between HB rates. The 
funnel plots were not included here in order to avoid repetition with national 
surveillance reports. In addition, the models used in this chapter differed from those 
used in national surveillance (national surveillance used case data with a Poisson 
distribution, offset by AOBD) to determine if rate had significantly changed over 
time. The outcomes are the same as have been described here.  
7.7 Ethical approval, data sources and access 
No ethical approval was required for the overall PhD project since it did not involve 
any direct contact with humans or animals. However, approval was required for 
accessing some of the individual datasets which held personal data and data on 
disease episodes affecting humans and animals, as described below.  
In order to receive the SMRSARL database, my supervisor needed to formally apply 
for access through the then director of the reference laboratory and the ‘gate holders 
of the data’, the Caldicott Guardian at NHS Greater Glasgow and Clyde. Release of 
the data was approved so long as personal identifiers were removed and codes 
replaced names. The application and approval stages took approximately 12 months. 
The approval email is shown in Appendix Document 1. 
Similarly, in order to receive the data used in Chapter 6, the annual counts of 
bacteraemia cases per hospital, my supervisor needed to formally apply for access 
through a consultant of public health medicine at HPS and the Caldicott Guardian at 
ISD. Release of the data was approved with the application and approval stages 
taking approximately 18 months. The approval email is shown in Appendix 
Document 2. 
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The data used in this PhD thesis was acquired from several additional sources.  
The number of bacteraemia cases by quarter and by HB, as was used in Chapter 2, is 
published on the HPS website and freely available, and hence no approval was 
required to access this dataset. The number of MRSA deaths is published and freely 
available from the GROS website. However, a special request was made for the 
number of MSSA deaths by year as this is not published. This request was made by 
emailing GROS and having follow-up discussions with the information analyst. Data 
were supplied free of charge. The number of AOBDs, and the hospital-level risk 
variables were accessed freely through the ISD website and so again, no approval 
was required to access these data.  
The prescribing datasets that were used in Chapter 5 were received following an 
email request to ISD. No formal approval was required. However, since the 
preparation of the databases was a lengthy process, we needed to pay for this service. 
It was approximately 12 months from applying for the data until receiving it.  
7.8 Novelty: what this thesis adds to the literature 
Each of the data chapters represents a publishable piece of work. Chapter 2 describes 
and compares MR and CFR of MRSA and MSSA in Scotland which, to my 
knowledge, has not been done before. Chapter 3 and Chapter 4 describe trends in 
national–level rates of resistance to 20 antimicrobials for both MRSA and MSSA, 
and discuss several other microbiological factors of interest, which have not been 
published elsewhere. In addition, the ‘sink-source’ model has been adapted to 
describe the flow of MRSA and MSSA through the community and healthcare 
settings which is an original use of this model. Chapter 5 investigates national-level 
prescribing data and how it is associated to resistance which has not yet been 
published for Scotland. Chapter 6 describes a hospital-level risk factor analyses 
which has not been conducted elsewhere as comprehensively as was shown in this 
thesis for S. aureus. 
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7.9 Concluding remarks 
MRSA is still a public health problem but the overall population-level burden has 
declined over time. This is a great public health success story as serious cases have 
declined and MRSA is no longer so great an issue as it once was.  It was once 
sensationalised in the media as the next major public health disaster. This did not 
happen but MRSA should not be forgotten and public health bodies should remain 
diligent and cognisant of this continued risk. Public health measures must be adhered 
to and remain in place in order to avoid a resurgence.  
In addition to MRSA, Clostridium difficile, another important hospital infection, has 
also declined and therefore there have been multiple benefits from public health 
activities. Despite this decline, there has been an increase in carbapenemase 
producing Enterobacteriaceae (CPE) which is an extremely antimicrobial-resistant 
family of bacteria. While Enterobacteriaceae (which includes Salmonella, 
Escherichia coli, Klebsiella sp, Proteus sp and Shigella sp) are part of the normal 
bacterial gut flora, they can cause urinary tract infections, intra-abdominal infections 
and bloodstream infections. Carbapenems are a class of very broad spectrum 
intravenous drugs which are reserved for serious infections or when other therapeutic 
options have failed (i.e. drug of last resort).   
To control these HAIs, it may be useful to consider the principles that were applied  
to control MRSA, namely; (1) identify cases, (2) stop transmission, (3) eliminate 
reservoirs, and in the case of antimicrobial resistance (4) antibiotic stewardship 
(Figure 7-1). However, as with MSSA, there may need to be a greater focus on some 
of these principles. For example, supposing the sink-source paradigm is true and 
MSSA constantly bombards and enters the hospital environment at a rate faster than 
it can be removed; then perhaps there needs to be a greater focus on identifying 
carriers by expanding screening to include MSSA too and eliminate these reservoirs 
through decolonisation. Furthermore, stopping transmission of MSSA could be 
achieved if stricter infection control measures were in place at hospital entrances. 
These suggestions, however, may be impractical and perhaps expensive. 
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While it has been a recognised issue in the medical and scientific world for decades, 
AMR is now a hot topic in the media and is gaining government priority and funding 
to tackle the issue worldwide. This is much needed and extremely important if new 
drugs are to be developed and diseases are to be controlled. Public health messages 
are also crucial to ensure engagement of the general public.  
As with elsewhere, disease surveillance systems in Scotland are not flawless. Cases 
in the community may be under-ascertained (i.e. not attend a GP surgery or hospital), 
or cases attending healthcare may be under-reported (i.e. diagnosed incorrectly, 
reported incorrectly or not at all) [157]. In the case of MSSA and MRSA, since 
bacteraemia is a serious condition leading to death if untreated, it is expected that 
under-ascertainment of bacteraemia in Scotland is low. Reporting of S. aureus 
bacteraemia cases is mandatory in Scotland and correct reporting of all deaths is also 
required by law so it is expected that under-reporting of morbidity and mortality 
events is also very low. There is, however, often uncertainty surrounding the cause of 
death in instances where a patient is suffering from co-morbidities (i.e. sequelae that 
an individual died with (e.g. secondary and tertiary causes) but not necessarily of (i.e. 
the primary cause of death)).  
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Throughout this thesis, I was involved in a number of important collaborations with 
individuals and groups at the SMRSARL, HPS, and within the university. These led 
to data and information sharing, and the analysis of datasets that perhaps otherwise 
would have remained unexplored. This thesis has shown that collaboration is key in 
this field, particularly as studies expand to become multi-disciplinary, and also that 
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Chapter 8: Appendices 
8.1 Appendices from Chapter 4 
Appendix Table 1: Spa types associated with clinical EMRSA-15, EMRSA-16 and others in time 
period B only. 
EMRSA-15 EMRSA16 'Others' 
Spa type obs. Spa type obs. Spa type obs. Spa type obs. 
t032 236 t2237 1 t018 32 t002 14 
t022 42 t2377 1 t871 22 t008 10 
t6057 29 t2892 1 t012 8 t127 7 
t020 16 t307 1 t019 6 t186 5 
t7894 14 t3211 1 t253 6 t398 5 
t025 9 t3212 1 t122 1 t437 2 
t379 7 t3490 1 t275 1 t612 2 
t1214 6 t3861 1 t486 1 t7344 2 
t628 5 t5302 1 t7356 1 t010 1 
t717 5 t651 1 Missing 6 t015 1 
t554 4 t8133 1 
  
t044 1 
t849 4 t819 1 t068 1 
t005 3 t8374 1 t088 1 
t1287 3 t8492 1 t10948 1 
t1370 3 t8695 1 t1222 1 
t1977 3 t965 1 t128 1 
t2004 3 t9760 1 t1467 1 
t2113 3 t9826 1 t172 1 
t5892 3 t9923 1 t2143 1 
t5951 3 Missing 432 t216 1 
t1415 2     t2191 1 
t557 2     t304 1 
t578 2     t324 1 
t756 2     t344 1 
t7900 2     t345 1 
t7943 2     t4364 1 
t10040 1     t442 1 
t1021 1     t458 1 
t1036 1     t657 1 
t1041 1     t690 1 
t10466 1     t701 1 
t11099 1     t786 1 
t1378 1     t843 1 
t1468 1     Missing 20 
t1516 1     
  
t1790 1     
t1924 1     
t1963 1     
t2062 1     
t223 1     
t2236 1     
obs= observations, number of times the spa type appears in the database.  
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8.2 Appendices from Chapter 5 
Appendix Table 2: Model output showing interaction between HB and time for (A) primary and 
(B) secondary prescribing rates.  
A) Primary care prescribing 
Model Coefficient Std. Error p-value 
Significance 
level 
Ciprofloxacin', p<0.0001, Adj. R2 = 0.65 
Year 0.02 0.005 <0.0001 *** 
LO - REF 
    
AA 0.28 0.04 <0.0001 *** 
FI 0.3 0.04 <0.0001 *** 
FV 0.41 0.04 <0.0001 *** 
GC 0.15 0.04 <0.0001 *** 
GR 0.43 0.04 <0.0001 *** 
LA 0.2 0.04 <0.0001 *** 
LO*Y - REF 
    
AA*Y -0.03 0.01 <0.0001 *** 
FI -0.03 0.01 0.0003 *** 
FV -0.03 0.01 0.003 ** 
GC -0.01 0.01 0.31 
 
GR -0.06 0.01 <0.0001 *** 
LA -0.02 0.01 0.02 * 
Clindamycin', p<0.0001, Adj. R2 = 0.69 
Year 0.07 0.01 <0.0001 *** 
LA - REF 
    
AA 0.19 0.05 0.0004 *** 
FI 0.29 0.05 <0.0001 *** 
FV 0.55 0.05 <0.0001 *** 
GC 0.37 0.05 <0.0001 *** 
GR 0.47 0.05 <0.0001 *** 
LO 0.52 0.05 <0.0001 *** 
LA*Y - REF 
    
AA -0.04 0.01 0.0002 *** 
FI -0.04 0.01 <0.0001 *** 
FV -0.06 0.01 <0.0001 *** 
GC -0.05 0.01 <0.0001 *** 
GR -0.08 0.01 <0.0001 *** 
LO -0.04 0.01 0.0005 *** 
Erythromycin', p<0.0001, Adj.R2 = 0.60 
Year 0.02 0 <0.0001 *** 
AA - REF 
    
FI 0.12 0.02 <0.0001 *** 
FV 0.09 0.02 <0.0001 *** 
GC 0.09 0.02 <0.0001 *** 
GR -0.04 0.02 0.03 * 
LA 0.07 0.02 0.0004 *** 
LO 0.15 0.02 <0.0001 *** 
AA*Y - REF 
    
FI*Y -0.03 0.004 <0.0001 *** 
FV*Y -0.03 0.004 <0.0001 *** 
GC*Y -0.03 0.004 <0.0001 *** 
GR*Y -0.01 0.004 0.004 ** 
LA*Y -0.03 0.004 <0.0001 *** 
LO*Y -0.03 0.004 <0.0001 *** 
Gentamycin'', p<0.0001, Adj.R2 = 0.47 
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Year 0.005 0.003 0.09 . 
AA - REF 
    
FI 0.17 0.02 <0.0001 *** 
FV 0.03 0.02 0.16 
 
GC 0.12 0.02 <0.0001 *** 
GR 0.15 0.02 <0.0001 *** 
LA 0.07 0.02 0.0005 *** 
LO 0.07 0.02 0.0005 *** 
AA*Y - REF 
    
FI*Y -0.02 0.004 <0.0001 *** 
FV*Y 0 0.005 0.92 
 
GC*Y -0.01 0.004 0.11 
 
GR*Y -0.02 0.004 <0.0001 *** 
LA*Y -0.01 0.004 0.07 . 
LO*Y -0.01 0.004 0.13 
 
Tetracycline', p<0.0001, Adj.R2 = 0.84 
Year 0.04 0.01 <0.0001 *** 
FV - REF 
    
AA 0.12 0.03 0.0003 *** 
FI 0.35 0.03 <0.0001 *** 
GC 0.31 0.03 <0.0001 *** 
GR 0.52 0.03 <0.0001 *** 
LA 0.6 0.03 <0.0001 *** 
LO 0.38 0.03 <0.0001 *** 
FV*HB - REF 
    
AA*Y -0.04 0.01 <0.0001 *** 
FI*Y -0.07 0.01 <0.0001 *** 
GC*Y -0.04 0.01 <0.0001 *** 
GR*Y -0.06 0.01 <0.0001 *** 
LA*Y -0.09 0.01 <0.0001 *** 
LO*Y -0.09 0.01 <0.0001 *** 
Trimethoprim, p<0.0001, Adj. R2 = 0.85 
Year 9.6 0.43 <0.0001 *** 
LA - REF 
    
AA 53.09 3.14 <0.0001 *** 
FI 46.36 3.1 <0.0001 *** 
FV 40.85 3.29 <0.0001 *** 
GC 37.58 3.1 <0.0001 *** 
GR 55.97 3.1 <0.0001 *** 
LO 30 3.1 <0.0001 *** 
LA*Y - REF 
    
AA*Y -7.21 0.62 <0.0001 *** 
FI*Y -5.46 0.61 <0.0001 *** 
FV*Y -6.49 0.75 <0.0001 *** 
GC*Y -5.66 0.61 <0.0001 *** 
GR*Y -8.29 0.61 <0.0001 *** 
LO*Y -6.16 0.61 <0.0001 *** 
’ data log transformed 
” data log(x+1) transformed 
Health Board abbreviations: AA = NHS Ayrshire and Arran, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS 
Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS Lanarkshire, LO = NHS Lothian  
Significance level: Significant = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 
1 = ‘ ’  
Std. Error = standard error 
Y = Year 
Health Board * Y = Interaction, within-Health Board trend over time (Year) 
- = represents reference Health Board 
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B) Secondary care prescribing 
Model Coefficient Std. Error p-value 
Significance 
level 
Ciprofloxacin, p<0.0001, Adj. R2 = 0.86 
Year -0.62 0.41 0.14 
 
GR – REF - - - - 
AA 6311.15 1149.85 <0.0001 *** 
FI 1640.59 1142.59 0.15 
 
FV 489.99 1142.59 0.67 
 
GC 8364.08 1142.59 <0.0001 *** 
LA 1330.2 1142.59 0.25 
 
LO 4159.52 1173.87 0.0006 *** 
GR*Y – REF - - - - 
AA*Y -3.14 0.57 <0.0001 *** 
FI*Y -0.82 0.57 0.15 
 
FV*Y -0.25 0.57 0.66 
 
GC*Y -4.16 0.57 <0.0001 *** 
LA*Y -0.67 0.57 0.24 
 
LO*Y -2.07 0.58 0.0006 *** 
Clindamycin’, p<0.0001, Adj. R2 = 0.67 
Year 0.03 0.02 0.06 . 
LA – REF - - - - 
AA 2.24 47.66 0.96 
 
FI 10.6 47.34 0.82 
 
FV 311.98 47.34 <0.0001 *** 
GC 266.08 47.34 <0.0001 *** 
GR 103.67 48.71 0.04 * 
LO 69.73 48.71 0.15 
 
LA*Y – REF - - - - 
AA*Y -0.001 0.02 0.97 
 
FI*Y -0.01 0.02 0.82 
 
FV*Y -0.16 0.02 <0.0001 *** 
GC*Y -0.13 0.02 <0.0001 *** 
GR*Y -0.05 0.02 0.04 * 
LO*Y -0.03 0.02 0.16 
 
Erythromycin’, p<0.0001, Adj. R2=0.93 
Year 0.03 0.01 0.003 ** 
GC – REF - - - - 
AA 162.32 29.25 <0.0001 *** 
FI 222.22 29.05 <0.0001 *** 
FV 133.41 29.05 <0.0001 *** 
GR 189.39 29.89 <0.0001 *** 
LA 158.29 29.05 <0.0001 *** 
LO 180.4 29.89 <0.0001 *** 
GC*Y – REF - - - - 
AA*Y -0.08 0.01 <0.0001 *** 
FI*Y -0.11 0.01 <0.0001 *** 
FV*Y -0.07 0.01 <0.0001 *** 
GR*Y -0.09 0.01 <0.0001 *** 
LA*Y -0.08 0.01 <0.0001 *** 
LO*Y -0.09 0.01 <0.0001 *** 
Gentamycin’, p<0.0001, Adj. R2 = 0.90 
Year 0.2 0.01 <0.0001 *** 
FV – REF - - - - 
AA 245.54 38.07 <0.0001 *** 
FI 303.98 37.82 <0.0001 *** 
GC 203.7 37.82 <0.0001 *** 
GR 233.4 38.91 <0.0001 *** 
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LA 81.59 37.82 0.03 * 
LO 425.29 38.91 <0.0001 *** 
FV*Y – REF - - - - 
AA*Y -0.12 0.02 <0.0001 *** 
FI*Y -0.15 0.02 <0.0001 *** 
GC*Y -0.1 0.02 <0.0001 *** 
GR*Y -0.12 0.02 <0.0001 *** 
LA*Y -0.04 0.02 0.03 * 
LO*Y -0.21 0.02 <0.0001 *** 
Tetracycline’, Interaction NS, additive model NS 
Year -0.01 0.06 0.83 
 
FV – REF - - - - 
AA -144.2 161.6 0.37 
 
FI -79.8 160.5 0.62 
 
GC 233.6 160.5 0.15 
 
GR 149.3 165.2 0.37 
 
LA 166.4 160.5 0.3 
 
LO -5.38 165.2 0.97 
 
FV*Y – REF - - - - 
AA*Y 0.07 0.08 0.38 
 
FI*Y 0.04 0.08 0.62 
 
GC*Y -0.12 0.08 0.15 
 
GR*Y -0.07 0.08 0.37 
 
LA*Y -0.08 0.08 0.3 
 
LO*Y 0.003 0.08 0.98 
 
Trimethoprim, p<0.0001, Adj.R2 = 0.92 
Year 1.9 0.24 <0.0001 *** 
LA – REF - - - - 
AA 1719.68 672.93 0.01 * 
FI 2059.62 668.44 0.003 ** 
FV 2793.96 668.44 <0.0001 *** 
GC 2413.4 668.44 0.0004 *** 
GR 1794.43 687.8 0.01 * 
LO 2315.86 687.8 0.001 ** 
LA*Y – REF - - - - 
AA*Y -0.86 0.34 0.01 * 
FI*Y -1.03 0.33 0.002 ** 
FV*Y -1.4 0.33 <0.0001 *** 
GC*Y -1.2 0.33 0.0005 *** 
GR*Y -0.89 0.34 0.01 * 
LO*Y -1.16 0.34 0.001 *** 
’ data log transformed 
Health Board abbreviations: AA = NHS Ayrshire and Arran, FI = NHS Fife, FV = NHS Forth Valley, GR = NHS 
Grampian, GC = NHS Greater Glasgow and Clyde, LA = NHS Lanarkshire, LO = NHS Lothian  
Significance level: Significant = ≤ 0.001 = ‘***’; ≤0.01 = ‘**’; ≤0.05 = ‘*’; Not significant = <0.1 & >0.05 = ‘.’; 
1 = ‘ ’  
Std. Error = standard error 
Y = Year 
NS = Non-significant 
Health Board * Y = Interaction, within-Health Board trend over time (Year) 
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Appendix Table 3: Univariate analyses: association between proportion resistant and (A) 
primary and (B) secondary care prescribing rate. 
 (A) 
Data Estimate Std. Error P-value Significance Adj. R2 
Ciprofloxacin 
R_MRSA t0 -0.03 0.12 0.82  -0.005 
R_MRSA t1 0.03 0.13 0.82  -0.005 
R_MRSA t2 0.04 0.13 0.79  -0.005 
R_MRSA t3 -0.05 0.13 0.74  -0.005 
R_MRSA t4 -0.03 0.14 0.82  -0.005 
R_MRSA t5 -0.06 0.14 0.68  -0.005 
R_MRSA t6 -0.21 0.14 0.13  0.008 
Clindamycin 
R_MRSA t0 0.29 0.07 0.0001 *** 0.06 
R_MRSA t1 0.34 0.07 <0.0001 *** 0.09 
R_MRSA t2 0.34 0.07 <0.0001 *** 0.09 
R_MRSA t3 0.34 0.08 <0.0001 *** 0.09 
R_MRSA t4 0.33 0.08 <0.0001 *** 0.09 
R_MRSA t5 0.3 0.08 0.0002 *** 0.07 
R_MRSA t6 0.28 0.08 0.0006 *** 0.06 
Erythromycin 
R_MRSA t0 -0.18 0.33 0.59  0.6 
R_MRSA t1 -0.09 0.34 0.78  -0.005 
R_MRSA t2 -0.09 0.34 0.79  -0.005 
R_MRSA t3 -0.4 0.34 0.25  0.002 
R_MRSA t4 0.25 0.34 0.47  -0.003 
R_MRSA t5 -0.13 0.35 0.71  -0.005 
R_MRSA t6 -0.27 0.35 0.44  -0.002 
Gentamicin 
R_MRSA t0 0.53 0.12 <0.0001 *** 0.08 
R_MRSA t1 0.56 0.13 <0.0001 *** 0.08 
R_MRSA t2 0.62 0.13 <0.0001 *** 0.1 
R_MRSA t3 0.59 0.14 <0.0001 *** 0.08 
R_MRSA t4 0.58 0.14 <0.0001 *** 0.08 
R_MRSA t5 0.6 0.15 <0.0001 *** 0.08 
R_MRSA t6 0.59 0.16 0.0003 *** 0.07 
Tetracycline 
R_MRSA t0 0.06 0.06 0.31  0.0002 
R_MRSA t1 0.09 0.06 0.12  0.007 
R_MRSA t2 0.06 0.05 0.27  0.001 
R_MRSA t3 0.08 0.05 0.13  0.007 
R_MRSA t4 0.08 0.05 0.12  0.008 
R_MRSA t5 0.1 0.06 0.06 . 0.01 
R_MRSA t6 0.1 0.06 0.09 . 0.01 
Trimethoprim 
R_MRSA t0 0.003 0.001 0.01 ** 0.03 
R_MRSA t1 0.002 0.001 0.02 * 0.02 
R_MRSA t2 0.002 0.001 0.1 . 0.009 
R_MRSA t3 0.001 0.001 0.31  0.0002 
R_MRSA t4 0.001 0.001 0.29  0.0008 
R_MRSA t5 0.001 0.001 0.28  0.0009 
R_MRSA t6 0.001 0.001 0.34  -0.0004 




Data Estimate Std. Error P-value Significance Adj. R2 
Ciprofloxacin 
R_MRSA t0 0.001 0.002 0.53  -0.005 
R_MRSA t1 0.0005 0.002 0.77  -0.007 
R_MRSA t2 0.001 0.002 0.75  -0.007 
R_MRSA t3 0.001 0.002 0.63  -0.007 
R_MRSA t4 0.001 0.002 0.52  -0.005 
R_MRSA t5 0.001 0.002 0.78  -0.009 
R_MRSA t6 0.001 0.001 0.25  -0.003 
Clindamycin 
R_MRSA t0 -0.004 0.09 0.96  -0.007 
R_MRSA t1 -0.12 0.09 0.18  0.006 
R_MRSA t2 -0.16 0.09 0.06 . 0.02 
R_MRSA t3 -0.14 0.09 0.11  0.01 
R_MRSA t4 -0.14 0.09 0.13  0.01 
R_MRSA t5 -0.17 0.09 0.06 . 0.02 
R_MRSA t6 -0.15 0.09 0.09 . 0.02 
Erythromycin 
R_MRSA t0 0.02 0.08 0.78  -0.007 
R_MRSA t1 0.07 0.09 0.44  -0.003 
R_MRSA t2 0.07 0.09 0.41  -0.003 
R_MRSA t3 0.1 0.09 0.25  0.003 
R_MRSA t4 0.01 0.09 0.88  -0.009 
R_MRSA t5 0.01 0.09 0.88  -0.009 
R_MRSA t6 0.1 0.09 0.27  0.002 
Gentamycin 
R_MRSA t0 0.14 0.03 <0.0001 *** 0.18 
R_MRSA t1 0.15 0.03 <0.0001 *** 0.19 
R_MRSA t2 0.13 0.03 <0.0001 *** 0.17 
R_MRSA t3 0.13 0.03 <0.0001 *** 0.18 
R_MRSA t4 0.13 0.03 <0.0001 *** 0.16 
R_MRSA t5 0.12 0.03 <0.0001 *** 0.15 
R_MRSA t6 0.12 0.03 0.0003 *** 0.12 
Tetracycline 
R_MRSA t0 0.01 0.03 0.61  -0.005 
R_MRSA t1 -0.0004 0.03 0.99  -0.008 
R_MRSA t2 0.01 0.02 0.64  -0.006 
R_MRSA t3 -0.003 0.02 0.89  -0.009 
R_MRSA t4 -0.01 0.02 0.56  -0.006 
R_MRSA t5 -0.03 0.02 0.22  0.005 
R_MRSA t6 -0.01 0.03 0.57  -0.007 
Trimethoprim 
R_MRSA t0 0.02 0.004 <0.0001 *** 0.18 
R_MRSA t1 0.02 0.004 <0.0001 *** 0.17 
R_MRSA t2 0.01 0.004 <0.0001 *** 0.11 
R_MRSA t3 0.01 0.004 0.0002 *** 0.1 
R_MRSA t4 0.02 0.004 0.0001 *** 0.12 
R_MRSA t5 0.01 0.004 0.0003 *** 0.12 
R_MRSA t6 0.02 0.004 0.0004 *** 0.12 
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8.3 Appendices from Chapter 6 




Appendix Table 4: Hospital MRSA ‘status’. 
The status of a hospital, either MRSA positive (i.e. had cases) versus MRSA negative (i.e. did not 
have cases), is shown for five financial years, 2006/07 to 2010/11 inclusive. A white box indicates 
that a hospital is negative and a black box indicates that a hospital was positive for that year. Hospitals 
that were positive for the study year (2007/2008) tended to be positive in other years. For hospitals 
with an '*' in the Status for Analysis column, the analyses were run with and without them to check 
that there was no change in the model. 
Hospital 
Code 2006/2007 2007/2008 2008/2009 2009/2010 2010/2011 Status for Analysis 
A101H           Negative 
A105H           Negative 
A110H           Negative 
A201H           Negative 
A207H           Negative 
A211H           Negative 
B103H           Negative 
B105H           Negative 
B114H           Negative 
B128H           Negative 
B129H           Negative 
B130H           Negative 
C101H           Negative 
C106H           Negative 
C108H           Negative 
C110H           Negative 
C113H           Negative 
C114H           Negative 
C122H           Negative 
C204H           Negative 
C310H           Negative 
















Financial year end 
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C406H           Negative 
F705H           Negative 
F708H           Negative 
F709H           Negative 
F711H           Negative 
F712H           Negative 
F716H           Negative 
F810H           Negative 
G111H           Negative 
G206H           Negative 
G302H           Negative 
G303H           Negative 
G408H           Negative 
G505H           Negative 
G515H           Negative 
G606H           Negative 
G610H           Negative 
H104H           Negative 
H106H           Negative 
H108H           Negative 
H201H           Negative 
H208H           Negative 
H210H           Negative 
H211H           Negative 
H212H           Negative 
H213H           Negative 
H217H           Negative 
H219H           Negative 
H223H           Negative 
L103H           Negative 
L104H           Negative 
L105H           Negative 
L203H           Negative 
L204H           Negative 
L206H           Negative 
L207H           Negative 
L209H           Negative 
L211H           Negative 
L213H           Negative 
L216H           Negative 
L218H           Negative 
L304H           Negative 
L305H           Negative 
L307H           Negative 
N103H           Negative 
N121H           Negative 
N151H           Negative 
N161H           Negative 
N181H           Negative 
N198H           Negative 
N331H           Negative 
N332H           Negative 
N335H           Negative 
N336H           Negative 
N337H           Negative 
N351H           Negative 
N352H           Negative 
N353H           Negative 
N431H           Negative 
N432H           Negative 
N434H           Negative 
N451H           Negative 
N492H           Negative 
N494H           Negative 
N496H           Negative 
N499H           Negative 
S102H           Negative 
S103H           Negative 
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S107H           Negative 
S108H           Negative 
S109H           Negative 
S210H           Negative 
S214H           Negative 
S217H           Negative 
S225H           Negative 
S305H           Negative 
S306H           Negative 
S310H           Negative 
S312H           Negative 
S313H           Negative 
S315H           Negative 
T105H           Negative 
T114H           Negative 
T115H           Negative 
T205H           Negative 
T207H           Negative 
T208H           Negative 
T209H           Negative 
T215H           Negative 
T304H           Negative 
T305H           Negative 
T309H           Negative 
T310H           Negative 
T311H           Negative 
T316H           Negative 
T317H           Negative 
V105H           Negative 
V106H           Negative 
V107H           Negative 
V113H           Negative 
V202H           Negative 
V204H           Negative 
V211H           Negative 
V214H           Negative 
Y101H           Negative 
Y103H           Negative 
Y106H           Negative 
Y107H           Negative 
Y108H           Negative 
Y109H           Negative 
Y110H           Negative 
Y114H           Negative 
Y120H           Negative 
Y123H           Negative 
Y124H           Negative 
Y126H           Negative 
Y129H           Negative 
Y130H           Negative 
Y134H           Negative 
Y136H           Negative 
Y139H           Negative 
A111H           Positive 
A210H           Positive 
B120H           Positive 
C206H           Positive 
C313H           Positive 
C418H           Positive 
F704H           Positive 
F805H           Positive 
G107H           Positive 
G207H           Positive 
G306H           Positive 
G307H           Positive 
G405H           Positive 
G513H           Positive 
G516H           Positive 
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H202H           Positive 
L106H           Positive 
L302H           Positive 
L308H           Positive 
N101H           Positive 
N102H           Positive 
N411H           Positive 
S113H           Positive 
S114H           Positive 
S116H           Positive 
S209H           Positive 
S308H           Positive 
S314H           Positive 
T101H           Positive 
T107H           Positive 
T202H           Positive 
V102H           Positive 
V201H           Positive 
Y104H           Positive 
A103H           Negative 
A208H           Positive 
A215H           Negative 
B118H           Negative 
C121H           Positive 
C407H           Positive* 
F701H           Negative 
F703H           Negative 
G109H           Positive 
H101H           Negative 
H103H           Positive 
H214H           Negative 
H215H           Negative* 
N183H           Positive* 
N333H           Positive* 
N334H           Positive 
N433H           Positive* 
S201H           Positive 
T312H           Positive 
T313H           Negative 
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Appendix Figure 2: Correlation analyses for potential variables of (A) size and (B) connectivity. 
The colour key (right-hand side of figure) shows the correlation coefficient in relation to colour; i.e. 
dark blue represents two variables with a strong positive correlation and dark red represents two 
variables with a strong negative correlation coefficient. The pie charts represent the correlation 
coefficient for a pair of variables (i.e. if the whole pie is dark blue, then correlation coefficient = 1, if 
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Appendix Table 5: List of all the variables considered in the risk factor analysis (Model 1: 








) Q Hospital size measured in square metres 
Average number of staffed 
beds 
Q 
Average number of available staffed beds for inpatients or 
day cases. 
Occupied bed days (OBD) Q 
Sum of the number of occupied beds for each day of the 
period. A bed occupied by an inpatient at the bed count is 
counted as one OBD. If it is simultaneously reserved for a 
second patient, it is counted as two OBD. 
Total patients discharged Q Total number of patients discharged. 
Total average staff per year Q Number of staff members (WTE). 
Average occupancy rate Q 
The average proportion of beds that were occupied by 
patients. 
Average length of stay Q 
The average patient length of stay in acute specialties per 
hospital in days (This was only carried out for model 2 since 
model 1 dataset included hospitals with no acute specialties 
and hence length of stay measured in weeks). 
ASY medical and dental Q Total average medical and dental staff per year (WTE). 
ASY nursing and midwifery Q Total average nursing and midwifery staff per year (WTE). 
ASY domestic staff Q 
Total average domestic staff per year (WTE (includes 
cleaners, cleaning supervisors and cleaning managers)). 
ASY support services staff Q 
Total average support services staff per year (WTE (includes 
general services, hotel services, maintenance and estates, 
sterile services)) 
PSR – medical and dental Q 
Patient to medical and dentistry staff ratios; total number of 
inpatients per hospital per year, divided by total number of 
staff members registered to and paid from that hospital per 
year (WTE). 
PSR – nurses and midwives Q 
Patient to nurses and midwives staff ratios; the total number 
of inpatients per hospital per year, divided by the total 
number of staff members registered to and paid from that 
hospital per year (WTE). 
PSR – domestic staff Q 
Patient to domestic staff ratios total number of inpatients per 
hospital per year, divided by total number of staff members 
registered to and paid from that hospital per year (WTE) 
Patients in Q/C 
Connectivity measure. Total number of patients moved to 
hospital A from other hospitals. 
Patients out Q/C 
Connectivity measure. Total number of patients moved from 
hospital A to other hospitals. 
Patients total Q/C 
Connectivity measure. Total number of patients moved to and 
from hospital A to other hospitals. 
Indegree Q/C 
Connectivity measure. Total number of hospitals that 
transferred patients to hospital A. 
Outdegree Q/C 
Connectivity measure. Total number of hospitals that 
received patients sent from hospital A. 
Closeness Centrality Q/C 
Connectivity measure. The mean distance (in terms of the 
number of steps from hospital A to hospital B for each 
hospital). 
Teaching hospital C If hospital was a teaching hospital (A1) versus any other type. 
Category A C If hospital was a category A hospital (General, mainly acute). 
Category B C If hospital was a category B hospital (long stay). 
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Category C C If hospital was a category C hospital (mental). 
Category D C 
If hospital was a category D hospital (psychiatry of learning 
difficulties). 
Category E C If hospital was a category E hospital (maternity). 
Category J C If hospital was a category J hospital (community). 
Hospital group C 
Three hospital groups that emerged from the NMS analysis 
(Figure 3). 1, Teaching hospital; 2, General hospital, no 
teaching; 3, Other (Categories B, C, D, E and J). 
Sum of specialties Q/C 
Total number of hospital specialties. See Supplementary 
Table 2 for complete list of specialties. 
Proportion of acute 
specialties 
Q 
Proportion of all specialties (Supplementary Table 2) that 
were acute 
Long Stay Specialties C 
Presence of only long stay specialties (Adolescent 
Psychiatry, Child Psychiatry, General Psychiatry, Geriatric 
Psychiatry, Geriatric Long Stay, Learning Disabilities, 
Young Chronic Sick). 
Intensive Care Unit C Intensive care unit. 
Haematology C If the hospital had a haematology specialty. 
Accident and Emergency 
(A&E) 
C If the hospital had an Accident and Emergency. 
A&E Attendance Q 
Total number of patients attending Accident and 
Emergency. 
Cleaning supplies Q Total cost of cleaning supplies (GBP). 
Number of cleaning cost 
units 




The cleaning supplies (GBP) divided by hospital size (in 
square meters). 
Standardised cleaning cost Q 
The cleaning number of cost units divided by hospital size (in 
square meters). 
Q=quantitative / continuous; C=categorical; WTE, Whole Time Equivalent; ASY, Average staff per year; PSR, 
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Appendix Table 6: Output of univariate analyses, binomial model with presence-absence of 
MRSA bacteraemia model. 




Teaching hospital Hospital classification 197.35 17.93 979.61 ns 
Category A Hospital classification 127.16 4.09 0.53 <0.0001 
Category B Hospital classification 214.44 -0.46 0.41 ns 
Category C Hospital classification 196.08 -17.6 1118.62 ns 
Category D Hospital classification 213.48 -1.33 1.06 ns 
Category E Hospital classification 214.15 -14.37 840.27 ns 
Category J Hospital classification 198.55 -2.04 0.62 <0.01 
NMS presence of specialties Specialties / activity type 107.3 4.42 1.12 <0.0001 
Sum of specialties Specialties / activity type 113.58 0.44 0.09 <0.0001 
Proportion specialties acute Specialties / activity type 165.66 0.04 0.01 <0.0001 
Only long-stay specialties Specialties / activity type 175.86 -3.68 1.02 <0.0001 
Only acute specialties  Specialties / activity type 210.54 0.82 0.36 <0.05 
Both specialty types Specialties / activity type 204.73 1.15 0.35 <0.001 
Log(Patients in) Connectivity 59.72 5.78 1.08 <0.0001 
Log(Patients out) Connectivity 65.06 4.62 0.89 <0.0001 
Log(Indegree) Connectivity 90.97 5.85 0.88 <0.0001 
Log(Outdegree) Connectivity 78.44 6.38 0.99 <0.0001 
Log(Closeness unweighted) Connectivity 96.09 32.41 5.2 <0.0001 
Closeness weighted Connectivity 104.17 3086.36 630.78 <0.0001 
Log(Eigenvector centrality) Connectivity 99.36 862.42 132.71 <0.0001 
Log(Betweeness centrality) Connectivity 84.65 2.41 0.34 <0.0001 
Closeness_threshold Connectivity 127.37 3.89 0.49 <0.0001 
Outdegree_threshold Connectivity 105.47 4.54 0.59 <0.0001 
Log(size in square metres) Size 120.73 3.59 0.53 <0.0001 
Log(Average staffed beds) Size 118.23 4.31 0.62 <0.0001 
Log(Occupied bed days) Size 120.27 3.94 0.57 <0.0001 
Log(total patients discharged) Size 99.4 2.82 0.42 <0.0001 
Log(total average staff per year) Size/ Staff 103.93 4.07 0.59 <0.0001 
Log(ASY medical and dental) Size/ Staff 111.27 2.85 0.4 <0.0001 
Log(ASY nursing and midwifery) Size / Staff 110.05 4.14 0.6 <0.0001 
Log(ASY domestic staff) Size / Staff 128.01 1.2 0.2 <0.0001 
Log(ASY support services staff) Size / Staff 121.63 0.03 0.01 <0.0001 
Log(Cleaning supplies GBP) Size / Cleaning 125.68 3.16 0.48 <0.0001 
Log(Number of cleaning cost 
units) 
Size / Cleaning 121.26 3.61 0.54 <0.0001 
Log(Pharmacy drugs supplies 
GBP) 
Size / Prescribing 125.79 2.18 0.32 <0.0001 
PSR – medical and dental Staff / Patient staff ratios 210.71 -0.001 0.001 ns 
PSR – nurses and midwives Staff / Patient staff ratios 160.37 0.12 0.02 <0.0001 
PSR – domestic staff Staff / Patient staff ratios 153.4 0.001 0.0004 <0.001 
PSR – support services staff Staff / Patient staff ratios 208.72 0.001 0.001 ns 
Cleaning 1 Cleaning 212.71 -2.99 3.01 ns 
Cleaning 2 Cleaning 212.66 0.03 0.02 ns 
Cleaning staff  Cleaning 214.1 -0.01 0.05 ns 
Average occupancy rate Other 207.23 0.04 0.01 <0.01 
SE: Standard Error; AIC: Akaike Information Criterion 










Appendix Table 7: Output of univariate analyses, Poisson model with MRSA bacteraemia case 
data. 




Teaching hospital Hospital classification 210.79 0.63 0.08 <0.0001 
NMS presence of specialties Specialties / activity type 238.68 0.26 0.05 <0.0001 
Sum of specialties Specialties / activity type 250.41 0.03 0.01 <0.0001 
Proportion specialties acute Specialties / activity type 233.76 0.04 0.01 <0.0001 
Only acute specialties Specialties / activity type 234.26 0.5 0.09 <0.0001 
Both specialty types Specialties / activity type 234.26 -0.5 0.09 <0.0001 
Log(Patients in) Connectivity 231.33 0.92 0.15 <0.0001 
Log(Patients out) Connectivity 221.26 1.23 0.19 <0.0001 
Log(Indegree) Connectivity 228.81 2.38 0.39 <0.0001 
Log(Outdegree) Connectivity 232.41 2.35 0.4 <0.0001 
Closeness unweighted Connectivity 224.97 8.94 1.39 <0.0001 
Log(Closeness weighted) Connectivity 235.14 2001.88 357.66 <0.0001 
Log(Eigenvector centrality) Connectivity 241.5 184.84 35.86 <0.0001 
Log(Betweeness centrality) Connectivity 233.14 0.65 0.11 <0.0001 
Log(size in square metres) Size 232.34 0.98 0.17 <0.0001 
Log(Average staffed beds) Size 239 1.04 0.2 <0.0001 
Log(Occupied bed days) Size 236.03 1.06 0.19 <0.0001 
Log(total patients discharged) Size 236.37 0.92 0.17 <0.0001 
Log(total average staff per year) Size/ Staff 228.77 1.12 0.18 <0.0001 
Log(ASY medical and dental) Size/ Staff 223.68 1.06 0.16 <0.0001 
Log(ASY nursing and midwifery) Size / Staff 230.73 1.1 0.18 <0.0001 
Log(ASY domestic staff) Size / Staff 247.7 -0.07 0.03 <0.05 
Log(ASY support services staff) Size / Staff 256.1 0.25 0.07 <0.0001 
Log(Cleaning supplies GBP) Size / Cleaning 254.61 0.3 0.07 <0.0001 
Log(Number of cleaning cost 
units) 
Size / Cleaning 232.15 0.98 0.17 <0.0001 
Log(Pharmacy drugs supplies 
GBP) 
Size / Prescribing 241.48 0.6 0.11 <0.0001 
PSR – medical and dental Staff / Patient staff ratios 257.96 -0.005 0.001 <0.001 
PSR – nurses and midwives Staff / Patient staff ratios 270.27 0.004 0.008 ns 
PSR – domestic staff Staff / Patient staff ratios 231.93 2.37e-05 4.88e-06 <0.0001 
PSR – support services staff Staff / Patient staff ratios 232.38 0.002 0.0005 <0.0001 
Cleaning 1 Cleaning 267.2 8.13 4.97 ns 
Cleaning 2 Cleaning 270.34 0.001 0.002 ns 
Cleaning staff Cleaning 269.9 -0.02 0.02 ns 
Average occupancy rate Other 258.06 0.02 0.01 <0.001 
Average length of stay Other 269.8 -0.02 0.025 ns 
SE: Standard Error; AIC: Akaike Information Criterion 
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Appendix Document 1: Approval granting access to the SMRSARL database from the NHS 
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Appendix Document 2: Approval for the release of hospital-level bacteraemia data from the 
Caldicott Guardian at ISD. 
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